
<html lang="en"     class="pb-page"  data-request-id="1e10d88d-fbf7-4705-affe-72d3658f10d5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;article:article:10.1021/acs.jmedchem.0c01243;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Selective Inhibitors of G2019S-LRRK2 Kinase Activity" /></meta><meta name="dc.Creator" content="Albert W.  Garofalo" /></meta><meta name="dc.Creator" content="Jessica  Bright" /></meta><meta name="dc.Creator" content="Stéphane  De Lombaert" /></meta><meta name="dc.Creator" content="Alyssa M. A.  Toda" /></meta><meta name="dc.Creator" content="Kerry  Zobel" /></meta><meta name="dc.Creator" content="Daniele  Andreotti" /></meta><meta name="dc.Creator" content="Claudia  Beato" /></meta><meta name="dc.Creator" content="Silvia  Bernardi" /></meta><meta name="dc.Creator" content="Federica  Budassi" /></meta><meta name="dc.Creator" content="Laura  Caberlotto" /></meta><meta name="dc.Creator" content="Peng  Gao" /></meta><meta name="dc.Creator" content="Cristiana  Griffante" /></meta><meta name="dc.Creator" content="Xinying  Liu" /></meta><meta name="dc.Creator" content="Luisa  Mengatto" /></meta><meta name="dc.Creator" content="Marco  Migliore" /></meta><meta name="dc.Creator" content="Fabio Maria  Sabbatini" /></meta><meta name="dc.Creator" content="Anna  Sava" /></meta><meta name="dc.Creator" content="Elena  Serra" /></meta><meta name="dc.Creator" content="Paolo  Vincetti" /></meta><meta name="dc.Creator" content="Mingliang  Zhang" /></meta><meta name="dc.Creator" content="Holly J.  Carlisle" /></meta><meta name="dc.Description" content="Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson’s disease in a dominantly inherited fashion. These pathogen..." /></meta><meta name="Description" content="Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson’s disease in a dominantly inherited fashion. These pathogen..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01243" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01243" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01243" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01243" /></link>
        
    
    

<title>Selective Inhibitors of G2019S-LRRK2 Kinase Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01243" /></meta><meta property="og:title" content="Selective Inhibitors of G2019S-LRRK2 Kinase Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0022.jpeg" /></meta><meta property="og:description" content="Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson’s disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01243"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01243&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01243&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01243&amp;href=/doi/10.1021/acs.jmedchem.0c01243" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14821-14839</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01215" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01345" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Selective Inhibitors of G2019S-LRRK2 Kinase Activity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Albert W. Garofalo</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Albert W. Garofalo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESCAPE Bio, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#076066756861666b686647627464667762656e682964686a"><span class="__cf_email__" data-cfemail="d4b3b5a6bbb2b5b8bbb594b1a7b7b5a4b1b6bdbbfab7bbb9">[email protected]</span></a>. Phone: 650-431-0140.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Albert+W.++Garofalo">Albert W. Garofalo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1837-417X" title="Orcid link">http://orcid.org/0000-0002-1837-417X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jessica Bright</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jessica Bright</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESCAPE Bio, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jessica++Bright">Jessica Bright</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stéphane De Lombaert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stéphane De Lombaert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESCAPE Bio, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=St%C3%A9phane++De+Lombaert">Stéphane De Lombaert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alyssa M. A. Toda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alyssa M. A. Toda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESCAPE Bio, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alyssa+M.+A.++Toda">Alyssa M. A. Toda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kerry Zobel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kerry Zobel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESCAPE Bio, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kerry++Zobel">Kerry Zobel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniele Andreotti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniele Andreotti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniele++Andreotti">Daniele Andreotti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claudia Beato</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudia Beato</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudia++Beato">Claudia Beato</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Silvia Bernardi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Silvia Bernardi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Bernardi">Silvia Bernardi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Federica Budassi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Federica Budassi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Federica++Budassi">Federica Budassi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laura Caberlotto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura Caberlotto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Caberlotto">Laura Caberlotto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peng Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peng Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, Tianjin 300456, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peng++Gao">Peng Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cristiana Griffante</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cristiana Griffante</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cristiana++Griffante">Cristiana Griffante</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinying Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinying Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, Tianjin 300456, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinying++Liu">Xinying Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luisa Mengatto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luisa Mengatto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luisa++Mengatto">Luisa Mengatto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marco Migliore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marco Migliore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marco++Migliore">Marco Migliore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabio Maria Sabbatini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabio Maria Sabbatini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabio+Maria++Sabbatini">Fabio Maria Sabbatini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Sava</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Sava</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Sava">Anna Sava</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Serra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Serra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Serra">Elena Serra</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paolo Vincetti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paolo Vincetti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Aptuit, an Evotec Company, Verona 37135, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Vincetti">Paolo Vincetti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingliang Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingliang Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, Tianjin 300456, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingliang++Zhang">Mingliang Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Holly J. Carlisle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Holly J. Carlisle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ESCAPE Bio, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Holly+J.++Carlisle">Holly J. Carlisle</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01243&amp;href=/doi/10.1021%2Facs.jmedchem.0c01243" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14821–14839</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 July 2020</li><li><span class="item_label"><b>Published</b> online</span>16 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01243" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01243</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14821%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlbert%2BW.%2BGarofalo%252C%2BJessica%2BBright%252C%2BSt%25C3%25A9phane%2BDe%2BLombaert%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01243%26title%3DSelective%2BInhibitors%2Bof%2BG2019S-LRRK2%2BKinase%2BActivity%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14839%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01243"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1804</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01243" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Selective Inhibitors of G2019S-LRRK2 Kinase Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Albert&quot;,&quot;last_name&quot;:&quot;W. Garofalo&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;Bright&quot;},{&quot;first_name&quot;:&quot;Stéphane&quot;,&quot;last_name&quot;:&quot;De Lombaert&quot;},{&quot;first_name&quot;:&quot;Alyssa&quot;,&quot;last_name&quot;:&quot;M. A. Toda&quot;},{&quot;first_name&quot;:&quot;Kerry&quot;,&quot;last_name&quot;:&quot;Zobel&quot;},{&quot;first_name&quot;:&quot;Daniele&quot;,&quot;last_name&quot;:&quot;Andreotti&quot;},{&quot;first_name&quot;:&quot;Claudia&quot;,&quot;last_name&quot;:&quot;Beato&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Bernardi&quot;},{&quot;first_name&quot;:&quot;Federica&quot;,&quot;last_name&quot;:&quot;Budassi&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Caberlotto&quot;},{&quot;first_name&quot;:&quot;Peng&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Cristiana&quot;,&quot;last_name&quot;:&quot;Griffante&quot;},{&quot;first_name&quot;:&quot;Xinying&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Mengatto&quot;},{&quot;first_name&quot;:&quot;Marco&quot;,&quot;last_name&quot;:&quot;Migliore&quot;},{&quot;first_name&quot;:&quot;Fabio&quot;,&quot;last_name&quot;:&quot;Maria Sabbatini&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Sava&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Serra&quot;},{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Vincetti&quot;},{&quot;first_name&quot;:&quot;Mingliang&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Holly&quot;,&quot;last_name&quot;:&quot;J. Carlisle&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14821-14839&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01243&quot;},&quot;abstract&quot;:&quot;Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson’s disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01243&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01243" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01243&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01243" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01243&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01243" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01243&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01243&amp;href=/doi/10.1021/acs.jmedchem.0c01243" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01243" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01243" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01243%26sid%3Dliteratum%253Aachs%26pmid%3D33197196%26genre%3Darticle%26aulast%3DGarofalo%26date%3D2020%26atitle%3DSelective%2BInhibitors%2Bof%2BG2019S-LRRK2%2BKinase%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14821%26epage%3D14839%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291012" title="Organic acids">Organic acids</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson’s disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is the most common form of parkinsonism and the second most common age-related neurodegenerative disease. It is estimated to affect about 1% of the population over age 65 with prevalence increasing with increasing age. It is a chronic disease marked by progressive disability and diminished quality of life. PD is characterized by motor symptoms that include resting tremor, rigidity, postural instability, impaired speech, and bradykinesia, which are predominantly driven by loss of dopaminergic neurons in the substantia nigra pars compacta. Non-motor symptoms including hyposmia, dysautonomia, and changes in sleep, cognition, and mood also occur with varying frequency. Current therapeutic strategies for PD are largely focused on controlling motor symptoms with dopamine replacement and by enhancing the activity of the remaining dopaminergic neurons. At present, no disease-modifying therapies exist that address the underlying neuropathological drivers of disease; this remains a significant unmet medical need for PD patients.</div><div class="NLM_p">It has long been known that family members of PD patients have an increased risk of developing the disease compared to the general population. In 2004, variants in the leucine-rich repeat kinase 2 (LRRK2) gene were shown to co-segregate with disease in familial PD.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> LRRK2 is a large, multidomain protein that is unusual for having two functional enzymatic domains: a Ras-like GTPase domain and a serine–threonine kinase domain. At least seven dominantly inherited pathogenic variants within LRRK2 have been identified. Of these, the G2019S variant occurring within the kinase domain is the most common, accounting for 4% of familial PD and up to 1% of apparently sporadic PD worldwide.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Interestingly, while some of the pathogenic variants are found within the kinase domain, all pathogenic variants have been reported to show increased autophosphorylation at S1292 when expressed in cells,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> implicating abnormal kinase activity as the likely cause of pathogenicity. LRRK2 kinase inhibition has therefore become a promising therapeutic strategy for PD, and several small-molecule LRRK2 kinase inhibitors are currently in clinical development.</div><div class="NLM_p last">While the therapeutic potential of LRRK2 kinase inhibitors is clear, this strategy is complicated by the potential for on-target safety liabilities associated with the loss of physiological LRRK2 activity. It has been found that LRRK2 has a role in mouse kidney and lung homeostasis, as implied in knockout and kinase-dead mutants.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Genetic knockout of LRRK2 in rodents causes vacuolization in specific cell types in kidney and lung, suggesting that normal LRRK2 plays a critical and nonredundant role in vesicular trafficking in those cell types in rodents.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Supporting these interpretations, pharmacological inhibition of LRRK2 kinase activity in rodents causes morphological changes in type II pneumocytes of the lung and proximal tubules in the kidney that are similar to those observed in knockout animals.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In nonhuman primates, strong inhibition of LRRK2 kinase activity also causes vacuolization in lung cells, although the effect is reversible and without apparent functional consequence over the duration tested.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, the safety risks associated with chronic LRRK2 kinase inhibition in humans cannot be fully assessed without long-term clinical observation. Because the majority of PD patients carrying the LRRK2-G2019S variant are heterozygous,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> a precision medicine approach of selectively targeting only the pathogenic activity while sparing the physiological LRRK2 activity could offer efficacy and safety advantages for this patient population.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We conducted a high-throughput screening campaign searching for inhibitors of G2019S-LRRK2 kinase activity on a 50K compound subset of the Aptuit library that was prioritized based on ligand efficiency.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> This set had generally lower molecular weight and better CNS multiparameter optimization (MPO) scores<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> as compared with the overall collection. Compounds that met a specified potency threshold in the primary screen were progressed to IC<sub>50</sub> determination in an 11-point biochemical concentration–response assay against both wild-type (WT) and G2019S-LRRK2 to confirm potency and assess selectivity. Out of this effort emerged indazole <b>1</b>, the single hit that exhibited a preference for inhibiting the G2019S mutant protein over WT protein by >10-fold.</div><div class="NLM_p">Lacking an X-ray crystal structure of LRRK2, we constructed a proprietary homology model of the kinase domain based on chimeric Aurora kinase A crystal structures where point mutations were introduced to mimic the LRRK2 hinge and glycine-rich loop regions combined. Mutated residues in the chimera included L210M, Y212L, P214S, and L215K in the hinge region and R137Q, P138L, K141D, K143S, and N146S in the glycine-rich loop. The homology model based on this chimera was then optimized to accommodate SAR observations. While not all of the structure–activity relationships described below were predicted by this model, certain aspects of the SAR were consistent with the general pose.</div><div class="NLM_p">Docking compound <b>1</b> in our homology model suggested that the indazole binds to the hinge, as shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. This pose agreed with our expectations as indazole is a privileged structure for kinase inhibitors and numerous crystal structures containing indazole ligands bound in the ATP site of kinases are available in the protein data bank (PDB). In the majority of these structures, the indazole functions as a hinge binder as demonstrated with the known LRRK2 inhibitor MLi-2.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In our model, N-1 of the indazole hydrogen bond donates to Glu1948 and N-2 accepts a hydrogen bond from Ala1950 within the ATP pocket. Our confidence in this binding mode was bolstered by the complete loss of activity  upon <i>N</i>-methylation of the indazole or replacement of the indazole with benzo[<i>d</i>]isoxazole (not shown). This binding pose suggested that substituents at the indazole C-3′ position  would be partially solvent-exposed and might therefore be used to modulate the properties of an inhibitor series. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, substitution of the available valence at C-3′ (R<sup>1</sup>) was tolerated and afforded a number of subnanomolar inhibitors. The addition of a methyl group (<b>2</b>) tripled the potency while maintaining selectivity. Larger groups afforded potencies of less than a nanomolar. The lower limit of reliable quantification of potency in the biochemical assay was ∼0.2 nM, and therefore, the actual IC<sub>50</sub> values for <b>4</b>, <b>6</b>, and <b>7</b> on G2019S-LRRK2 were likely lower than 0.2 nM. For compound <b>4</b>, potency against both mutant and WT was such that selectivity could not be accurately determined in the biochemical assays. In general, the preferred substitution at C-3′ tended to be an aromatic or heteroaromatic ring as demonstrated with analogues <b>3</b>–<b>7</b>. Other substituents such as bromine (<b>8</b>), carboxamide (<b>9</b>), and benzoylamine (<b>10</b>) also improved potency relative to compound <b>1</b>. However, not all substituents at C-3′ were found to increase potency, as is apparent with butanoylamine <b>11</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Homology model of the LRRK2 kinase domain depicting compound <b>1</b> docked into the ATP pocket. Principal hydrogen-bonding interactions involve both N-1 and N-2 of the indazole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biochemical Inhibitory Potency and Selectivity of C-7-Unsubstituted 4,7-Dihydrotetrazolo[1,5-<i>a</i>]pyrimidines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0016.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0017.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">In vitro biochemical (IVB) potency values are the geometric mean of a minimum of two IC<sub>50</sub> values determined in independent experiments. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">We also varied the methyl substituents on the dihydrotetrazolopyrimidine during our initial investigations. Removal of the C-5 methyl as in compound <b>12</b> completely abolished activity on both WT and G2019S-LRRK2. Single carbon homologation at C-5 (compound <b>13</b>) also had a detrimental effect on potency, as well as the preference for G2019S inhibition over WT. Similarly, homologation to the <i>N</i>-ethyltetrazolopyrimidine (compound <b>14</b>) decreased potency; however, in this case, selectivity was preserved. Though additional substituents were tried at N-4 (R<sup>3</sup>), none exhibited an improved combination of potency and selectivity over the methyl group found in <b>1</b> (<i>cf</i>. compounds <b>15</b>–<b>18</b>).</div><div class="NLM_p">In an effort to better understand key interacting elements in these inhibitors, we examined the role of the amide by preparing the <i>N</i>-methylamide <b>19</b> and thioamide <b>20</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). <i>N</i>-Methylation of the amide resulted in complete loss of activity, suggesting a potentially important hydrogen-bonding interaction with the amide NH occurring within the binding pocket. Of course, other factors such as a change in molecular conformational or an unfavorable steric interaction cannot be ruled out. Since thioamides are known to be weaker hydrogen bond acceptors than amides,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> the lack of any reduction in activity observed for compound <b>20</b> coupled with maintenance of  selectivity for G2019S-LRRK2 inhibition suggested that the carbonyl oxygen is not involved in critical hydrogen bonding.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Amide substitutions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We further elaborated the dihydrotetrazolopyrimidine by incorporating substituents at C-7 (R<sup>2</sup> and R<sup>3</sup>), as shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Addition of a single methyl group at C-7 of (<i>R</i>)-configuration, compound <b>21</b>, improved inhibition of both WT and G2019S-LRRK2 but most importantly increased the G2019S over WT selectivity to 43-fold. The (<i>S</i>)-enantiomer, <b>22</b>, had the opposite effect on both potency and selectivity. The same pattern with respect to potency was also observed with compounds <b>23</b> and <b>24</b>. The previously demonstrated increases in potency with 3-(pyridin-4-yl) and 3-(2-morpholinopyridin-4-yl) indazole were preserved in compounds <b>25</b>–<b>27</b>, although biochemical selectivity could not be accurately determined due to the above-described assay limitations.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biochemical Inhibitory Potency and Selectivity of C-7-Substituted 4,7-Dihydrotetrazolo[1,5-<i>a</i>]pyrimidines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0018.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0019.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">In vitro biochemical (IVB) potency values are the geometric mean of a minimum of two IC<sub>50</sub> values determined in independent experiments. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">The synthesis of compounds <b>21</b>–<b>27</b> employed commercially available, racemic 4,7-dihydro-4,5,7-trimethyltetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic acid (<b>32</b>), which was separated into its individual enantiomers by chiral high-performance liquid chromatography (HPLC). To determine the absolute configuration of these inhibitors, we prepared <b>21</b> and <b>22</b> from the resolved carboxylic acids. A small-molecule X-ray crystallographic analysis of the carboxylic acid used to prepare the eutomer, <b>21</b>, was obtained and indicated the (<i>R</i>)-stereochemistry assigned to this compound (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0004.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Determination of absolute stereochemistry from chiral carboxylic acids. (a) Chiral HPLC separation using an (R,R)-Whelk-O 1 column (25 cm × 2 cm), 10 μm, eluting with 40:60 <i>n</i>-hexane:EtOH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also looked at  geminal substitution on the dihydropyrimidine, which afforded compounds with greatly increased preference for inhibition of the G2019S protein. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compound <b>28</b> is 108-fold more potent against G2019S-LRRK2 than WT. The selectivity obtained with geminal substitution appears to result from decreased affinity for binding in the WT ATP-binding pocket rather than a significantly increased affinity for the G2019S ATP-binding pocket. As before, adding substituents to the indazole, as in compounds <b>29</b>–<b>31</b>, boosted the potency of these inhibitors. In the case of compound <b>29</b>, methyl substitution at the indazole C-3 afforded a subnanomolar inhibitor with 190-fold selectivity. Aryl substituted  compounds, <b>30</b> and <b>31</b>,  were too potent in our assay to gauge their biochemical selectivity. However, selectivity of these two analogues was confirmed by cellular activity assays (vide infra).</div><div class="NLM_p">During the course of our investigations, we also evaluated the effects of replacing the indazole with other known hinge binders and related bicycles (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Replacing the indazole with either indole, as in compound <b>33</b>, or benzimidazole, compound <b>34</b>, resulted in complete loss of activity against both WT and G2019S-LRRK2. Imidazopyridines <b>35</b> and <b>36</b> were also ineffective replacements for indazole (<i>cf</i>. compound <b>2</b>) as was indolinone <b>37</b>. Interesting results were observed with benzimidazolones <b>38</b>–<b>40</b>. Analogue <b>38</b> exhibited >36-fold selectivity but lost potency relative to compound <b>1</b>. Alkylation of the cyclic urea afforded compounds with quite different profiles. Analogue <b>39</b> lost all activity against both WT and G2019S-LRRK2, likely due to an unfavorable steric interaction with the hinge, while analogue <b>40</b> was both potent against G2019S-LRRK2 and very selective. Phthalimide <b>41</b> had a potency and selectivity profile similar to <b>40</b>, as did isoindolinone <b>42</b>. The most successful indazole replacement was 1-aminoisoquinoline. Compound <b>43</b> had equivalent selectivity compared with compound <b>21</b> with a G2019S-LRRK2 IC<sub>50</sub> = 12 nM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biochemical Potency and Selectivity of LRRK2 Inhibitors with Alternative Hinge Binders</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0020.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0021.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">In vitro biochemical (IVB) potency values are the geometric mean of a minimum of two IC<sub>50</sub> values determined in independent experiments. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">We profiled a number of these inhibitors for potency and selectivity in cellular assays (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Inhibition of phosphorylation at two sites on LRRK2, S935, and S1292 was measured in HEK293 cell lines stably overexpressing human WT or G2019S-LRRK2. S1292 is an autophosphorylation site that is positively correlated with  LRRK2 kinase activity.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Although this is not the case with S935, which is more highly phosphorylated on the inactive fraction of LRRK2 in cells, S935 nonetheless becomes dephosphorylated in response to inhibitor binding and is therefore a useful pharmacodynamic marker.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Inhibitor IC<sub>50</sub> values determined using pS935 and pS1292 on G2019S-LRRK2 were well correlated. For WT-LRRK2, IC<sub>50</sub> values measured on pS935 were consistently higher than those measured on pS1292, resulting in a trend toward greater selectivity on pS935.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Cellular Potencies for Inhibition of pS935-LRRK2, pS1292-LRRK2, and pThr73-Rab10</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">pS935-LRRK2<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="3" align="center">pS1292-LRRK2<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" colspan="3" align="center">pThr73-Rab10<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">WT IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">G2019S IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ratio WT/G2019S</th><th class="colsep0 rowsep0" align="center">WT IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">G2019S IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ratio WT/G2019S</th><th class="colsep0 rowsep0" align="center">WT IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">G2019S IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">ratio WT/G2019S</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">377</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">74.4</td><td class="colsep0 rowsep0" align="left">9.2</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">3300</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">157</td><td class="colsep0 rowsep0" align="left">242</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">189</td><td class="colsep0 rowsep0" align="left">>53</td><td class="colsep0 rowsep0" align="left">2180</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">5220 (8743)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">46.1 (106)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">113 (82)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">380</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">9736</td><td class="colsep0 rowsep0" align="left">137</td><td class="colsep0 rowsep0" align="left">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">1140</td><td class="colsep0 rowsep0" align="left">14.7</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">272</td><td class="colsep0 rowsep0" align="left">12.1</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">20.9</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">145 (259)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">1.1 (1.5)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">132 (173)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">33.7</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">473</td><td class="colsep0 rowsep0" align="left">4.7</td><td class="colsep0 rowsep0" align="left">101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">1060 (2092)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.1 (2.5)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">339 (837)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">117</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">3924</td><td class="colsep0 rowsep0" align="left">11.4</td><td class="colsep0 rowsep0" align="left">344</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Cellular potencies are reported as the geometric mean of a minimum of two IC<sub>50</sub> values determined in independent experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Potency on pS935-LRRK2 was measured with a fluorescence resonance energy-transfer (FRET)-based assay.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">pS1292-LRRK2 was measured with a Meso Scale Discovery (MSD) electrochemiluminescence assay.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">pThr73-Rab10 inhibition was measured with an immunoblot-based assay.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">pS935 IC<sub>50</sub> and selectivity values shown in parentheses were determined with an immunoblot-based assay performed on the same cell lysates that were evaluated in the pThr73-Rab10 assay. ND = not determined.</p></div></div></div><div class="NLM_p">Inhibition of LRRK2 phosphotransferase activity to an endogenously expressed substrate, Rab10, was assessed for three of the most potent and selective inhibitors (<b>23</b>, <b>30</b>, and <b>31</b>) in cell lines overexpressing either WT-LRRK2 or G2019S-LRRK2 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Potency and selectivity in the pThr-Rab10 assay were well aligned with the inhibition of pS935-LRRK2 in the same cell lines. Compound <b>31</b> (EB-42486) exhibited a WT/G2019S selectivity ratio of >300-fold on pS935-LRRK2 and on the substrate pThr73-Rab10 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In contrast, the nonselective inhibitor, MLi-2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), showed no preference for the G2019S-LRRK2 variant. The level of selectivity exhibited by compound <b>31</b> is remarkable, given that G2019S-LRRK2 differs from WT-LRRK2 by only a single amino acid within the ATP-binding pocket. This compound was also profiled at 100 nM (>500-fold biochemical G2019S IC<sub>50</sub>) against a panel of 409 kinases using a commercial, active site-directed competition binding assay to determine its kinome selectivity. Even at this high concentration relative to its on-target potency, compound <b>31</b> exhibited impressive kinome selectivity in this panel, with only six kinases being highly inhibited: HPK1, JNK1, JNK2, JNK3, TTK, and YSK4.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0005.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of pThr73-Rab10 in HEK293 cell lines overexpressing either WT-LRRK2 or G2019S-LRRK2. (A) Compound <b>31</b> inhibited phosphorylation of the LRRK2 substrate, Rab10, 344-fold more potently in the G2019S-LRRK2 overexpression line (IC<sub>50</sub> = 11.4 ± 1.1 nM, <i>n</i> = 3) compared to that in the WT-LRRK2 overexpression line (IC<sub>50</sub> = 3,924 ± 1.6 nM, <i>n</i> = 3). (B) MLi-2 showed similar potency on pThr73-Rab10 in both cell lines (HEK/G2019S-LRRK2 IC<sub>50</sub> = 8.5 ± 1.3 nM, <i>n</i> = 3; HEK/WT-LRRK2 IC<sub>50</sub> = 12.5 ± 1.1 nM, <i>n</i> = 3). (C) Compound <b>31</b> inhibited pS935-LRRK2 837-fold more potently in the G2019S-LRRK2 line (IC<sub>50</sub> = 2.5 ± 1.1 nM, <i>n</i> = 3) compared to that in the WT-LRRK2 line (IC<sub>50</sub> = 2,092 ± 1.4 nM, <i>n</i> = 3). (D) MLi-2 showed similar potency on pS935-LRRK2 in both cell lines (HEK/G2019S-LRRK2 IC<sub>50</sub> = 2.8 ± 1.2 nM, <i>n</i> = 3; HEK/WT-LRRK2 IC<sub>50</sub> = 3.9 ± 1.1 nM, <i>n</i> = 3). Potency is reported as the geometric mean of IC<sub>50</sub> values ± geometric standard deviation. Error bars show standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In general, the compounds described herein were found to have disappointing in vitro absorption, distribution, metabolism, and excretion (ADME) properties (e.g., low solubility, substrates for efflux transporters). However, it was desirable to develop in vitro–in vivo correlations during the early stage of our explorations, and based on the exceptional potency and selectivity for G2019S-LRRK2 measured in cellular activity assays, analogue <b>31</b> was selected for pharmacokinetic (PK) profiling in CD-1 mice (summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Following a single 2 mg/kg oral dose in fasted mice, a mean maximum plasma concentration of 0.299 μM was measured approximately 30 min post dose. The mean residence time (MRT) after oral dosing was 2.89 h. The compound exhibited moderate clearance, which was commensurate with an IV half-life of 0.87 h, and  reasonable oral bioavailability of ∼40% was observed. Bioanalytical assessment of brain tissue after 2 mg/kg oral dosing showed no compound exposure in the brain. This observation was consistent with in vitro experiments in MDCKII-MDR1 cells indicating that <b>31</b> is subject to P-glycoprotein-mediated efflux.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of 31 (EB-42486) in Fasted CD-1 Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">IV administration<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (0.5 mg/kg)</th><th class="colsep0 rowsep0" align="center">oral administration<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (2 mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM/h)</td><td class="colsep0 rowsep0" align="left">0.528 ± 0.023</td><td class="colsep0 rowsep0" align="left">0.847 ± 0.060</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="left">0.615 ± 0.029<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.299 ± 0.024</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.50 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.87 ± 0.09</td><td class="colsep0 rowsep0" align="left">1.85 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h)</td><td class="colsep0 rowsep0" align="left">1.14 ± 0.12</td><td class="colsep0 rowsep0" align="left">2.89 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">38.1 ± 1.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">40.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Dosed as a solution of the free base (0.25 mg/mL) in a mixture of dimethyl sulfoxide (DMSO), solutol, and water (5:5:90).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Dosed as a fine suspension of the free base (0.2 mg/mL) in a mixture of DMSO, solutol, and water (5:5:90).</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Initial concentration. MRT, mean residence time; <i>F</i>, bioavailability.</p></div></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Synthetic Chemistry</h3><div class="NLM_p">Compounds <b>1</b> and <b>2</b> were prepared by coupling commercially available aminoindazoles with carboxylic acid <b>49</b>. Compounds <b>3</b>–<b>5</b>, <b>7</b>–<b>8</b>, and <b>13</b>–<b>17</b> were prepared as shown for compound <b>3</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Suzuki–Miyaura cross-coupling of 3-bromo-5-nitroindazole (<b>44</b>) with 4-pyridylboronic acid, followed by reduction of the nitro group afforded aminoindazole <b>46</b>. Separately, the Biginelli reaction<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> was employed to form tetrazolo[1,5-<i>a</i>]pyrimidine <b>48</b>, which was hydrolyzed to give carboxylic acid <b>49</b>. T3P-mediated coupling of aminoindazole <b>46</b> and carboxylic acid <b>49</b> afforded inhibitor <b>3</b>. Compounds <b>6</b> and <b>9</b>–<b>11</b> were prepared as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> for compound <b>6</b>. Compound <b>18</b> was prepared as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Ester <b>48</b> was treated with allyl bromide and hydrolyzed to give carboxylic acid <b>53</b>. Coupling of <b>53</b> with 1<i>H</i>-indazol-5-amine followed by deprotection and acylation gave <b>18</b>.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Inhibitor <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) 4-pyridylboronic acid, KOAc, Pd(amphos)Cl<sub>2</sub>, EtOH, 100 °C; (b) Zn, NH<sub>4</sub>Cl, EtOH, 80 °C, 56%, two steps; (c) EtOAc, formaldehyde (37 wt % in H<sub>2</sub>O), AcOH, EtOH, 120 °C, microwave, 62%; (d) MeI, Cs<sub>2</sub>CO<sub>3</sub>, 50 °C; (e) LiOH, EtOH, tetrahydrofuran (THF), H<sub>2</sub>O, 55 °C, 59%, two steps; and (f) T3P, EtOAc, Et<sub>3</sub>N, 15 °C or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), pyridine, 30 °C, 5%.</p></p></figure><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Inhibitor <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) <b>49</b>, T3P, Et<sub>3</sub>N, EtOAc, 60 °C, 16%; and (b) (4-sulfamoylphenyl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF), H<sub>2</sub>O, 100 °C, 16%.</p></p></figure><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Inhibitor <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) allyl bromide, NaH, THF, 15 °C, 27%; (b) LiOH·H<sub>2</sub>O, EtOH, H<sub>2</sub>O, 15 °C, 66%; (c) 1<i>H</i>-indazol-5-amine, T3P, EtOAc, Et<sub>3</sub>N, 20 °C, 50%; (d) 1,3-dimethylbarbituric acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, DCM, EtOH, 55 °C, 57%; and (e) CH<sub>3</sub>COCl, Et<sub>3</sub>N, DCM, 15 °C, 6%.</p></p></figure><div class="NLM_p">The <i>N</i>-methylamide, <b>19</b>, and the thioamide, <b>20</b>, were prepared as shown in <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Amide bond coupling between 5-methylamino indazole, <b>56</b>, and carboxylic acid <b>49</b> gave <b>19</b> and treatment of compound <b>1</b> with Lawesson’s reagent afforded <b>20</b>.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-Methyl Amide <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU), DMF, Et<sub>3</sub>N, 21%.</p></p></figure><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Thioamide <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) Lawesson’s reagent, dioxane, 18 h, 100 °C, 3%.</p></p></figure><div class="NLM_p">Compounds <b>21</b>–<b>25</b> were prepared by coupling either <b>(</b><i><b>R</b></i><b>)-32</b> or <b>(</b><i><b>S</b></i><b>)-32</b> with commercially available 5-aminoindazoles.</div><div class="NLM_p">The synthesis of compounds <b>26</b> and <b>27</b> is shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The pinacolborane, <b>58</b>, was prepared in two steps from 3-bromo-5-nitro-1<i>H</i>-indazole (<b>44</b>). Suzuki–Miyaura cross-coupling with 4-(4-bromopyridin-2-yl)morpholine followed by nitro group reduction gave amine <b>60</b>. Amide bond coupling with <b>(</b><i><b>R</b></i><b>)-32</b> afforded <b>61</b>. Treatment of <b>61</b> with 4 M HCl successfully removed the SEM protecting group but also caused racemization of the chiral center. The enantiomeric pairs, <b>26</b> and <b>27</b>, were then isolated using chiral chromatography.</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Inhibitors <b>26</b> and <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) SEM-Cl, NaH, DMF, 0 °C - r.t., 60%; (b) bis(pinacolato)diboron, KOAc, 1,4-dioxane, Pd(dppf)Cl<sub>2</sub>, 100 °C; (c) 4-(4-bromopyridin-2-yl)morpholine, Cs<sub>2</sub>CO<sub>3</sub>, THF, water, Pd(dppf)Cl<sub>2</sub>, 100 °C, 44%, two steps; (d) NH<sub>4</sub>Cl, Fe, EtOH, water, 80 °C, 80%; (e) <b>(</b><i><b>R</b></i><b>)-32</b>, Et<sub>3</sub>N, HATU, DMF, 0 °C - r.t., 33%; (f) 4 M HCl, dioxane, THF, r.t., 18%; and (g) chiral chromatography.</p></p></figure><div class="NLM_p">The gem-dimethyl-4,7-dihydrotetrazolopyrimidines <b>28</b>–<b>31</b> were prepared as shown for compound <b>28</b> in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Condensation of aminotetrazole with methyl 2-acetyl-3-methyl-2-butenoate afforded tetrazolopyrimidine <b>64</b>. <i>N</i>-Methylation with MeI followed by LiOH hydrolysis gave carboxylic acid <b>66</b>, which was coupled with <i>N</i>-(1)-Boc-5-aminoindazole and deprotected to afford compound <b>28</b>.</div><figure id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Inhibitor <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) EtOH, 4 Å molecular sieves, reflux, 56%; (b) MeI, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 97%; (c) LiOH, THF; (d) <i>N</i>-(1)-Boc-5-aminoindazole, HATU, Et<sub>3</sub>N, DMF, r.t.; and (e) trifluoroacetic acid (TFA), DCM, 0 °C - r.t., 4%, three steps.</p></p></figure><div class="NLM_p">Compounds <b>33</b>, <b>34</b>, <b>37</b>, <b>38</b>, <b>39</b>, and <b>40</b> were similarly prepared using commercially available amine and carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b>. Compound <b>35</b> was prepared as shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Bromination of 2-methyl-5-nitropyridine (<b>68</b>) gave bromide <b>69</b>. Formation of amine <b>70</b> with NH<sub>4</sub>OH followed by cyclization with Ac<sub>2</sub>O and nitro group reduction afforded 3-methylimidazo[1,5-<i>a</i>]pyridin-6-amine (<b>72</b>), which was then coupled with carboxylic acid <b>49</b> to yield compound <b>35</b>.</div><figure id="sch8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Inhibitor <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) 2-methyl-5-nitropyridine, <i>N</i>-bromosuccinimide (NBS), benzoyl peroxide, CCl<sub>4</sub>, 80 °C, 31%; (b) NH<sub>4</sub>OH, dioxane, 25 °C; (c) Ac<sub>2</sub>O, PTSA, 100 °C, 32%, two steps; (d) H<sub>2</sub>, 10% Pd/C, MeOH, 25 °C; and (e) <b>49</b>, HATU, <i>i</i>-Pr<sub>2</sub>NEt, DMF, 25 °C, 16%, two steps.</p></p></figure><div class="NLM_p">Compound <b>36</b> was prepared as shown in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a> starting from 4-bromopyridine-2-carbonitrile (<b>73</b>). Grignard addition followed by concomitant reduction of the imine with NaBH<sub>4</sub> gave amine <b>74</b>. Formation of the formamide and cyclization with POCl<sub>3</sub> gave imidazopyridine <b>76</b>. Coupling of <b>76</b> with amide <b>77</b> afforded compound <b>36</b>.</div><figure id="sch9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Inhibitor <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) MeMgBr, NaBH<sub>4</sub>, THF, MeOH, 25 °C, 94%; (b) ethyl formate, AlMe<sub>3</sub>, toluene, 90 °C, 10%; (c) POCl<sub>3</sub>, toluene, 80 °C, 93%; (d) CDI, NH<sub>3</sub>·H<sub>2</sub>O, THF, 20 °C, 5%; and (e) Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, dioxane, 90 °C, 2%.</p></p></figure><div class="NLM_p">The synthesis of compound <b>43</b> is summarized in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>. Boc protection of 6-nitroisoquinolin-1-amine (<b>78</b>) followed by reduction of the nitro group, coupling with carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b>, and deprotection yielded target <b>43</b>.</div><figure id="sch10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0015.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Inhibitor <b>43</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) (Boc)<sub>2</sub>O, 4-dimethylaminopyridine (DMAP), CH<sub>3</sub>CN, 70 °C, 70%; (b) H<sub>2</sub>, 10% Pd/C, EtOH, r.t., 97%; (c) <b>(</b><i><b>R</b></i><b>)-32</b>, EDCI, DMAP, pyridine, 70 °C, 93%; and (d) TFA, DCM, r.t, 51%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Our efforts to find G2019S-LRRK2 selective inhibitors for a targeted therapeutic approach in a genetically defined PD patient population have resulted in the discovery of compound <b>31</b> (EB-42486). Employing a ligand-based drug design approach starting from a single HTS hit led to a series of potent and highly selective G2019S-LRRK2 inhibitors, as measured in a biochemical and confirmed by several cellular assays. To the best of our knowledge, this is the first identification of small molecules that can precisely target a prominent pathogenic mutation in LRRK2. Though only a single amino acid within the ATP-binding pocket differentiates WT from G2019S-LRRK2, selectivity of >200-fold for biochemical kinase activity and >300-fold for cellular activity on an endogenously expressed substrate have been demonstrated. While compounds disclosed herein were found to be poorly brain-penetrant, the initial SAR emerging from the investigation of this class of compounds constitutes a promising starting point for the continued, focused development of additional G2019S-LRRK2 selective compounds with improved pharmacokinetic properties.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Materials and Methods</h3><div class="NLM_p">Reagents and solvents were obtained from commercial sources and used as supplied. <sup>1</sup>H NMR spectra were recorded on either a Bruker Avance 400, a Bruker Avance III 400, or an Agilent Direct Drive spectrometer. The spectra were acquired in the stated solvent, and chemical shifts (δ) are reported in ppm relative to the residual solvent peak. Chemical shifts are given in parts per million using conventional abbreviations for designation of major peaks, e.g., s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; br, broad. Mass spectrometry was performed using an ultraperformance liquid chromatography/mass spectrometry (UPLC/MS) AcquityTM system equipped with a PDA detector and coupled to a Waters single quadrupole mass spectrometer. Where thin-layer chromatography (TLC) has been used, <i>R<sub>f</sub></i> is the distance traveled by the compound divided by the distance traveled by the solvent on a TLC plate. Chiral SFC separation was performed using a Thar SFC Prep 80 instrument and a Phenomenex Lux Cellulose-2 column (250 mm ×25 mm, 10 μm). Purities of all target compounds were greater than 95% as determined by HPLC analysis. Compounds were analyzed for and found not to contain pan assay interference (PAINS) substructural features.</div><div class="NLM_p">All experiments utilizing animals were conducted under protocols approved by the WuXi Institutional Animal Care and Use Committee (IACUC).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-4,5-dimethyl-4<i>H</i>,7<i>H</i>-[1,2,3,4]tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>1</b>)</h4><div class="NLM_p last">Carboxylic acid <b>49</b> (110 mg, 0.43 mmol) was dissolved in 3 mL of DMF. Et<sub>3</sub>N (119 μL, 0.85 mmol), 1<i>H</i>-indazol-5-amine (113 mg, 0.85 mmol), and HATU (194 mg, 0.51 mmol) were added at 0 °C, and the reaction mixture was stirred at 0 °C for 2 h. The solvent was evaporated, and the residue was taken up in CH<sub>3</sub>CN (1 mL with 0.1% formic acid) and then purified by reversed-phase column chromatography using a 2–10% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent to give a purple solid (22 mg) of insufficient purity. The material was then further purified by silica gel chromatography using a 0–10% MeOH/EtOAc gradient eluent to afford <b>1</b> as a pale pink solid (4.1 mg, 2%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.99 (br s, 1H), 9.99 (s, 1H), 8.14 (s, 1H), 8.04 (s, 1H), 7.44–7.55 (m, 2H), 5.28 (s, 2H), 3.43 (s, 3H), 2.25 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 311.1. Found 311.0.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4,5-Dimethyl-<i>N</i>-(3-methyl-2<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>2</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>49</b> in 2 mL of DCM were added (COCl)<sub>2</sub> (98 mg, 770 μmol) and one drop of DMF. The mixture was stirred at 25 °C for 30 min and concentrated to afford 4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carbonyl chloride as a yellow solid. Next, a solution of 3-methyl-1<i>H</i>-indazol-5-amine (70 mg, 475.62 μmol) in pyridine (1 mL) was cooled to 0 °C and then 4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carbonyl chloride (122 mg, 571 μmol) in CH<sub>3</sub>CN (0.2 mL) was added dropwise to the solution. The resulting mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (0.1% TFA) to afford <b>2</b> (36.9 mg, 17%) as a solid, pale yellow TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.58 (br s, 1H), 9.95 (s, 1H), 8.08 (s, 1H), 7.46–7.38 (m, 2H), 5.28 (s, 2H), 3.43 (s, 3H), 2.45 (s, 3H), 2.25 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.1. Found 325.1.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4,5-Dimethyl-<i>N</i>-(3-(pyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>3</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>49</b> (100 mg, 512 μmol) in DCM (5 mL) was added T3P (50 wt % in EtOAc, 0.457 mL, 768 μmol) and Et<sub>3</sub>N (156 mg, 1.54 mmol) followed by amine <b>46</b> (118 mg, 564 μmol). The reaction mixture was stirred at 15 °C for 12 h and concentrated. The mixture was purified by preparative HPLC (neutral) and further purified by additional preparative HPLC (0.1% TFA) to afford <b>3</b> (14 mg, 5%) as a light-yellow, solid TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.99 (s, 1H), 10.16 (s, 1H), 8.88 (d, <i>J</i> = 6.0 Hz, 2H), 8.68 (s, 1H), 8.26 (d, <i>J</i> = 6.0 Hz, 2H), 7.59–7.76 (m, 2H), 5.32 (s, 2H), 3.46 (s, 3H), 2.29 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>18</sub>N<sub>9</sub>O [M + H]<sup>+</sup>: 388.2. Found: 388.1.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4,5-Dimethyl-<i>N</i>-(3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>4</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>49</b> (100 mg, 512 μmol) in DCM (3 mL) were added T3P (50 wt % in EtOAc, 424 mg, 666 μmol), Et<sub>3</sub>N (156 mg, 1.54 mmol), and 3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-amine (182 mg, 615 mmol). The mixture was stirred at 15 °C for 12 h. The residue was purified by preparative HPLC to afford <b>4</b> (41 mg, 15%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.44 (s, 1H), 10.06 (s, 1H), 8.52 (s, 1H), 8.28 (d, <i>J</i> = 5.1 Hz, 1H), 7.58–7.66 (m, 2H), 7.28 (s, 1H), 7.22 (d, <i>J</i> = 5.3 Hz, 1H), 5.30 (s, 2H), 3.72–3.77 (m, 4H), 3.50–3.55 (m, 4H), 3.44 (s, 3H), 2.27 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>23</sub>H<sub>25</sub>N<sub>10</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 473.2. Found: 473.3.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4,5-Dimethyl-<i>N</i>-(3-(6-morpholinopyrimidin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>5</b>)</h4><div class="NLM_p last">A mixture of 3-(6-morpholinopyrimidin-4-yl)-1<i>H</i>-indazol-5-amine (150 mg, 507 μmol), carboxylic acid <b>49</b> (66 mg, 338 μmol), Et<sub>3</sub>N (103 mg, 1.01 mmol, 141 μL), and T3P (50 wt % in EtOAc, 258 mg, 406 μmol, 241 μL) in DCM (2 mL) was degassed and purged with N<sub>2</sub> (3×); then, the mixture was stirred at 20 °C for 12 h under a N<sub>2</sub> atmosphere. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (0.1% TFA) to afford <b>5</b> (11 mg, 5%) as a solid, red TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.81 (s, 1H), 10.12 (s, 1H), 8.74–8.69 (m, 2H), 7.74–7.68 (m, 1H), 7.66–7.60 (m, 1H), 7.44–7.40 (m, 1H), 5.30 (s, 2H), 3.76 (d, <i>J</i> = 8.6 Hz, 8H), 3.43 (s, 3H), 2.27 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>22</sub>H<sub>23</sub>N<sub>11</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 474.2. Found 474.2.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4,5-Dimethyl-<i>N</i>-(3-(4-sulfamoylphenyl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>6</b>)</h4><div class="NLM_p last">To a solution of bromoindazole <b>51</b> (50.0 mg, 128 μmol) and (4-sulfamoylphenyl)boronic acid (25.8 mg, 128 μmol) in 2 mL of DMF and 0.5 mL of H<sub>2</sub>O were added tetrakis(triphenylphosphine)palladium(0) (14.8 mg, 12.9 μmol) and Na<sub>2</sub>CO<sub>3</sub> (41 mg, 385 μmol). The mixture was stirred at 100 °C for 12 h under a N<sub>2</sub> atmosphere. The reaction mixture was filtered, and the filtrate was concentrated to give a residue. The residue was purified by preparative HPLC (0.1% TFA) to afford <b>6</b> (12 mg, 16%) as a solid, white TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.44 (s, 1H), 10.06 (s, 1H), 8.50 (s, 1H), 8.10 (m, <i>J</i> = 8.6 Hz, 2H), 7.97 (m, <i>J</i> = 8.6 Hz, 2H), 7.61 (s, 2H), 7.42 (s, 2H), 5.30 (s, 2H), 3.44 (s, 3H), 2.25–2.29 (m, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>9</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: 466.1. Found: 466.1.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-(1<i>H</i>-Benzo[<i>d</i>]imidazol-2-yl)-1<i>H</i>-indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>7</b>)</h4><div class="NLM_p last">To a solution of 3-(1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-1<i>H</i>-indazol-5-amine (60.0 mg, 240.7 μmol) and carboxylic acid <b>49</b> (46.98 mg, 240.7 μmol) in pyridine (1 mL) was added EDCI (69.21 mg, 361.05 μmol). The reaction mixture was stirred at 30 °C for 12 h and then concentrated. The residue was purified by prep-HPLC (neutral) to afford the product (27.6 mg, 25%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.75–13.47 (m, 1H), 13.11–12.85 (m, 1H), 10.15 (s, 1H), 8.76 (s, 1H), 7.82–7.46 (m, 4H), 7.27–7.17 (m, 2H), 5.33 (s, 2H), 3.44 (s, 3H), 2.29 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>21</sub>H<sub>19</sub>N<sub>10</sub>O [M + H]<sup>+</sup>: 427.2. Found 427.1.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(3-Bromo-1<i>H</i>-indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>8</b>)</h4><div class="NLM_p last">To a solution of 3-bromo-1<i>H</i>-indazol-5-amine (30 mg, 141 μmol) and carboxylic acid <b>49</b> (28 mg, 141 μmol) in 2 mL of EtOAc were added T3P (50 wt % in EtOAc, 270 mg, 424 μmol, 252 μL) and Et<sub>3</sub>N (57 mg, 565 μmol, 79 μL). The mixture was stirred at 60 °C for 12 h. The reaction mixture was then concentrated under reduced pressure to remove the solvent. The residue was purified by preparative HPLC (0.1% TFA) to afford <b>8</b> (9 mg, 15%) as a yellow, solid TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.18–13.54 (m, 1H), 10.09 (s, 1H), 8.08 (s, 1H), 7.51–7.59 (m, 2H), 5.29 (s, 2H), 3.43 (s, 3H), 2.26 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>14</sub>H<sub>14</sub>BrN<sub>8</sub>O [M + H]<sup>+</sup>: 389.0. Found: 389.0.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(3-Carbamoyl-1<i>H</i>-indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>9</b>)</h4><div class="NLM_p last">To a solution of 5-amino-1<i>H</i>-indazole-3-carboxamide (120 mg, 681 μmol) in DCM (4 mL) were added T3P (50 wt % in EtOAc, 650 mg, 1.02 mmol, 607 μL) and carboxylic acid <b>49</b> (133 mg, 681 μmol). The reaction mixture was stirred at 15 °C for 30 min and then Et<sub>3</sub>N (344 mg, 3.41 mmol, 474 μL) was added, and the reaction mixture was stirred at 15 °C for 12 h. The reaction mixture was concentrated to give a residue, and the residue was purified by preparative HPLC (0.1% TFA) to afford <b>9</b> (23 mg, 7%) as a white, solid TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.48 (s, 1H), 10.02 (s, 1H), 8.50 (s, 1H), 7.75–7.61 (m, 2H), 7.56 (d, <i>J</i> = 8.8 Hz, 1H), 7.32 (s, 1H), 5.29 (s, 2H), 3.43 (s, 3H), 2.26 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>16</sub>N<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 354.13. Found 354.1.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(3-Benzamido-2<i>H</i>-indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>10</b>)</h4><div class="NLM_p last">To a stirred solution of N-(5-amino-1<i>H</i>-indazol-3-yl)benzamide (100 mg, 396 μmol) and carboxylic acid <b>49</b> (77.4 mg, 396 μmol) in 2 mL of DCM were added T3P (50 wt % in EtOAc, 757 mg, 1.19 mmol, 707 μL) and Et<sub>3</sub>N (160.45 mg, 1.59 mmol, 220.70 μL). The reaction mixture was then stirred at 25 °C for 12 h and concentrated. The residue was purified by preparative HPLC (neutral) to afford <b>10</b> (11.51 mg, 6%) as a colorless gum. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.97 (s, 1H) 7.94–8.09 (m, 3H) 7.43–7.62 (m, 5H) 5.24 (s, 2H) 3.39 (s, 3H) 2.21 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>21</sub>H<sub>20</sub>N<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 430.2. Found 430.2.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-Butyramido-2<i>H</i>-indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>11</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-(5-amino-1<i>H</i>-indazol-3-yl)butyramide (70 mg, 320 μmol) in 5 mL of DCM were added T3P (50 wt % in EtOAc, 408 mg, 641 μmol, 381 μL), carboxylic acid <b>49</b> (68.9 mg, 352 μmol), and Et<sub>3</sub>N (97.4 mg, 962 μmol, 134 μL). The mixture was stirred at 40 °C for 12 h and concentrated. The residue was dissolved in DMF (2 mL) and purified by preparative HPLC (0.04% NH<sub>4</sub>OH/10 mM NH<sub>4</sub>HCO<sub>3</sub>) to afford <b>11</b> (14.5 mg, 11%) as a yellow gum. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.60 (s, 1H), 10.22 (s, 1H), 9.97 (s, 1H), 7.99 (s, 1H), 7.55 (br d, <i>J</i> = 8.68 Hz, 1H) 7.40 (d, <i>J</i> = 8.93 Hz, 1H), 5.28 (s, 2H), 3.43 (s, 3H), 2.34–2.40 (m, 2H), 2.25 (s, 3H), 1.66 (sxt, <i>J</i> = 7.29 Hz, 2H), 0.97 (t, <i>J</i> = 7.34 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>2</sub>2N<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 396.2. Found 396.1.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-4-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>12</b>)</h4><div class="NLM_p last">To a solution of 4-methyl-7<i>H</i>-tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic acid (90 mg, 496.82 μmol) and 1<i>H</i>-indazol-5-amine (66.15 mg, 496.82 μmol) in 2 mL of DMF were added DIEA (192.63 mg, 1.49 mmol, 259.61 μL), EDCI (142.86 mg, 745.23 μmol), and HOBt (100.70 mg, 745.23 μmol). The mixture was stirred at 15 °C for 15 h. The mixture was then purified by preparative HPLC to afford <b>12</b> (37.45 mg, 18%) as a gray, solid TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.01 (br s, 1H), 9.63 (s, 1H), 8.09 (s, 1H), 8.03 (s, 1H), 7.60 (s, 1H), 7.50 (d, <i>J</i> = 0.7 Hz, 2H), 5.26 (s, 2H), 3.43 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>13</sub>H<sub>13</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 297.1. Found 297.1.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 5-Ethyl-<i>N</i>-(1<i>H</i>-indazol-5-yl)-4-methyl-4<i>H</i>,7<i>H</i>-[1,2,3,4]tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>13</b>)</h4><div class="NLM_p last">A solution of 5-ethyl-4-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic acid (34 mg, 0.16 mmol) and 1<i>H</i>-indazol-5-amine (43 mg, 0.32 mmol) in 1.5 mL of anhydrous DMF was stirred at 0 °C. HATU (74 mg, 0.2 mmol) was then added followed by Et<sub>3</sub>N (45 μL, 0.32 mmol). The reaction mixture was stirred for 30 min at 0 °C and concentrated to give a residue. The residue was taken up in CH<sub>3</sub>CN (with 0.1% TFA) and purified by reversed-phase chromatography using a 2–10% CH<sub>3</sub>CN/H<sub>2</sub>0 (0.1% formic acid) gradient eluent to afford <b>13</b> as a red solid of insufficient purity. The compound was then repurified on silica gel using a 0–20% MeOH/EtOAc gradient eluent to give <b>13</b> (32 mg, 62%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.00 (br s, 1H), 9.97 (s, 1H), 8.15 (s, 1H), 8.04 (s, 1H), 7.33–7.70 (m, 2H), 5.31 (s, 2H), 3.43 (s, 3H), 2.63 (q, <i>J</i> = 7.60 Hz, 2H), 1.17 (t, <i>J</i> = 7.45 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.1. Found 325.3.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-Ethyl-<i>N</i>-(1<i>H</i>-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>14</b>)</h4><div class="NLM_p last">Ethyl 4-ethyl-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (136 mg, 0.573 mmol) and 1<i>H</i>-indazol-5-amine (153 mg, 1.15 mmol) were added to anhydrous DMF (1.5 mL) at 0 °C, and HATU (262 mg, 0.688 mmol) and Et<sub>3</sub>N (160 μL, 1.15 mmol) were added. The mixture was stirred for 3 h and then allowed to warm to r.t. The temperature was then increased to 40 °C, and another portion of HATU (131 mg) and 1<i>H</i>-indazol-5-amine (76.5 mg) was added. The reaction was then stirred at 40 °C for an additional 3 h. Water was added, and the mixture was extracted with EtOAc. The combined organic phases were concentrated, and the residue was triturated with water and then with MeOH to afford <b>14</b> (53 mg, 29%) as a pale purple solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.00 (br s, 1H), 10.00 (br s, 1H), 8.15 (br s, 1H), 8.05 (s, 1H), 7.50 (br s, 2H), 5.28 (br s, 2H), 3.92 (d, <i>J</i> = 7.26 Hz, 2H), 2.26 (s, 3H), 1.24 (t, <i>J</i> = 6.93 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.2. Found 325.3.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-5-methyl-4-[2-(morpholin-4-yl)ethyl]-4<i>H</i>,7<i>H</i>-[1,2,3,4]tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>15</b>)</h4><div class="NLM_p last">5-Methyl-4-(2-morpholinoethyl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic acid (40 mg, 0.12 mmol) was dissolved in 1.5 mL of DMF. Et<sub>3</sub>N (32 μL, 0.23 mmol), 1<i>H</i>-indazol-5-amine (18 mg, 0.14 mmol), and HATU (52 mg, 0.14 mmol) were added at 0 °C, and the reaction mixture was stirred for 3 h. The temperature was brought to 40 °C, and additional HATU (52 mg, 0.14 mmol) and 1<i>H</i>-indazol-5-amine (18 mg, 0.14 mmol) were added. Stirring at 40 °C was continued for 3 h. H<sub>2</sub>O (15 mL) was added followed by EtOAc (15 mL). The organic layer was separated, concentrated, and the residue was purified by reversed-phase chromatography using a 0–10% MeOH/EtOAc gradient eluent to give a solid, which was further purified on reversed-phase preparative TLC using the same gradient to afford <b>15</b> (4.5 mg, 10%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.91 (br s, 1H), 10.02 (br s, 1H), 8.14 (s, 1H), 8.04 (s, 1H), 7.41–7.57 (m, 2H), 5.27 (s, 2H), 3.97 (t, <i>J</i> = 6.7 Hz, 2H), 3.52 (t, <i>J</i> = 4.4 Hz, 4H), 2.56 (t, <i>J</i> = 6.7 Hz, 2H), 2.41–2.48 (m, 4H), 2.26 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>23</sub>N<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 410.2. Found 410.3.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i><sup>6</sup>-(1<i>H</i>-Indazol-5-yl)-<i>N</i><sup>4</sup>,<i>N</i><sup>4</sup>,5-trimethyltetrazolo[1,5-<i>a</i>]pyrimidine-4,6(7<i>H</i>)-dicarboxamide (<b>16</b>)</h4><div class="NLM_p last">To a solution of 4-(dimethylcarbamoyl)-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic acid (85.0 mg, 337 μmol) and 1<i>H</i>-indazol-5-amine (45.0 mg, 337 μmol) in DCM (5 mL) were added T3P (50 wt % in EtOAc, 322 mg, 506 μmol, 301 μL) and Et<sub>3</sub>N (102 mg, 1.01 mmol, 141 μL). The mixture was stirred at 15 °C for 2 h and concentrated to give a residue. The residue was purified by preparative HPLC (with 0.1% TFA) to afford <b>16</b> (38 mg, 23%) as a light pink, solid TFA salt. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.14 (s, 1H), 8.05 (s, 1H), 7.58–7.49 (m, 2H), 5.32 (s, 2H), 3.17 (s, 3H), 3.14 (s, 3H), 2.24 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>18</sub>N<sub>9</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 368.15. Found: 368.2.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-5-methyl-4-phenyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>17</b>)</h4><div class="NLM_p last">To a solution of 5-methyl-4-phenyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic acid (130 mg, 505 μmol) and 1<i>H</i>-indazol-5-amine (81 mg, 606 μmol) in EtOAc (2 mL) were added T3P (50 wt % in EtOAc, 965 mg, 1.52 mmol) and Et<sub>3</sub>N (204 mg, 2.02 mmol). The mixture was stirred at 60 °C for 12 h and concentrated to give a residue. The residue was purified by preparative HPLC (with 0.1% TFA) to afford <b>17</b> (31 mg, 16%) as a red, gummy TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.43–7.61 (m, 7H) 5.41 (s, 2H), 1.88 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>18</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 373.14. Found: 373.1.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Acetyl-<i>N</i>-(1<i>H</i>-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>18</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-(2<i>H</i>-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (50 mg, 169 μmol) and Et<sub>3</sub>N (34.2 mg, 337 μmol, 47.0 μL) in DCM (6 mL) was added acetyl chloride (19.9 mg, 253 μmol, 18.1 μL) at 15 °C and the reaction mixture was stirred for 0.5 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC to give <b>18</b> (4.1 mg, 6%) as a gummy, yellow TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.01 (br s, 1H), 10.41 (s, 1H), 8.18 (s, 1H), 8.06 (s, 1H), 7.55–7.46 (m, 2H), 5.22 (d, <i>J</i> = 1.3 Hz, 2H), 2.59 (s, 3H), 2.33–2.30 (m, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>15</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 339.1. Found 339.1.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-<i>N</i>,4,5-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>19</b>)</h4><div class="NLM_p last">Carboxylic acid <b>49</b> (70 mg, 0.36 mmol) and <i>N</i>-methyl-1<i>H</i>-indazol-5-amine (<b>56</b>) (79 mg, 0.54 mmol) were dissolved in anhydrous DMF (2 mL). Then, the solution was cooled to 0 °C with an ice–water bath and Et<sub>3</sub>N (0.1 mL, 0.72 mmol) and HATU (164 mg, 0.43 mmol) were added. The mixture was stirred at 0 °C for 30 min and then at r.t. overnight. The solution was loaded directly on a C18 column and purified by reversed-phase chromatography using a 5–30% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent. The purest fractions were combined, evaporated under reduced pressure, and subjected to an additional purification by silica gel chromatography using a 0–20% MeOH/EtOAc gradient eluent to afford <b>19</b> (25 mg, 21%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.15 (br s, 1H), 8.06 (s, 1H), 7.77 (d, <i>J</i> = 1.54 Hz, 1H), 7.52 (d, <i>J</i> = 8.80 Hz, 1H), 7.34 (dd, <i>J</i> = 8.80, 1.98 Hz, 1H), 4.94 (br s, 2H), 3.31 (s, 3H), 3.19 (s, 3H), 1.96 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.2. Found 325.2.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carbothioamide (<b>20</b>)</h4><div class="NLM_p last">Lawesson’s reagent (782 mg, 1.93 mmol) was added to a solution of compound <b>1</b> (300 mg, 0.95 mmol) in 8 mL of anhydrous dioxane. The solution was stirred at 100 °C for 2 h. Additional Lawesson’s reagent (782 mg, 1.93 mmol) was added, and stirring was continued at 100 °C for 18 h. The solvent was removed to afford the crude product that was purified by preparative HPLC to afford 108 mg of <b>20</b>, which was insufficiently pure (∼80%). Thirty milligrams of this material was taken up in DMSO and further purified by reversed-phase chromatography using a 0–50% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient as eluent to give <b>20</b> (10 mg, 3%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.17 (br s, 1H), 11.80 (s, 1H), 8.38 (s, 1H), 8.13 (s, 1H), 7.49–7.66 (m, 2H), 5.30 (s, 2H), 3.45 (s, 3H), 2.18 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 327.1. Found 327.2.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>rac</i>-<i>N</i>-(1<i>H</i>-Indazol-5-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>21</b> and <b>22</b>)</h4><div class="NLM_p">A solution of compound <b>32</b> (70 mg, 0.34 mmol) and 1<i>H</i>-indazol-5-amine (89 mg, 0.67 mmol) in 2 mL of anhydrous DMF was stirred at 0 °C, and HATU (153 mg, 0.402 mmol) was added followed by Et<sub>3</sub>N (94 μL, 0.67 mmol). The resulting mixture was then stirred for 2 h at r.t. Water (15 mL) was added, and the mixture was extracted with EtOAc (15 mL). The organic layer was concentrated, and the residue was purified by reversed-phase chromatography using a 2–10% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent to give a solid, which was triturated with MeOH to afford a racemic mixture of compounds <b>21</b> and <b>22</b> (21 mg, 19%) as a pale purple solid.</div><div class="NLM_p last">The enantiomers were then separated using semipreparative chiral HPLC (column: Whelk O1 (R,R) (25 cm × 2.0 cm), 10 μm; mobile phase: <i>n</i>-hexane/EtOH 40/60% v/v; flow rate: 17 mL/min. DAD detection: 220 nm; loop: 3000 μL). Solubilization: 13 mg in 3 mL of 1:1 hexafluoro-2-propanol/EtOH.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>R</i>)-<i>N</i>-(1<i>H</i>-Indazol-5-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>21</b>)</h4><div class="NLM_p last">Second eluting enantiomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.99 (br s, 1H), 10.17 (br s, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.29–7.63 (m, 2H), 5.74 (d, <i>J</i> = 6.38 Hz, 1H), 3.43 (s, 3H), 2.19 (s, 3H), 1.57 (d, <i>J</i> = 6.16 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.1. Found 325.2.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>S</i>)-<i>N</i>-(1<i>H</i>-Indazol-5-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>22</b>)</h4><div class="NLM_p last">First eluting enantiomer. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.99 (br s, 1H), 10.17 (s, 1H), 8.16 (s, 1H), 8.05 (d, <i>J</i> = 0.75 Hz, 1H), 7.43–7.57 (m, 2H), 5.74 (q, <i>J</i> = 6.02 Hz, 1H), 3.43 (s, 3H), 2.19 (d, <i>J</i> = 1.00 Hz, 3H), 1.57 (d, <i>J</i> = 6.53 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.1. Found 325.2.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(3-methyl-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>23</b>)</h4><div class="NLM_p last">Carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (35 mg, 0.17 mmol) and 3-methyl-1<i>H</i>-indazol-5-amine (48 mg, 0.33 mmol) were dissolved in 2 mL of anhydrous DMF. The solution was then cooled to 0 °C in an ice–water bath, and Et<sub>3</sub>N (0.05 mL, 0.33 mmol) and HATU (76 mg, 0.20 mmol) were added. The reaction mixture was stirred at 0 °C for 5 min and then at r.t. for 6 h. The material was purified by reversed-phase chromatography using a 5–25% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent. Product-containing fractions were combined and further purified by silica gel column chromatography using a 0–10% MeOH/EtOAc gradient eluent to afford <b>23</b> (33 mg, 57%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.58 (s, 1H), 10.15 (s, 1H), 8.11 (s, 1H), 7.43 (s, 2H), 5.74 (d, <i>J</i> = 6.16 Hz, 1H), 3.43 (s, 3H), 2.47 (s, 3H), 2.20 (d, <i>J</i> = 0.88 Hz, 3H), 1.57 (d, <i>J</i> = 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>19</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 339.3. Found 339.2.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-4,5,7-Trimethyl-<i>N</i>-(3-methyl-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>24</b>)</h4><div class="NLM_p last">To a stirred solution of methyl 4,5,7-trimethyl-7<i>H</i>-tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (25 g, 112 mmol) in 1 L of toluene were added 3-methyl-1<i>H</i>-indazol-5-amine (14.67 g, 99.67 mmol) and AlMe<sub>3</sub> (2 M, 112 mL). The reaction mixture was then stirred at 120 °C for 12 h. After cooling to 0 °C, the reaction mixture was quenched with saturated aqueous potassium sodium tartrate (1 L) and filtered. The solid obtained was washed with water (2 L) and petroleum ether (2 L) and then concentrated. This process was repeated an additional 3×, and material from all four batches was combined and purified by silica gel chromatography using a 0.5–1.7% MeOH/DCM gradient eluent to give the racemic product (60 g, 40%) as an off-white solid. Thirty grams of the solid was dissolved in a mixture of MeOH (1L), CH<sub>3</sub>CN (2 L), <i>i</i>-PrOH (3 L), and CHCl<sub>3</sub> (0.5 L) and stirred at 20 °C for 0.5 h. The mixture was separated by SFC to give 24 (14 g, 46%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.58 (s, 1H), 10.15 (s, 1H), 8.10 (s, 1H), 7.42 (s, 2H), 5.73 (q, <i>J</i> = 6.0 Hz, 1H), 3.42 (s, 3H), 2.47–2.43 (m, 3H), 2.19 (s, 3H), 1.56 (d, <i>J</i> = 6.4 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>19</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 339.1. Found 339.2.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(3-(pyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>25</b>)</h4><div class="NLM_p last">(<i>R</i>)-<i>N</i>-(3-Bromo-1<i>H</i>-indazol-5-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (50 mg, 0.12 mmol), (pyridin-4-yl)boronic acid (31 mg, 0.25 mmol), and Na<sub>2</sub>CO<sub>3</sub> (39 mg, 0.37 mmol) were suspended in 2 mL of DMF and 0.5 mL of water. The mixture was purged with N<sub>2</sub> for 5 min, and then Pd(PPh<sub>3</sub>)<sub>4</sub> (7 mg, 0.006 mmol) was added. The reaction mixture was stirred at 100 °C for 6 h under N<sub>2</sub>, and then it was irradiated using a microwave at 100 °C for 30 min. The mixture was partitioned between water and EtOAc; the phases were separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The material was purified by silica gel chromatography eluting with a 0–100% EtOAc/cyclohexane gradient followed by a 0–10% MeOH/EtOAc gradient to afford <b>25</b> of insufficient purity. The material was then further purified by reversed-phase chromatography using a 0–25% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent to afford <b>25</b> (5 mg, 10%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.58 (br s, 1H), 10.30 (s, 1H), 8.67–8.78 (m, 2H), 8.59 (s, 1H), 7.87–7.97 (m, 2H), 7.64 (s, 2H), 5.62–5.95 (m, 1H), 3.45 (s, 3H), 2.22 (s, 3H), 1.58 (d, <i>J</i> = 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>20</sub>H<sub>20</sub>N<sub>9</sub>O [M + H]<sup>+</sup>: 402.2. Found 402.2.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>rac</i>-4,5,7-Trimethyl-<i>N</i>-(3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>26</b> and <b>27</b>)</h4><div class="NLM_p">To a solution of carboxamide <b>61</b> (35 mg, 0.06 mmol) in 2 mL of THF was added 0.5 mL of 4 M HCl in dioxane. The reaction mixture was stirred at r.t. for 1 h. At this point, reaction monitoring indicated degradation of the starting material in addition to the formation of the desired product. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness. The residue was redissolved in THF (2 mL) and tetra-<i>n</i>-butylammonium fluoride (TBAF, 1 M in THF, 1 mL). The reaction mixture was stirred at r.t. over the weekend and then at 70 °C for 3 h. After cooling to r.t., the mixture was diluted with EtOAc, washed with water, and concentrated. The material was purified by reversed-phase column chromatography using a 5–25% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent to afford a racemic mixture of <b>26</b> and <b>27</b> (5 mg, 18%).</div><div class="NLM_p last">The enantiomers were then separated using chiral HPLC (column: Chiralpak AD-H (25 cm × 2.0 cm), 5 μm; mobile phase: <i>n</i>-hexane/EtOH/MeOH 70/15/15% v/v; flow rate: 18 mL/min. DAD detection: 220 nm; loop: 500 μL). Solubilization: 3 mg in 1 mL of EtOH.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Second eluting enantiomer. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.57 (s, 1H), 8.27 (d, <i>J</i> = 5.28 Hz, 1H), 7.55–7.66 (m, 2H), 7.39 (s, 1H), 7.31–7.36 (m, 1H), 5.76 (q, <i>J</i> = 6.24 Hz, 1H), 3.82–3.93 (m, 4H), 3.57–3.65 (m, 4H), 3.52 (s, 3H), 2.30 (d, <i>J</i> = 1.10 Hz, 3H), 1.70 (d, <i>J =</i> 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>10</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 487.2. Found 487.8.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>S</i>)-4,5,7-Trimethyl-<i>N</i>-(3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>27</b>)</h4><div class="NLM_p last">First eluting enantiomer. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.57 (s, 1H), 8.27 (d, <i>J</i> = 5.28 Hz, 1H), 7.55–7.66 (m, 2H), 7.39 (s, 1H), 7.31–7.36 (m, 1H), 5.76 (q, <i>J</i> = 6.24 Hz, 1H), 3.82–3.93 (m, 4H), 3.57–3.65 (m, 4H), 3.52 (s, 3H), 2.30 (d, <i>J</i> = 1.10 Hz, 3H), 1.70 (d, <i>J</i> = 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>24</sub>H<sub>27</sub>N<sub>10</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 487.2. Found 487.8.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-4,5,7,7-tetramethyl-4<i>H</i>,7<i>H</i>-[1,2,3,4]tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>28</b>)</h4><div class="NLM_p last">Carboxamide <b>67</b> (7.5 mg, 0.017 mmol) was dissolved in 2 mL of DCM. TFA (0.5 mL) was added dropwise at 0 °C, and the reaction mixture was stirred at r.t. for 3 h. The solvent was evaporated under reduced pressure, and the material was purified by preparative HPLC to afford <b>28</b> (2.1 mg, 4%, three steps) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.15 (d, <i>J</i> = 1.10 Hz, 1H), 8.06 (s, 1H), 7.47–7.63 (m, 2H), 3.46–3.54 (m, 3H), 2.23 (s, 3H), 1.90 (s, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>19</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 339.2. Found 339.8.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4,5,7,7-Tetramethyl-<i>N</i>-(3-methyl-2<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>29</b>)</h4><div class="NLM_p last">To a solution of methyl ester <b>65</b> (50 mg, 339 μmol) and 3-methyl-1<i>H</i>-indazol-5-amine (100 mg, 421 μmol) in 2 mL of toluene was added Al(CH<sub>3</sub>)<sub>3</sub> (2 M in toluene, 679.45 μL), and the mixture was stirred at 90 °C for 12 h. The reaction was quenched with MeOH (2 mL), and then the mixture was concentrated. The residue was purified by preparative HPLC to afford <b>29</b> (20 mg, 16%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.08 (s, 1H) 7.46 (s, 2H) 3.49 (s, 3H) 2.55 (s, 3H) 2.22 (s, 3H) 1.88 (s, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>21</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 353.2. Found 353.2.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4,5,7,7-Tetramethyl-<i>N</i>-(3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>30</b>)</h4><div class="NLM_p last">Carboxylic acid <b>66</b> (210 mg, 21% pure by NMR, 0.31 mmol theoretical) and 3-(2-morpholinopyridin-4-yl)-1<i>H</i>-indazol-5-amine (109 mg, 0.37 mmol) were dissolved in 2.5 mL of anhydrous DMF. The solution was cooled to 0 °C with an ice–water bath, and Et<sub>3</sub>N (87 μL, 0.62 mmol) and HATU (143 mg, 0.38 mmol) were sequentially added. The mixture was stirred at 0 °C for 5 min and then at r.t. for 18 h. The mixture was partitioned between EtOAc and water and extracted. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The material was purified by column chromatography (silica gel 110 NH<sub>2</sub>) using a 0–10% MeOH/EtOAc gradient eluent to afford material of insufficient purity. The material was then further purified by chiral semipreparative HPLC (Chiralcel OD-H column; 25 cm × 2.0 cm) to afford <b>30</b> (10 mg, 7%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.45 (br s, 1H), 10.34 (s, 1H), 8.56 (s, 1H), 8.30 (d, <i>J</i> = 5.06 Hz, 1H), 7.61 (d, <i>J</i> = 1.10 Hz, 2H), 7.29 (s, 1H), 7.23 (dd, <i>J</i> = 5.28, 1.10 Hz, 1H), 3.68–3.82 (m, 4H), 3.50–3.61 (m, 4H), 3.45 (s, 3H), 2.14 (s, 3H), 1.79 (s, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>25</sub>H<sub>29</sub>N<sub>10</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 501.2. Found 501.3.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4,5,7,7-Tetramethyl-<i>N</i>-(3-phenyl-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>31</b>)</h4><div class="NLM_p last">To a solution of ester <b>65</b> (70 mg, 0.3 mmol) and 3-phenyl-1<i>H</i>-indazol-5-amine (93 mg, 0.44 mmol) in anhydrous toluene (3 mL) was added Al(CH<sub>3</sub>)<sub>3</sub> (2 M in toluene, 0.44 mL, 0.89 mmol). The reaction mixture was stirred for 18 h at 90 °C. The reaction was cooled to r.t., quenched with water, and extracted with DCM. The organic phase was passed through a phase separator and concentrated under reduced pressure. The crude material was purified by reversed-phase column chromatography using a 5–50% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent to afford material of insufficient purity. The material was then further purified by chiral semipreparative HPLC (Chiralcel OD-H column; 25 cm × 2.0 cm) to afford <b>30</b> (11 mg, 9%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.22 (br s, 1H), 10.32 (s, 1H), 8.51 (s, 1H), 7.93 (d, <i>J</i> = 7.26 Hz, 2H), 7.52–7.63 (m, 4H), 7.38–7.47 (m, 1H), 3.44 (s, 3H), 2.14 (s, 3H), 1.79 (s, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>22</sub>H<sub>23</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 415.2. Found 415.2.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4,5-Dimethyl-<i>N</i>-(3-methyl-1<i>H</i>-indol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>33</b>)</h4><div class="NLM_p last">To a solution of 3-methyl-1<i>H</i>-indol-5-amine (90 mg, 615 μmol) and carboxylic acid <b>49</b> (120 mg, 615 μmol) in 2 mL of pyridine was added EDCI (177 mg, 923 μmol). The mixture was stirred at 25 °C for 4 h and concentrated. The residue was purified by preparative HPLC to afford <b>33</b> (12 mg, 6%) as a pale pink solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (br s, 1H) 9.79 (s, 1H) 7.84 (s, 1H) 7.21–7.30 (m, 2H) 7.10 (s, 1H) 5.27 (s, 2H) 3.43 (s, 3H) 2.25 (s, 3H) 2.23 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>18</sub>N<sub>7</sub>O [M + H]<sup>+</sup>: 324.1. Found 324.1.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(1<i>H</i>-Benzo[<i>d</i>]imidazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>34</b>)</h4><div class="NLM_p last">Carboxylic acid <b>49</b> (70 mg, 0.36 mmol) and 1<i>H</i>-benzo[<i>d</i>]imidazol-5-amine (96 mg, 0.72 mmol) were dissolved in anhydrous DMF (2 mL). Then, the solution was cooled to 0 °C with an ice–water bath and Et<sub>3</sub>N (0.10 mL, 0.72 mmol) and HATU (164 mg, 0.43 mmol) were added. The mixture was stirred at 0 °C for 30 min and then at r.t. overnight. The mixture was then diluted with water and concentrated under reduced pressure to remove some of the DMF before purifying the material by reversed-phase chromatography using a 2–15% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent. Product-containing fractions were combined, evaporated to dryness, and subjected to an additional purification by reversed-phase chromatography using a 2–25% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% ammonium hydroxide) gradient eluent to afford <b>34</b> (20 mg, 18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.77 (br s, 1H) 8.20 (s, 1H) 8.02 (s, 1H) 7.53 (d, <i>J</i> = 8.60 Hz, 1H) 7.31–7.41 (m, 1H) 5.25 (s, 2H) 3.43 (s, 3H) 2.25 (d, <i>J</i> = 1.32 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 311.1. Found 311.0.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4,5-Dimethyl-<i>N</i>-(3-methylimidazo[1,5-<i>a</i>]pyridin-6-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>35</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>49</b> (65 mg, 333 μmol) in 4 mL of DMF were added amine <b>72</b> (49.0 mg, 333 μmol) and <i>i-</i>Pr<sub>2</sub>NEt (129 mg, 999 μmol). A solution of HATU (190 mg, 499 μmol) in 1 mL of DMF was then added to the mixture dropwise at 0 °C. The mixture was stirred at 0 °C for 1 h and then at 25 °C for 11 h. The reaction mixture was concentrated and purified by preparative HPLC (neutral condition) to afford <b>35</b> (21 mg, 16%, two steps) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 1H) 8.71 (s, 1H) 7.51 (d, <i>J</i> = 10 Hz, 1H) 7.23 (s, 1H) 6.74–6.78 (m, 1H) 5.27 (s, 2H) 3.43 (s, 3H) 2.53 (s, 3H) 2.25 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.1. Found 325.0.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4,5-Dimethyl-<i>N</i>-(1-methylimidazo[1,5-<i>a</i>]pyridin-7-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>36</b>)</h4><div class="NLM_p last">To a solution of 4,5-dimethyl-7<i>H</i>-tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>77</b>) (10 mg, 52 μmol) and 7-bromo-1-methyl-imidazo[1,5-<i>a</i>]pyridine (<b>76</b>) (10.9 mg, 51.5 μmol) in 2 mL of dioxane were added Cs<sub>2</sub>CO<sub>3</sub> (33.6 mg, 103 μmol), Pd<sub>2</sub>(dba)<sub>3</sub> (4.7 mg, 5.2 μmol), and Xantphos (4.2 mg, 7.2 μmol). The reaction mixture was then stirred at 90 °C under N<sub>2</sub> for 12 h and concentrated to give a residue. The residue was purified by preparative TLC using 33% EtOH/EtOAc as eluent followed by preparative HPLC to afford <b>36</b> (2.2 mg, 2%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.96 (s, 1H), 8.19 (d, <i>J</i> = 7.5 Hz, 1H), 8.16 (s, 1H), 7.92 (s, 1H), 6.68 (dd, <i>J</i> = 2.0, 7.6 Hz, 1H), 5.27 (s, 2H), 3.44 (s, 3H), 2.35 (s, 3H), 2.25 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 325.1. Found 325.1.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4,5-Dimethyl-<i>N</i>-(2-oxoindolin-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>37</b>)</h4><div class="NLM_p last">To a solution of 5-aminoindolin-2-one (73 mg, 492 μmol) in 2 mL of DCM were added carboxylic acid <b>49</b> (80 mg, 410 μmol), T3P (50 wt % in EtOAc, 783 mg, 1.23 mmol), and Et<sub>3</sub>N (166 mg, 1.64 mmol, 228 μL). The reaction mixture was then stirred at 25 °C for 12 h. The mixture was concentrated, washed with MeOH (3 mL), filtered, and dried under vacuum to afford <b>37</b> (54 mg, 37%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H) 9.83 (s, 1H) 7.53 (s, 1H) 7.37 (br d, <i>J</i> = 8.38 Hz, 1H) 6.75 (d, <i>J</i> = 8.38 Hz, 1H) 5.22 (s, 2H) 3.47 (s, 2H) 3.40 (s, 3H) 2.20 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>15</sub>H<sub>16</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 326.1. Found 326.2.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4,5-Dimethyl-<i>N</i>-(2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>38</b>)</h4><div class="NLM_p last">To a solution of 5-amino-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-one (76 mg, 512 μmol) in 1 mL of DCM were added carboxylic acid <b>49</b> (100 mg, 512 μmol) and T3P (50 wt % in EtOAc, 489 mg, 768 μmol). The reaction mixture was then stirred at 20 °C for 30 min. Et<sub>3</sub>N (153 mg, 1.54 mmol, 214 μL) was added, and the reaction mixture was stirred at 20 °C for 12 h. The reaction mixture was washed with CH<sub>3</sub>CN (1 mL), saturated aqueous NaHCO<sub>3</sub> (1 mL), and H<sub>2</sub>O (5 mL) and then concentrated to afford <b>38</b> (28 mg, 16%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.52 (br s, 3H), 7.46 (s, 1H), 7.08 (br d, <i>J</i> = 7.5 Hz, 1H), 6.84 (br d, <i>J</i> = 7.9 Hz, 1H), 5.24 (br s, 2H), 3.41 (s, 3H), 2.21 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 327.1. Found 327.2.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(1-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>39</b>)</h4><div class="NLM_p last">Carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (50 mg, 0.24 mmol) and 5-amino-1-methyl-1,3-dihydro-2<i>H</i>-benzimidazol-2-one (78 mg, 0.48 mmol) were dissolved in 2.5 mL of anhydrous DMF. The solution was then cooled to 0 °C with an ice–water bath, and Et<sub>3</sub>N (0.07 mL, 0.48 mmol) and HATU (109 mg, 0.29 mmol) were sequentially added. The mixture was stirred at 0 °C for 5 min and then at r.t. for 18 h. The mixture was diluted with water (20 mL) and extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The material was purified by reversed-phase column chromatography using a 5–60% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent to afford <b>39</b> (32 mg, 37%) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (s, 1H), 10.07 (s, 1H), 7.53 (d, <i>J</i> = 1.32 Hz, 1H), 7.17 (dd, <i>J</i> = 8.36, 1.76 Hz, 1H), 7.03 (d, <i>J</i> = 8.36 Hz, 1H), 5.71 (q, <i>J</i> = 5.87 Hz, 1H), 3.42 (s, 3H), 3.26 (s, 3H), 2.17 (s, 3H), 1.54 (d, <i>J</i> = 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>19</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 355.2. Found 355.2.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(3-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>40</b>)</h4><div class="NLM_p last">5-Amino-3-methyl-1<i>H</i>-benzimidazol-2-one hydrochloride (200 mg, 1 mmol) was passed through a strong cation-exchange column eluting with MeOH followed by 1 M NH<sub>3</sub> in MeOH to afford the free base. The free base (78.mg, 0.48 mmol) and carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (50 mg, 0.24 mmol) were dissolved in 2.5 mL of anhydrous DMF. The solution was then cooled to 0 °C with an ice–water bath, and Et<sub>3</sub>N (70 μL, 0.48 mmol) and HATU (109 mg, 0.29 mmol) were added. The mixture was stirred at 0 °C for 5 min and then at r.t. for 18 h. The reaction mixture was diluted with water (20 mL) and extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The material was purified by reversed-phase column chromatography using a 5–50% CH<sub>3</sub>CN/H<sub>2</sub>O gradient eluent to afford <b>40</b> (37 mg, 43%) as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.78 (s, 1H), 10.09 (s, 1H), 7.54 (d, <i>J</i> = 1.32 Hz, 1H), 7.13 (dd, <i>J</i> = 8.36, 1.76 Hz, 1H), 6.93 (d, <i>J</i> = 8.36 Hz, 1H), 5.72 (q, <i>J</i> = 6.16 Hz, 1H), 3.43 (s, 3H), 3.26 (s, 3H), 2.18 (d, <i>J</i> = 0.88 Hz, 3H), 1.55 (d, <i>J</i> = 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>19</sub>N<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 355.2. Found 355.2.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>R</i>)-<i>N</i>-(1,3-Dioxoisoindolin-5-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>41</b>)</h4><div class="NLM_p last">To a stirred solution of carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (120 mg, 0.573 mmol), 5-aminoisoindoline-1,3-dione (111 mg, 0.688 mmol), and TEA (0.32 mL, 2.3 mmol) in DMF (3.3 mL) at 0 °C was added T3P (50% solution in DMF, 0.417 mL, 0.688 mmol). The reaction mixture was stirred at r.t. for 18 h. The mixture was diluted with H<sub>2</sub>O (20 mL) and extracted with EtOAc (2 × 20 mL). The organic phases were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The material was purified by preparative HPLC to afford racemic <i>N</i>-(1,3-dioxoisoindolin-5-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (29 mg, 0.082 mmol). 24.4 mg of this racemic mixture was separated by chiral preparative HPLC to afford <b>41</b> (second eluting enantiomer, 7.2 mg) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.24 (br s, 1H), 10.71 (br s, 1H), 8.19 (d, <i>J</i> = 1.51 Hz, 1H), 7.93 (dd, <i>J</i> = 8.28, 1.76 Hz, 1H), 7.81 (d, <i>J</i> = 8.28 Hz, 1H), 5.78 (d, <i>J</i> = 6.27 Hz, 1H), 3.45 (s, 3H), 2.20 (d, <i>J</i> = 0.75 Hz, 3H), 1.55 (d, <i>J</i> = 6.27 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>16</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 354.1. Found 354.2.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(1-oxoisoindolin-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>42</b>)</h4><div class="NLM_p last">To a stirred solution of carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (120 mg, 0.573 mmol), 5-aminoisoindolin-1-one (102 mg, 0.688 mmol), and Et<sub>3</sub>N (0.32 mL, 2.3 mmol) in DMF (3.3 mL) at 0 °C was added T3P (50% solution in DMF, 0.417 mL, 0.688 mmol). The reaction mixture was stirred at r.t. for 18 h. The mixture was diluted with H<sub>2</sub>O (20 mL) and extracted with EtOAc (20 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The material was purified by preparative HPLC. The product-containing fractions were collected and lyophilized to give racemic 4,5,7-trimethyl-<i>N</i>-(1-oxoisoindolin-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (13 mg, 0.038 mmol) as a white solid. 7.34 mg of this racemic mixture was separated by chiral preparative HPLC to give <b>42</b> (second eluting enantiomer, 1.7 mg, 0.01 mmol) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.46 (s, 1H), 8.41 (s, 1H), 8.00 (s, 1H), 7.58–7.68 (m, 2H), 5.75 (q, <i>J</i> = 5.80 Hz, 1H), 4.36 (s, 2H), 3.44 (s, 3H), 2.18 (d, <i>J</i> = 1.00 Hz, 3H), 1.55 (d, <i>J</i> = 6.27 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>18</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 340.1. Found 340.2.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>R</i>)-<i>N</i>-(1-Aminoisoquinolin-6-yl)-4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>43</b>)</h4><div class="NLM_p last">Bis-carbamate <b>81</b> (40 mg, 0.073 mmol) was dissolved in 3 mL of DCM. TFA (1 mL) was then added to the solution, and the reaction mixture was stirred for 1.5 h at r.t. Volatiles were removed under reduced pressure, and the crude material was purified by reversed-phase column chromatography using a 5–50% CH<sub>3</sub>CN/H<sub>2</sub>O (0.1% formic acid) gradient eluent. The white solid obtained was passed through a strong cation-exchange column eluting with 1 M NH<sub>3</sub> in MeOH to afford <b>43</b> (13 mg, 51%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.07–8.18 (m, 2H), 7.75 (d, <i>J</i> = 5.94 Hz, 1H), 7.55 (dd, <i>J</i> = 9.02, 1.98 Hz, 1H), 6.83 (d, <i>J</i> = 5.72 Hz, 1H), 6.67 (s, 2H), 5.78 (q, <i>J</i> = 6.16 Hz, 1H), 3.45 (s, 3H), 2.20 (d, <i>J</i> = 0.88 Hz, 3H), 1.56 (d, <i>J</i> = 6.38 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>19</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 351.2. Found 351.2.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-Nitro-3-(pyridin-4-yl)-1<i>H</i>-indazole (<b>45</b>)</h4><div class="NLM_p last">A mixture of indazole <b>44</b> (450 mg, 1.86 mmol), 4-pyridylboronic acid (274 mg, 2.23 mmol), KOAc (547 mg, 5.58 mmol), and Pd(Amphos)Cl<sub>2</sub> (132 mg, 186 μmol, 132 μL) in 6 mL of EtOH and 1.5 mL of H<sub>2</sub>O was degassed and purged with N<sub>2</sub> (3×). The mixture was then stirred at 100 °C for 16 h under N<sub>2</sub>. The residue was diluted with 2 M HCl (40 mL) and EtOAc (20 mL). A yellow solid formed, which was collected and dried under vacuum to afford <b>45</b> (350 mg), which was used without further purification. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>12</sub>H<sub>9</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 241.1. Found 240.8.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 3-(Pyridin-4-yl)-1<i>H</i>-indazol-5-amine (<b>46</b>)</h4><div class="NLM_p last">To a solution of <b>45</b> (350 mg, 1.46 mmol) in 4 mL of EtOH and 1 mL of H<sub>2</sub>O were added Zn (476 mg, 7.29 mmol) and NH<sub>4</sub>Cl (390 mg, 7.29 mmol), and the mixture was stirred at 80 °C for 12 h. The mixture was then filtered, and the solid that was collected was dissolved in 10 mL of DMF and filtered. The filtrate was concentrated to yield <b>46</b> (220 mg, 56% two steps) as a yellow gum, which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.19 (br s, 1 H), 8.62 (br d, <i>J</i> = 6 Hz, 2H), 7.90 (br d, <i>J</i> = 6 Hz, 2H), 7.34 (d, <i>J</i> = 9 Hz, 1 H), 7.18 (s, 1H), 6.86 (br d, <i>J</i> = 9 Hz, 1 H), 5.02 (s, 2H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>12</sub>H<sub>11</sub>N<sub>4</sub> [M + H]<sup>+</sup>: 211.1. Found 211.1.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Ethyl 4,5-Dimethyl-4<i>H</i>,7<i>H</i>-[1,2,3,4]tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (<b>48</b>)</h4><div class="NLM_p last">To a mixture of 5-aminotetrazole monohydrate (<b>36</b>, 606 mg, 5.88 mmol), formaldehyde aqueous solution (36.5–38% in H<sub>2</sub>O; 477 mg, 5.88 mmol), and EtOAc (742 μL, 5.88 mmol) in EtOH (1.5 mL) was added a catalytic amount of acetic acid (84 μL, 1.5 mmol). The mixture was then heated under microwave irradiation at 120 °C for 10 min. Volatiles were removed under reduced pressure, and the residue was purified on Biotage (C18, 30 g cartridge, reverse phase, H<sub>2</sub>O/CH<sub>3</sub>CN as eluent, 95:5–60:40) to afford <b>48</b> as a white solid (765 mg, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.89 (s, 1H) 5.10 (d, <i>J</i> = 0.66 Hz, 2H) 4.14 (q, <i>J</i> = 7.04 Hz, 2H) 2.35 (s, 3H) 1.25 (t, <i>J</i> = 7.04 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>8</sub>H<sub>12</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 210.1. Found 210.2.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4,5-Dimethyl-4<i>H</i>,7<i>H</i>-[1,2,3,4]tetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic Acid (<b>49</b>)</h4><div class="NLM_p">To a solution of ester <b>48</b> (200 mg, 0.96 mmol) in DMF (4 mL) were added Mel (119 μL, 1.91 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (405 mg, 1.24 mmol), and the mixture was stirred at 50 °C for 1 h. Cooled H<sub>2</sub>O (15 mL) was then added, and the mixture was extracted with EtOAc (15 mL). The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford a residue. The residue was purified by silica gel chromatography using a 0–20% EtOAc/cyclohexane gradient eluent to give ethyl 4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (95 mg) as a colorless oil. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>9</sub>H<sub>13</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 224.1. Found 224.2.</div><div class="NLM_p last">LiOH (54 mg, 1.28 mmol) was added to a solution of ester <b>48</b> (95 mg, 0.43 mmol) in an EtOH/THF/H<sub>2</sub>O mixture (4:1:0.6, 4.15 mL). The mixture was stirred at 55 °C for 1 h. Subsequently, the mixture was acidified with 1 M HCl and extracted with DCM (10 mL × 3). The pH of the aqueous layer was brought to pH = 7 with 1 M NaOH and extracted with DCM (10 mL). The combined organic layers were concentrated in vacuo to afford <b>49</b> (110 mg, 59%, two steps) as a white solid, which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.55 (br s, 1 H), 5.06 (s, 2H), 3.42 (s, 3H), 2.52 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>9</sub>H<sub>13</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 196.1. Found 196.1.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-(3-Bromo-1<i>H</i>-indazol-5-yl)-4,5-dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>51</b>)</h4><div class="NLM_p last">To a solution of 3-bromo-1<i>H</i>-indazol-5-amine (<b>50</b>) (30 mg, 141 μmol) and carboxylic acid <b>49</b> (27.6 mg, 141 μmol) in 2 mL of EtOAc were added T3P (50 wt % in EtOAc, 270 mg, 424 μmol) and Et<sub>3</sub>N (78.8 μL, 566 μmol). The mixture was then stirred at 60 °C for 12 h and concentrated. The residue was purified by preparative HPLC (with 0.1% TFA) to afford <b>51</b> (8.7 mg, 16%) as a yellow solid TFA salt. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.18–13.54 (m, 1 H), 10.09 (s, 1H), 8.08 (s, 1H), 7.51–7.59 (m, 2H), 5.29 (s, 2H), 3.43 (s, 3H), 2.26 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>14</sub>H<sub>14</sub>BrN<sub>8</sub>O [M + H]<sup>+</sup>: 389.0, 391.0. Found 389.0, 390.9.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Ethyl 4-Allyl-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (<b>52</b>)</h4><div class="NLM_p last">To a solution of ester <b>48</b> (2.0 g, 9.6 mmol) in THF (15 mL) was added NaH (574 mg, 14.3 mmol, 60% purity) at 0 °C, and the mixture was stirred at 15 °C for 0.5 h. Allyl bromide (1.50 g, 12.4 mmol, 2.20 mL) was then added at 0 °C. The reaction mixture was stirred at 15 °C for 16 h, quenched with H<sub>2</sub>O (100 mL) at 0 °C, and extracted with EtOAc (25 mL × 3). The combined organic layers were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a residue. The residue was purified by silica gel chromatography using a 0–20% EtOAc/petroleum ether gradient eluent to give <b>52</b> (820 mg, 27%) as a yellow oil. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>11</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 250.1. Found: 250.3.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 4-Allyl-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic Acid (<b>53</b>)</h4><div class="NLM_p last">To a solution of compound <b>52</b> (820 mg, 2.57 mmol) in EtOH (10 mL) and H<sub>2</sub>O (10 mL) was added LiOH·H<sub>2</sub>O (324 mg, 7.71 mmol). The mixture was stirred at 15 °C for 16 h and concentrated. The reaction mixture was then acidified with 1 N HCl to pH = 3. The resulting precipitate was collected by filtration to give the product (510 mg, 66%) as a white solid, which was used without further purification. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>9</sub>H<sub>12</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 222.1. Found: 222.3.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 4-Allyl-<i>N</i>-(1<i>H</i>-indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>54</b>)</h4><div class="NLM_p last">To a stirred solution of carboxylic acid <b>53</b> (300 mg, 1.36 mmol) in DCM (3 mL) were added 1<i>H</i>-indazol-5-amine (181 mg, 1.36 mmol) and T3P (50 wt % in EtOAc, 1.29 g, 2.03 mmol), and the reaction mixture was stirred at 20 °C for 0.5 h. Et<sub>3</sub>N (412 mg, 4.07 mmol) was then added, and the reaction mixture was stirred at 20 °C for 12 h. The reaction mixture was concentrated, and the residue was purified by preparative HPLC (0.04% NH<sub>4</sub>OH/10 mM NH<sub>4</sub>HCO<sub>3</sub>) to give <b>54</b> (230 mg, 50%) as a purple solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.04 (br s, 1 H), 10.07 (s, 1H), 8.14 (s, 1H), 8.02 (s, 1H), 7.44–7.51 (m, 2H), 5.88–5.99 (m, 1 H), 5.14–5.25 (m, 2H), 4.51 (br d, <i>J</i> = 4 Hz, 2H), 3.15 (d, <i>J</i> = 5 Hz, 2H), 2.19 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>16</sub>H<sub>17</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 337.1. Found: 337.1.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(1<i>H</i>-Indazol-5-yl)-5-methyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>55</b>)</h4><div class="NLM_p last">Carboxamide <b>54</b> (200 mg, 594.62 μmol), 1,3-dimethylbarbituric acid (186 mg, 1.19 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (68.7 mg, 59.5 μmol) in 10 mL of DCM and 5 mL of EtOH were degassed and then heated to 55 °C for 12 h under N<sub>2</sub>. After cooling to 20 °C, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by prep-HPLC (0.04% NH<sub>4</sub>OH/10 mM NH<sub>4</sub>HCO<sub>3</sub>) to give <b>55</b> (100 mg, 57%) as a white solid. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>13</sub>H<sub>13</sub>N<sub>8</sub>O [M + H]<sup>+</sup>: 297.1. Found: 297.3.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-Bromo-5-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-indazole (<b>57</b>)</h4><div class="NLM_p last">To a solution of 3-bromo-5-nitro-1<i>H</i>-indazole (<b>44</b>) (400 mg, 1.65 mmol) in DMF (7 mL) at 0 °C was added NaH (60% w/w, 79 mg, 1.98 mmol), and the mixture was stirred for 15 min. SEM-Cl (0.35 mL, 1.98 mmol) was then added, and the reaction mixture was warmed to r.t. and stirred for 2 h. The reaction was carefully quenched with a sat. aq. NH<sub>4</sub>Cl, and the mixture was extracted with EtOAc. The combined organic extracts were concentrated to dryness under reduced pressure and purified by silica gel chromatography using a 0–40% EtOAc/cyclohexane gradient eluent to afford <b>57</b> (372 mg, 60%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 (d, <i>J</i> = 1.8 Hz, 1H), 8.38 (dd, <i>J</i> = 2.0, 9.2 Hz, 1H), 7.68 (d, <i>J</i> = 9.2 Hz, 1H), 5.76 (s, 2H), 3.68–3.52 (m, 2H), 0.95–0.87 (m, 2H), −0.03 (s, 9H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>13</sub>H<sub>19</sub>BrN<sub>3</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 372.0, 374.0. Found 372.2, 374.1.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 5-Nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-indazole (<b>58</b>)</h4><div class="NLM_p">Indazole <b>57</b> (372 mg, 1.0 mmol), bis(pinacolato)diboron (279 mg, 1.1 mmol), and KOAc (294 mg, 3.0 mmol) were suspended in 3 mL of 1,4-dioxane. The mixture was purged with N<sub>2</sub> for 5 min, and then Pd(dppf)Cl<sub>2</sub> (36 mg, 0.05 mmol) was added. The resulting mixture was heated to 100 °C for 1 h under a N<sub>2</sub> atmosphere. The mixture was partitioned between water and EtOAc and extracted. The combined organic layers were washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure to afford <b>58</b>, which was used without further purification.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.05 (d, <i>J</i> = 2.20 Hz, 1 H) 8.32 (dd, <i>J</i> = 9.24, 2.20 Hz, 1 H) 7.72 (d, <i>J</i> = 9.24 Hz, 1 H) 5.89 (s, 2H) 3.54–3.61 (m, 2H) 1.46 (s, 12 H) 0.86–0.91 (m, 2H) −0.05 (s, 9H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>13</sub>H<sub>19</sub>BrN<sub>3</sub>O<sub>3</sub>Si [M+H-C<sub>6</sub>H<sub>10</sub>]<sup>+</sup>: 338.1. Found 338.2.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 4-(4-(5-Nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-indazol-3-yl)pyridin-2-yl)morpholine (<b>59</b>)</h4><div class="NLM_p last">Boronic ester <b>58</b> (crude, 1.0 mmol), 4-(4-bromopyridin-2-yl)morpholine (292 mg, 1.2 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (977 mg, 3.0 mmol) were suspended in 5 mL of THF and 1 mL of water. The mixture was purged with N<sub>2</sub> for 5 min, and then Pd(dppf)Cl<sub>2</sub> (73 mg, 0.10 mmol) was added. The reaction mixture was stirred at 100 °C for 1 h under N<sub>2</sub>. The mixture was partitioned between water and EtOAc and extracted. The combined organic layers were washed with water, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The material was purified by silica gel chromatography using a 0–30% EtOAc/cyclohexane gradient eluent to afford <b>59</b> (200 mg, 44%, two steps) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.99 (d, <i>J</i> = 2.0 Hz, 1H), 8.44–8.35 (m, 2H), 7.74 (d, <i>J</i> = 9.2 Hz, 1H), 7.24 (dd, <i>J</i> = 1.3, 5.1 Hz, 1H), 7.21 (s, 1H), 5.85 (s, 2H), 3.94–3.88 (m, 4H), 3.70–3.61 (m, 6H), 0.99–0.88 (m, 2H), −0.03 (s, 9H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>22</sub>H<sub>30</sub>N<sub>5</sub>O<sub>4</sub>Si [M + H]<sup>+</sup>: 456.2. Found 456.4.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-(2-Morpholinopyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-indazol-5-amine (<b>60</b>)</h4><div class="NLM_p last">A mixture of nitroindazole <b>59</b> (200 mg, 0.44 mmol), NH<sub>4</sub>Cl (26 mg, 0.48 mmol), and iron powder (98 mg, 1.8 mmol) in 4 mL of EtOH/H<sub>2</sub>O (1:1) was stirred at 80 °C for 30 min. The solids were filtered through a celite pad, washing with EtOH. Volatiles were removed under vacuum, and the residue was redissolved in EtOAc. Water was added, and the two phases were separated. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure to afford <b>60</b> (150 mg, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33 (d, <i>J</i> = 5.1 Hz, 1H), 7.47 (d, <i>J</i> = 8.8 Hz, 1H), 7.26–7.18 (m, 3H), 6.96 (dd, <i>J</i> = 2.0, 8.8 Hz, 1H), 5.74 (s, 2H), 3.94–3.87 (m, 4H), 3.77 (br s, 2H), 3.66–3.60 (m, 6H), 0.99–0.85 (m, 2H), −0.04 (s, 9H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>22</sub>H<sub>32</sub>N<sub>5</sub>O<sub>2</sub>Si [M + H]<sup>+</sup>: 426.2. Found 426.4.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (<i>R</i>)-4,5,7-Trimethyl-<i>N</i>-(3-(2-morpholinopyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-indazol-5-yl)-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>61</b>)</h4><div class="NLM_p last">Carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (35 mg, 0.17 mmol) and amine <b>60</b> (71 mg, 0.17 mmol) were dissolved in 2 mL of anhydrous DMF. Then, the solution was cooled to 0 °C with an ice–water bath and Et<sub>3</sub>N (0.05 mL, 0.33 mmol) and HATU (76 mg, 0.20 mmol) were added. The mixture was stirred at 0 °C for 5 min, at room temperature overnight, heated at 50 °C for 2 h, and then at 70 °C for an additional 2 h. The mixture was partitioned between water and EtOAc and extracted. The combined organic layers were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent was removed under vacuum. The material was purified by silica gel chromatography using a 50–100% EtOAc/cyclohexane gradient eluent to afford material of insufficient purity. The material was then further purified by silica gel chromatography (silica gel 110 NH<sub>2</sub>) using a 0–80% EtOAc/cyclohexane gradient eluent to afford <b>61</b> (35 mg, 33%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.52 (s, 1H), 8.36 (d, <i>J</i> = 5.1 Hz, 1H), 8.28 (s, 1H), 7.69–7.57 (m, 2H), 7.28–7.26 (m, 1H), 5.81 (s, 2H), 5.61 (q, <i>J</i> = 5.9 Hz, 1H), 3.93–3.83 (m, 4H), 3.70–3.56 (m, 6H), 3.49 (s, 3H), 2.31 (s, 3H), 1.74 (d, <i>J</i> = 6.4 Hz, 3H), 1.02–0.86 (m, 2H), 0.00–0.07 (m, 9H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>30</sub>H<sub>41</sub>N<sub>10</sub>O<sub>3</sub>Si [M + H]<sup>+</sup>: 617.3. Found 617.4.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Methyl 5,7,7-Trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (<b>64</b>)</h4><div class="NLM_p last">A mixture of 5-aminotetrazole monohydrate (<b>63</b>) (66 mg, 0.64 mmol) and methyl 2-acetyl-3-methyl-2-butenoate<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (<b>62</b>) (100 mg, 0.64 mmol) was heated in 5 mL of EtOH in the presence of molecular sieves for 4 h at reflux. The reaction was cooled to r.t., filtered, and concentrated to afford <b>64</b> (80 mg, 56%) as a white solid, which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 3.79–3.88 (m, 3H), 2.38–2.48 (m, 3H), 1.94–2.02 (m, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>9</sub>H<sub>14</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 224.1. Found 224.3.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Methyl 4,5,7,7-Tetramethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylate (<b>65</b>)</h4><div class="NLM_p last">To a solution of methyl ester <b>64</b> (73 mg, 0.33 mmol) in DMF (5 mL) were added MeI (0.12 mL, 2.0 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (699 mg, 2.0 mmol), and the mixture was stirred at 50 °C for 0.5 h. The solvent was evaporated, and the material was extracted with water and EtOAc. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford <b>65</b> (75 mg, 97%) as a white solid, which was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.84 (s, 1H), 3.76–3.88 (m, 3H), 3.47–3.58 (m, 3H), 2.21–2.32 (m, 3H), 1.78–1.92 (m, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>10</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 238.1. Found 238.2.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 4,5,7,7-Tetramethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxylic Acid (<b>66</b>)</h4><div class="NLM_p last">To a solution of methyl ester <b>65</b> (75 mg, 0.32 mmol) in 2.0 mL of THF was added a solution of LiOH (39 mg, 0.93 mmol) in H<sub>2</sub>O (2 mL). The mixture was stirred at 50 °C for 15 h. The solvent was evaporated, and the remaining aqueous solution was acidified with 1 M HCl to pH = 1, extracted with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford <b>66</b> (118 mg) as a colorless oil, which was of sufficient purity for further elaboration. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.34–3.39 (m, 3H), 1.90 (s, 3H), 1.64–1.71 (m, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>9</sub>H<sub>14</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 224.1. Found 224.2.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>tert</i>-Butyl 5-(4,5,7,7-Tetramethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamido)-1<i>H</i>-indazole-1-carboxylate (<b>67</b>)</h4><div class="NLM_p last">Carboxylic acid <b>66</b> (60 mg, 0.27 mmol) was dissolved in 2 mL of DMF, and Et<sub>3</sub>N (0.075 mL, 0.54 mmol), <i>N</i>-(1)-Boc-5-aminoindazole (53.8 mg, 0.4 mmol), and HATU (103 mg, 0.27 mmol) were added. The reaction mixture was then stirred at r.t. for 1 h. The solvent was evaporated, and the residue was extracted with EtOAc and water. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The material was purified by preparative HPLC to afford <b>67</b> (7.5 mg) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (br s, 1H), 8.04–8.22 (m, 3H), 7.45–7.57 (m, 1H), 3.52 (s, 3H), 1.90–1.99 (m, 3H), 1.72–1.77(m, 9H), 1.59 (s, 6H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>21</sub>H<sub>27</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 439.2. Found 439.8.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 2-(Bromomethyl)-5-nitropyridine (<b>69</b>)</h4><div class="NLM_p last">To a solution of 2-methyl-5-nitropyridine (<b>68</b>) (5.0 g, 36 mmol) in CCl<sub>4</sub> (75 mL) were added benzoyl peroxide (1.75 g, 7.24 mmol) and NBS (7.09 g, 39.82 mmol). The mixture was stirred at 80 °C for 12 h and then concentrated. The material was purified by column chromatography using a 0–10% EtOAc/petroleum ether gradient eluent to afford <b>69</b> (2.5 g, 31%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.38 (d, <i>J</i> = 3 Hz, 1 H), 8.49 (dd, <i>J</i> = 9, 3 Hz, 1 H), 7.67 (d, <i>J</i> = 9 Hz, 1 H), 4.61 (s, 2H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>6</sub>H<sub>6</sub>BrN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 217.0, 219.0. Found 217.0, 219.0.</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (5-Nitropyridin-2-yl)methanamine (<b>70</b>)</h4><div class="NLM_p last">To a mixture of NH<sub>3</sub>·H<sub>2</sub>O (10 mL) and dioxane (30 mL) was added nitropyridine <b>69</b> (2.45 g, 11.3 mmol) in dioxane (10 mL). The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was then concentrated to afford <b>70</b> (1.70 g) as a brown oil, which was used without further purification. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>6</sub>H<sub>8</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 154.1. Found 154.1.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 3-Methyl-6-nitroimidazo[1,5-<i>a</i>]pyridine (<b>71</b>)</h4><div class="NLM_p last">To a solution of methanamine <b>70</b> (1.70 g, 11 mmol) in Ac<sub>2</sub>O (30 mL) was added PTSA (1.91 g, 11.1 mmol). The mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to 25 °C, poured into ice water (100 mL), and extracted with EtOAc (50 mL × 3). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The material was purified by column chromatography using a 0–50% EtOAc/petroleum ether gradient eluent to afford <b>71</b> (650 mg, 32%, two steps) as a red solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.81 (s, 1H), 7.36–7.45 (m, 2H), 7.27–7.35 (m, 1 H), 2.70 (s, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>8</sub>H<sub>8</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 178.1. Found 178.1.</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 3-Methylimidazo[1,5-<i>a</i>]pyridin-6-amine (<b>72</b>)</h4><div class="NLM_p last">To a solution of nitroimidazopyridine <b>71</b> (70 mg, 395 μmol) in 60 mL of MeOH was added 10% Pd/C (110 mg). The mixture was degassed and purged with H<sub>2</sub> (3×) and stirred at 25 °C for 0.5 h under a H<sub>2</sub> atmosphere (15 psi). The reaction mixture was filtered, and the filtrate was concentrated to afford <b>72</b> (50 mg) as a green oil, which was used without further purification. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>8</sub>H<sub>10</sub>N<sub>3</sub> [M + H]<sup>+</sup>: 148.1. Found 148.3.</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 1-(4-Bromopyridin-2-yl)ethan-1-amine (<b>74</b>)</h4><div class="NLM_p last">Into a 100 mL three-necked, round-bottom flask, purged and maintained with an inert atmosphere of nitrogen, was placed a solution of MeMgBr (3 M, 16.39 mL) in 25 mL of THF. A solution of 4-bromopyridine-2-carbonitrile (<b>73</b>) (3 g, 16.39 mmol) in 15 mL of THF was added dropwise at 25 °C over 30 min. MeOH (10 mL) was then added dropwise followed by addition of NaBH<sub>4</sub> (3.10 g, 81.96 mmol) in five portions. The resulting mixture was stirred at 25 °C for 2 h and diluted with EtOAc (40 mL) and H<sub>2</sub>O (30 mL) at 0 °C. The pH was brought to 9 with 1 M NaOH, and the solid was removed by filtration. The filtrate was extracted with EtOAc, and the combined organic layers were concentrated to afford <b>74</b> (3.1 g, 94%) as a yellow oil, which was used without further purification. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>7</sub>H<sub>10</sub>BrN<sub>2</sub> [M + H]<sup>+</sup>: 201.0, 203.0. Found 201.0, 203.0.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(1-(4-Bromopyridin-2-yl)ethyl)formamide (<b>75</b>)</h4><div class="NLM_p last">To a solution of 1-(4-bromopyridin-2-yl)ethan-1-amine (<b>74</b>) (3.1 g, 15 mmol) and ethyl formate (1.14 g, 15.4 mmol) in 30 mL of toluene was added AlMe<sub>3</sub> (2.0 M in toluene, 7.7 mL). The mixture was stirred at 90 °C for 5 h and quenched by the addition of 15 mL of H<sub>2</sub>O at 0 °C. The mixture was then concentrated, and the residue was diluted with MeOH (50 mL) and filtered. The filtrate was concentrated and purified by silica gel chromatography using a 0–100% EtOAc/petroleum ether gradient eluent to afford <b>75</b> (410 mg, 10%) as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (d, <i>J</i> = 5.2 Hz, 1H), 8.21 (s, 1H), 7.45–7.38 (m, 2H), 7.02–7.00 (m, 1H), 5.21–5.14 (m, 1H), 1.49 (d, <i>J</i> = 6.8 Hz, 3H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>8</sub>H<sub>10</sub>BrN<sub>2</sub>O [M + H]<sup>+</sup>: 229.0, 231.0. Found 228.9, 230.8.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 7-Bromo-1-methylimidazo[1,5-<i>a</i>]pyridine (<b>76</b>)</h4><div class="NLM_p last">To a solution of <i>N</i>-(1-(4-bromopyridin-2-yl)ethyl)formamide (<b>75</b>) (410 mg, 1.8 mmol) in 4 mL of toluene was added POCl<sub>3</sub> (549 mg, 3.58 mmol, 333 μL) under N<sub>2</sub>, and the mixture was stirred at 80 °C for 2 h. The pH was brought to 10 carefully with saturated aqueous Na<sub>2</sub>CO<sub>3</sub> at 0 °C and extracted with EtOAc (30 mL × 3). The combined organic layers were concentrated in vacuo to afford <b>76</b> (350 mg, 93%) as a brown solid, which was used without further purification. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>8</sub>H<sub>8</sub>BrN<sub>2</sub> [M + H]<sup>+</sup>: 211.0, 213.0. Found 210.9, 213.0.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 4,5-Dimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamide (<b>77</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>49</b> (2.0 g, 10 mmol) in 40 mL of THF was added CDI (1.83 g, 11.3 mmol). The mixture was stirred at 20 °C for 1.5 h and then NH<sub>3</sub>·H<sub>2</sub>O (7.18 g, 51.2 mmol, 7.89 mL, 25% purity) was added, and the reaction mixture was stirred at 20 °C for 0.25 h. The reaction mixture was concentrated and purified by preparative HPLC to give <b>77</b> (0.1 g, 5%) as a white solid. MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>7</sub>H<sub>11</sub>N<sub>6</sub>O [M + H]<sup>+</sup>: 195.1. Found 195.0.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> <i>tert</i>-Butyl (<i>tert</i>-Butoxycarbonyl)(6-nitroisoquinolin-1-yl)carbamate (<b>79</b>)</h4><div class="NLM_p last">A suspension of 6-nitroisoquinolin-1-amine (<b>78</b>) (110 mg, 0.54 mmol), di-<i>tert</i>-butyl dicarbonate (335 mg, 1.53 mmol), and DMAP (3.5 mg) in 3.0 mL of CH<sub>3</sub>CN was stirred at 70 °C for 1 h. Volatiles were then removed under reduced pressure, and the residue was purified by silica gel chromatography using a 0–20% EtOAc/cyclohexane gradient eluent. Product-containing fractions were combined to afford <b>79</b> (160 mg, 70%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.84 (d, <i>J</i> = 2.0 Hz, 1H), 8.64 (d, <i>J</i> = 5.5 Hz, 1H), 8.41 (dd, <i>J</i> = 2.2, 9.0 Hz, 1H), 8.17 (d, <i>J</i> = 9.2 Hz, 1H), 7.88 (d, <i>J</i> = 5.7 Hz, 1H), 1.36 (s, 18H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>24</sub>N<sub>3</sub>O<sub>6</sub> [M + H]<sup>+</sup>: 390.2. Found 390.2.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>tert</i>-Butyl (6-Aminoisoquinolin-1-yl)(<i>tert</i>-butoxycarbonyl)carbamate (<b>80</b>)</h4><div class="NLM_p last">Carbamate <b>79</b> (160 mg, 0.41 mmol) was dissolved in 5.0 mL of EtOH, and 10% Pd/C (50 mg) was added. The mixture was left to react under H<sub>2</sub> (1 atm) at room temperature for 90 min. The catalyst was then removed by filtration, washing with EtOH. The filtrate was concentrated and dried under reduced pressure to afford <b>80</b> (143 mg, 97%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.04 (d, <i>J</i> = 5.7 Hz, 1H), 7.50 (d, <i>J</i> = 9.0 Hz, 1H), 7.38 (d, <i>J</i> = 5.7 Hz, 1H), 7.05 (dd, <i>J</i> = 2.1, 8.9 Hz, 1H), 6.78 (d, <i>J</i> = 2.0 Hz, 1H), 6.06 (s, 2H), 1.31 (s, 18H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 360.2. Found 360.4.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>tert</i>-Butyl (<i>R</i>)-(<i>tert</i>-Butoxycarbonyl)(6-(4,5,7-trimethyl-4,7-dihydrotetrazolo[1,5-<i>a</i>]pyrimidine-6-carboxamido)isoquinolin-1-yl)carbamate (<b>81</b>)</h4><div class="NLM_p last">Carboxylic acid <b>(</b><i><b>R</b></i><b>)-32</b> (55 mg, 0.26 mmol) and <i>bis</i>-carbamate <b>80</b> (114 mg, 0.32 mmol) were dissolved in 0.5 mL of pyridine (0.5 mL). EDCI (61 mg, 0.32 mmol) and DMAP (3 mg, 0.025 mmol) were then added. The resulting solution was stirred at 70 °C for 16 h. The mixture was diluted with EtOAc and washed with water (3×) and brine (1×). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness under reduced pressure. The crude material was purified by reversed-phase column chromatography using a 0–60% CH<sub>3</sub>CN/H<sub>2</sub>O gradient eluent (0.1% formic acid) followed by silica gel chromatography (silica gel 110 NH<sub>2</sub>) using a 50–100% EtOAc/cyclohexane gradient eluent to afford <b>81</b> (43 mg, 29%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 8.49 (d, <i>J</i> = 1.8 Hz, 1H), 8.33 (d, <i>J</i> = 5.7 Hz, 1H), 7.91–7.77 (m, 3H), 5.81 (q, <i>J</i> = 6.2 Hz, 1H), 3.45 (s, 3H), 2.22 (s, 3H), 1.57 (d, <i>J</i> = 6.4 Hz, 3H), 1.31 (s, 18H). MS-ESI (<i>m</i>/<i>z</i>) calcd for C<sub>27</sub>H<sub>35</sub>N<sub>8</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 551.3. Found 551.3.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> LRRK2 Biochemical Assays</h3><div class="NLM_p last">Biochemical tests were carried out using purified truncated LRRK2 enzymes (WT and G2019S) and reagents from LifeTechnologies. Inhibition of LRRKtide substrate phosphorylation was assessed using a homogeneous time-resolved fluorescence (HTRF) assay. Briefly, a 2 nM nominal concentration of enzymes was preincubated for 15 min with inhibitors before the addition of 0.4 μM LRRKtide and 25 μM ATP. Assays were carried out in a 384-well plate in a final volume of 10 μL. After 1 h incubation, the reaction was stopped with a LanthaScreen time-resolved (TR-FRET) Dilution Buffer containing 10 mM ethylenediamine tetraacetic acid (EDTA) and 2 nM Tb-anti-pERM(pLRRKtide) Ab, and HTRF signal was read in an Envision reader.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> pS935-LRRK2 Cellular Assays</h3><div class="NLM_p last">HEK293 cells stably transfected with human LRRK2 or the G2019S variant of human LRRK2 (HEK/WT-LRRK2 and HEK/G2019S-LRRK2 lines) were seeded into 384-well poly-<span class="smallcaps smallerCapital">d</span>-lysine-coated plates at a density of 5K cell/well in 50 μL of DMEM medium supplemented with 1% serum. LRRK2 inhibitors (0.25 μL) in DMSO were added using an acoustic dispenser. After 2 h incubation at 37 °C, the medium was removed, and phospho-LRRK2 (Ser935) kit reagents from CisBio were added following the manufacturer’s instructions. HTRF signal was read using an Envision reader.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> pS1292-LRRK2 Cellular Assays</h3><div class="NLM_p last">HEK/WT-LRRK2 or HEK/G2019S-LRRK2 cells were seeded into 96-well poly-<span class="smallcaps smallerCapital">d</span>-lysine-coated plates at a density of 30–50K cell/well in 100 μL of DMEM medium supplemented with 1% serum. After addition of 1 μL of test article in 100% DMSO, an additional 100 μL of medium was added to each well. After 2 h incubation at 37 °C, the medium was removed, and after washing with phosphate-buffered saline (PBS), Lysis Buffer plus phosphatase inhibitors were added. After shaking for 1 h at 4 °C, lysates were transferred into MSD assay plates precoated with mouse monoclonal anti-LRRK2 antibody at a concentration of 1 μg/mL for 1 h at r.t. Plates were sealed and incubated overnight at 4 °C, with shaking. The unbound proteins were removed by washing plates with TBST. Rabbit anti-pS1292 antibody diluted 1:400 in 1% Blocker A/TBST was added and incubated for 2 h at r.t. with shaking. The antibody was removed by washing, and MSD Sulfo-Tag labeled antirabbit diluted 1:500 in 3% Blocker A/TBST was added and incubated in the dark for 1 h at RT, with shaking. The antibody solution was removed by washing plates, and Read Buffer was added. Plates were read immediately in an MSD reader (e.g., MSD Sector 6000).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> pThr73-Rab10 and pS935-LRRK2 Cellular Immunoblot-Based Assays</h3><div class="NLM_p last">HEK/WT-LRRK2 or HEK/G2019S-LRRK2 cells were seeded into 24-well plates (Corning 353047) at 100 000 cells/well in 500 μL EMEM media containing 1% FBS. Approximately 24 h after plating, cells were treated with 250 μL EMEM media containing 1% FBS and 3.75 μL test article in 100% DMSO. After a 2 h incubation, cells were washed with DPBS, and 50 μL of lysis buffer was added to each well. Lysis buffer contained 1% sodium dodecyl sulfate (SDS), 25 μM Tris pH 7.4, 137 μM NaCl, and 2.7 μM KCl in water supplemented with protease inhibitors (Thermo Scientific, 78425) and phosphatase inhibitors (G Biosciences, 786–452; G Biosciences, 786–782). After incubating the plate on an orbital shaker for 5 min at 800 rpm at RT, the cell lysates were collected, heated at 65 °C for 10 min, and load dye (Cell signaling, 7722S) was added according to the manufacturer’s instructions. Levels of pThr73-Rab10, total Rab10, pS935-LRRK2, and total LRRK2 were quantified from immunoblots. For pS935 and total LRRK2, samples were diluted 1:30 and 8 μL of sample was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For pThr73-Rab10 and total Rab10, 10 μL of sample was separated by SDS-PAGE. Antibodies were used at the following dilutions: LRRK2 total antibody (1:10 000, Antibodies Incorporated, cat #75–253), pS935 antibody (1:2000, Abcam, ab133450), rab10 total antibody (1:2000, United States Biological, 030583), and pRab10 antibody (1:500, Abcam, ab230261).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Pharmacokinetics</h3><div class="NLM_p last">Following intravenous bolus and oral gavage administration of compound to fasted male CD-1 mice, blood samples were collected at 0.25, 0.5, 1, 2, 4, 8, and 12 h from the saphenous vein into polypropylene tubes at each time point, blood was transferred to EDTA-K2 tubes, and plasma was prepared by centrifugation. Brain samples were homogenized with 4 volumes (w/v) of 15 mM PBS/ACN (2:1). Levels of EB-42486 in plasma and brain samples were determined by liquid chromatography and tandem mass spectrometry analyses (LC-MS/MS). Plasma PK profile was analyzed by noncompartmental approaches using Phoenix WinNonlin 6.3 software program.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i101"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01243" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40515" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40515" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01243?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Compound <b>1</b> homology model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Kinase panel for compound <b>31</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Crystal data for compound <b>(</b><i><b>R</b></i><b>)-32</b>; <sup>1</sup>H NMR and HPLC traces for compounds <b>1</b>, <b>4</b>, <b>7</b>, <b>19</b>, <b>20</b>, <b>21</b>, <b>22</b>, <b>23</b>, <b>25</b>, <b>26</b>, <b>30</b>, and <b>31</b>; and table of geometric mean and geometric standard deviation of biochemical potency (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">jm0c01243_si_001.pdb (337.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">jm0c01243_si_002.csv (2.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">jm0c01243_si_003.csv (14.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">jm0c01243_si_004.pdf (1.18 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01243" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Albert W. Garofalo</span> - <span class="hlFld-Affiliation affiliation">ESCAPE
Bio, South
San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1837-417X" title="Orcid link">http://orcid.org/0000-0002-1837-417X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3b5c5a49545d5a57545a7b5e48585a4b5e59525415585456"><span class="__cf_email__" data-cfemail="117670637e77707d7e705174627270617473787e3f727e7c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica Bright</span> - <span class="hlFld-Affiliation affiliation">ESCAPE
Bio, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stéphane De Lombaert</span> - <span class="hlFld-Affiliation affiliation">ESCAPE
Bio, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alyssa M. A. Toda</span> - <span class="hlFld-Affiliation affiliation">ESCAPE
Bio, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kerry Zobel</span> - <span class="hlFld-Affiliation affiliation">ESCAPE
Bio, South
San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniele Andreotti</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudia Beato</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Bernardi</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federica Budassi</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Caberlotto</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peng Gao</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, Tianjin 300456, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cristiana Griffante</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinying Liu</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, Tianjin 300456, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Mengatto</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marco Migliore</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabio Maria Sabbatini</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Sava</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Serra</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Vincetti</span> - <span class="hlFld-Affiliation affiliation">Aptuit,
an Evotec Company, Verona 37135, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingliang Zhang</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, Tianjin 300456, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Holly J. Carlisle</span> - <span class="hlFld-Affiliation affiliation">ESCAPE
Bio, South
San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl2"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">HPK1</td><td class="NLM_def"><p class="first last">hematopoietic progenitor kinase 1</p></td></tr><tr><td class="NLM_term">IVB</td><td class="NLM_def"><p class="first last">in vitro biochemical</p></td></tr><tr><td class="NLM_term">JNK1</td><td class="NLM_def"><p class="first last">c-Jun <i>N</i>-terminal kinase 1</p></td></tr><tr><td class="NLM_term">JNK2</td><td class="NLM_def"><p class="first last">c-Jun <i>N</i>-terminal kinase 2</p></td></tr><tr><td class="NLM_term">JNK3</td><td class="NLM_def"><p class="first last">c-Jun <i>N</i>-terminal kinase 3</p></td></tr><tr><td class="NLM_term">LRRK2</td><td class="NLM_def"><p class="first last">leucine-rich repeat kinase 2</p></td></tr><tr><td class="NLM_term">MPO</td><td class="NLM_def"><p class="first last">multiparameter optimization</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PTSA</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">propylphosphonic anhydride</p></td></tr><tr><td class="NLM_term">TTK</td><td class="NLM_def"><p class="first last">dual specificity protein kinase TTK</p></td></tr><tr><td class="NLM_term">YSK</td><td class="NLM_def"><p class="first last">serine/threonine-protein kinase 25</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 16 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Paisán-Ruı́z, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilks, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Brug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez de Munain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Silva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti-Masso, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span> <span> </span><span class="NLM_article-title">Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2004.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2Fj.neuron.2004.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=15541308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=595-600&author=C.+Pais%C3%A1n-Ru%C4%B1%CC%81zauthor=S.+Jainauthor=E.+W.+Evansauthor=W.+P.+Gilksauthor=J.+Simonauthor=M.+van+der+Brugauthor=A.+Lopez+de+Munainauthor=S.+Aparicioauthor=A.+M.+Gilauthor=N.+Khanauthor=J.+Johnsonauthor=J.+R.+Martinezauthor=D.+Nichollauthor=I.+M.+Carreraauthor=A.+S.+Penaauthor=R.+de+Silvaauthor=A.+Leesauthor=J.+F.+Marti-Massoauthor=J.+Perez-Turauthor=N.+W.+Woodauthor=A.+B.+Singleton&title=Cloning+of+the+gene+containing+mutations+that+cause+PARK8-linked+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neuron.2004.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the gene containing mutations that cause PARK8-linked parkinson's disease</span></div><div class="casAuthors">Paisan-Ruiz, Coro; Jain, Shushant; Evans, E. Whitney; Gilks, William P.; Simon, Javier; van der Brug, Marcel; Lopez de Munain, Adolfo; Aparicio, Silvia; Gil, Angel Martinez; Khan, Naheed; Johnson, Janel; Martinez, Javier Ruiz; Nicholl, David; Carrera, Itxaso Marti; Pena, Amets Saenz; de Silva, Rohan; Lees, Andrew; Marti-Masso, Jose Felix; Perez-Tur, Jordi; Wood, Nick W.; Singleton, Andrew B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-600</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Parkinson's disease (PD; OMIM #168600) is the second most common neurodegenerative disorder in the Western world and presents as a progressive movement disorder.  The hallmark pathol. features of PD are loss of dopaminergic neurons from the substantia nigra and neuronal intracellular Lewy body inclusions.  Parkinsonism is typically sporadic in nature; however, several rare familial forms are linked to genetic loci, and the identification of causal mutations has provided insight into the disease process.  PARK8, identified in 2002 by Funayama and colleagues, appears to be a common cause of familial PD.  We describe here the cloning of a novel gene that contains missense mutations segregating with PARK8-linked PD in five families from England and Spain.  Because of the tremor obsd. in PD and because a no. of the families are of Basque descent, we have named this protein dardarin, derived from the Basque word dardara, meaning tremor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGrs2XdLqQkrVg90H21EOLACvtfcHk0lj5tMsbcQlnxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjK&md5=8f00086cb6a3d80e9a5ee4229c1055d5</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2004.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2004.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DPais%25C3%25A1n-Ru%25C4%25B1%25CC%2581z%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DEvans%26aufirst%3DE.%2BW.%26aulast%3DGilks%26aufirst%3DW.%2BP.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BBrug%26aufirst%3DM.%26aulast%3DLopez%2Bde%2BMunain%26aufirst%3DA.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DGil%26aufirst%3DA.%2BM.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DJ.%2BR.%26aulast%3DNicholl%26aufirst%3DD.%26aulast%3DCarrera%26aufirst%3DI.%2BM.%26aulast%3DPena%26aufirst%3DA.%2BS.%26aulast%3Dde%2BSilva%26aufirst%3DR.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DMarti-Masso%26aufirst%3DJ.%2BF.%26aulast%3DPerez-Tur%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DN.%2BW.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26atitle%3DCloning%2520of%2520the%2520gene%2520containing%2520mutations%2520that%2520cause%2520PARK8-linked%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuron%26date%3D2004%26volume%3D44%26spage%3D595%26epage%3D600%26doi%3D10.1016%2Fj.neuron.2004.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biskup, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachergus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulihan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uitti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calne, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoessl, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patenge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajal, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieregge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmus, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Myhsok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meitinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strom, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wszolek, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, T.</span></span> <span> </span><span class="NLM_article-title">Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2004.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2Fj.neuron.2004.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=15541309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=601-607&author=A.+Zimprichauthor=S.+Biskupauthor=P.+Leitnerauthor=P.+Lichtnerauthor=M.+Farrerauthor=S.+Lincolnauthor=J.+Kachergusauthor=M.+Hulihanauthor=R.+J.+Uittiauthor=D.+B.+Calneauthor=A.+J.+Stoesslauthor=R.+F.+Pfeifferauthor=N.+Patengeauthor=I.+C.+Carbajalauthor=P.+Viereggeauthor=F.+Asmusauthor=B.+M%C3%BCller-Myhsokauthor=D.+W.+Dicksonauthor=T.+Meitingerauthor=T.+M.+Stromauthor=Z.+K.+Wszolekauthor=T.+Gasser&title=Mutations+in+LRRK2+cause+autosomal-dominant+parkinsonism+with+pleomorphic+pathology&doi=10.1016%2Fj.neuron.2004.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</span></div><div class="casAuthors">Zimprich, Alexander; Biskup, Saskia; Leitner, Petra; Lichtner, Peter; Farrer, Matthew; Lincoln, Sarah; Kachergus, Jennifer; Hulihan, Mary; Uitti, Ryan J.; Calne, Donald B.; Stoessl, A. Jon; Pfeiffer, Ronald F.; Patenge, Nadja; Carbajal, Iria Carballo; Vieregge, Peter; Asmus, Friedrich; Mueller-Myhsok, Bertram; Dickson, Dennis W.; Meitinger, Thomas; Strom, Tim M.; Wszolek, Zbigniew K.; Gasser, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-607</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We have previously linked families with autosomaldominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8).  By high-resoln. recombination mapping and candidate gene sequencing in 46 families, we have found six disease-segregating mutations (five missense and one putative splice site mutation) in a gene encoding a large, multifunctional protein, LRRK2 (leucine-rich repeat kinase 2).  It belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.  Within affected carriers of families A and D, six post mortem diagnoses reveal brainstem dopaminergic degeneration accompanied by strikingly diverse pathologies.  These include abnormalities consistent with Lewy body Parkinson's disease, diffuse Lewy body disease, nigral degeneration without distinctive histopathol., and progressive supranuclear palsy-like pathol.  Clin. diagnoses of Parkinsonism with dementia or amyotrophy or both, with their assocd. pathologies, are also noted.  Hence, LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders assocd. with parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9aK6wacZJhbVg90H21EOLACvtfcHk0lh2kNnuCM8-9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjL&md5=9ae4c87ce3172e29829e317d94b5cdaa</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2004.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2004.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DZimprich%26aufirst%3DA.%26aulast%3DBiskup%26aufirst%3DS.%26aulast%3DLeitner%26aufirst%3DP.%26aulast%3DLichtner%26aufirst%3DP.%26aulast%3DFarrer%26aufirst%3DM.%26aulast%3DLincoln%26aufirst%3DS.%26aulast%3DKachergus%26aufirst%3DJ.%26aulast%3DHulihan%26aufirst%3DM.%26aulast%3DUitti%26aufirst%3DR.%2BJ.%26aulast%3DCalne%26aufirst%3DD.%2BB.%26aulast%3DStoessl%26aufirst%3DA.%2BJ.%26aulast%3DPfeiffer%26aufirst%3DR.%2BF.%26aulast%3DPatenge%26aufirst%3DN.%26aulast%3DCarbajal%26aufirst%3DI.%2BC.%26aulast%3DVieregge%26aufirst%3DP.%26aulast%3DAsmus%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Myhsok%26aufirst%3DB.%26aulast%3DDickson%26aufirst%3DD.%2BW.%26aulast%3DMeitinger%26aufirst%3DT.%26aulast%3DStrom%26aufirst%3DT.%2BM.%26aulast%3DWszolek%26aufirst%3DZ.%2BK.%26aulast%3DGasser%26aufirst%3DT.%26atitle%3DMutations%2520in%2520LRRK2%2520cause%2520autosomal-dominant%2520parkinsonism%2520with%2520pleomorphic%2520pathology%26jtitle%3DNeuron%26date%3D2004%26volume%3D44%26spage%3D601%26epage%3D607%26doi%3D10.1016%2Fj.neuron.2004.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Paisán-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span> <span> </span><span class="NLM_article-title">LRRK2: Cause, risk, and mechanism</span>. <i>J. Parkinson’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.3233/JPD-130192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.3233%2FJPD-130192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23938341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=85-103&author=C.+Pais%C3%A1n-Ruizauthor=P.+A.+Lewisauthor=A.+B.+Singleton&title=LRRK2%3A+Cause%2C+risk%2C+and+mechanism&doi=10.3233%2FJPD-130192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2: cause, risk, and mechanism</span></div><div class="casAuthors">Paisan-Ruiz, Coro; Lewis, Patrick A.; Singleton, Andrew B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Parkinson's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-103</span>CODEN:
                <span class="NLM_cas:coden">JPDOAP</span>;
        ISSN:<span class="NLM_cas:issn">1877-7171</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  In 2004 it was first shown that mutations in LRRK2 can cause Parkinson's disease.  This initial discovery was quickly followed by the observation that a single particular mutation is a relatively common cause of Parkinson's disease across varied populations.  Further genetic investigation has revealed a variety of genetic ties to Parkinson's disease across this gene.  These include common alleles with quite broad effects on risk, likely through both alterations at the protein sequence level, and in the context of expression.  A great deal of functional characterization of LRRK2 and disease-causing mutations in this protein has occurred over the last 9 years, and considerable progress has been made.  Particular attention has been paid to the kinase activity of LRRK2 as a therapeutic target, and while it is no means certain that this is viable target it is likely that this hypothesis will be tested in clin. trials sooner rather than later.  We believe that the future goals for LRRK2 research are, while challenging, relatively clear and that the next 10 years of research promises to be perhaps more exciting than the last.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1IVJK9Tqs7Vg90H21EOLACvtfcHk0lh2kNnuCM8-9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygs73M&md5=6e7ceb0477f0a4551ac71849daa4a0b1</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.3233%2FJPD-130192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJPD-130192%26sid%3Dliteratum%253Aachs%26aulast%3DPais%25C3%25A1n-Ruiz%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DP.%2BA.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26atitle%3DLRRK2%253A%2520Cause%252C%2520risk%252C%2520and%2520mechanism%26jtitle%3DJ.%2520Parkinson%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D3%26spage%3D85%26epage%3D103%26doi%3D10.3233%2FJPD-130192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Monfrini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fonzo, A.</span></span> <span> </span><span class="NLM_article-title">Leucine-rich repeat kinase (LRRK2) genetics and Parkinson’s Disease</span>. <i>Adv. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1007%2F978-3-319-49969-7_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=28353276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A280%3ADC%252BC1cvit1Wktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=3-30&author=E.+Monfriniauthor=A.+Di+Fonzo&title=Leucine-rich+repeat+kinase+%28LRRK2%29+genetics+and+Parkinson%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease</span></div><div class="casAuthors">Monfrini Edoardo; Di Fonzo Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Advances in neurobiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-30</span>
        ISSN:<span class="NLM_cas:issn">2190-5215</span>.
    </div><div class="casAbstract">The discovery of LRRK2 mutations as a cause of Parkinson's disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research.  Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide.  The G2385R and R1628P variants represent validated risk factors for PD in Asian populations.  Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations.  Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2.  Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling.  In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnB6AiTVLfbGK_SFaaT9INfW6udTcc2eYJz6b66sJIaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvit1Wktw%253D%253D&md5=a1539e7798089f0919e6315c12d2ee9f</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-49969-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-49969-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DMonfrini%26aufirst%3DE.%26aulast%3DDi%2BFonzo%26aufirst%3DA.%26atitle%3DLeucine-rich%2520repeat%2520kinase%2520%2528LRRK2%2529%2520genetics%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DAdv.%2520Neurobiol.%26date%3D2017%26volume%3D14%26spage%3D3%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rascol, O.</span></span> <span> </span><span class="NLM_article-title">LRRK2 in Parkinson disease: challenges of clinical trials</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/s41582-019-0301-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1038%2Fs41582-019-0301-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=31980808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FksVWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=97-107&author=E.+Tolosaauthor=M.+Vilaauthor=C.+Kleinauthor=O.+Rascol&title=LRRK2+in+Parkinson+disease%3A+challenges+of+clinical+trials&doi=10.1038%2Fs41582-019-0301-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 in Parkinson disease: challenges of clinical trials</span></div><div class="casAuthors">Tolosa Eduardo; Tolosa Eduardo; Vila Miquel; Vila Miquel; Vila Miquel; Klein Christine; Rascol Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the most common monogenic forms of Parkinson disease (PD) is caused by mutations in the LRRK2 gene that encodes leucine-rich repeat kinase 2 (LRRK2).  LRRK2 mutations, and particularly the most common mutation Gly2019Ser, are observed in patients with autosomal dominant PD and in those with apparent sporadic PD, who are clinically indistinguishable from those with idiopathic PD.  The discoveries that pathogenic mutations in the LRRK2 gene increase LRRK2 kinase activity and that small-molecule LRRK2 kinase inhibitors can be neuroprotective in preclinical models of PD have placed LRRK2 at the centre of disease modification efforts in PD.  Recent investigations also suggest that LRRK2 has a role in the pathogenesis of idiopathic PD and that LRRK2 therapies might, therefore, be beneficial in this common subtype of PD.  In this Review, we describe the characteristics of LRRK2-associated PD that are most relevant to the development of LRRK2-targeted therapies and the design and implementation of clinical trials.  We highlight strategies for correcting the effects of mutations in the LRRK2 gene, focusing on how to identify which patients are the optimal candidates and how to decide on the timing of such trials.  In addition, we discuss challenges in implementing trials of disease-modifying treatment in people who carry LRRK2 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMCbhG8-7gs-xsqfvU0ziafW6udTcc2eaMx70LTPeKKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FksVWgtw%253D%253D&md5=31b4f3fb058921649726eafedc11c8a3</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fs41582-019-0301-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-019-0301-2%26sid%3Dliteratum%253Aachs%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DVila%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DRascol%26aufirst%3DO.%26atitle%3DLRRK2%2520in%2520Parkinson%2520disease%253A%2520challenges%2520of%2520clinical%2520trials%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2020%26volume%3D16%26spage%3D97%26epage%3D107%26doi%3D10.1038%2Fs41582-019-0301-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Pichon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanoy, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Brug, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span> <span> </span><span class="NLM_article-title">Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">164ra161</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.3004485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23241745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=Z.+Shengauthor=S.+Zhangauthor=D.+Bustosauthor=T.+Kleinheinzauthor=C.+E.+Le+Pichonauthor=S.+L.+Dominguezauthor=H.+O.+Solanoyauthor=J.+Drummondauthor=X.+Zhangauthor=X.+Dingauthor=F.+Caiauthor=Q.+Songauthor=X.+Liauthor=Z.+Yueauthor=M.+P.+van+der+Brugauthor=D.+J.+Burdickauthor=J.+Gunzner-Tosteauthor=H.+Chenauthor=X.+Liuauthor=A.+A.+Estradaauthor=Z.+K.+Sweeneyauthor=K.+Scearce-Levieauthor=J.+G.+Moffatauthor=D.+S.+Kirkpatrickauthor=H.+Zhu&title=Ser1292+autophosphorylation+is+an+indicator+of+LRRK2+kinase+activity+and+contributes+to+the+cellular+effects+of+PD+mutations&doi=10.1126%2Fscitranslmed.3004485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004485%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBustos%26aufirst%3DD.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLe%2BPichon%26aufirst%3DC.%2BE.%26aulast%3DDominguez%26aufirst%3DS.%2BL.%26aulast%3DSolanoy%26aufirst%3DH.%2BO.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3Dvan%2Bder%2BBrug%26aufirst%3DM.%2BP.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DSer1292%2520autophosphorylation%2520is%2520an%2520indicator%2520of%2520LRRK2%2520kinase%2520activity%2520and%2520contributes%2520to%2520the%2520cellular%2520effects%2520of%2520PD%2520mutations%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persohn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmelen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grevot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Putten, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span> <span> </span><span class="NLM_article-title">LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4209</span>– <span class="NLM_lpage">4223</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddr348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1093%2Fhmg%2Fddr348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=21828077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=4209-4223&author=M.+C.+Herzigauthor=C.+Kollyauthor=E.+Persohnauthor=D.+Theilauthor=T.+Schweizerauthor=T.+Hafnerauthor=C.+Stemmelenauthor=T.+J.+Troxlerauthor=P.+Schmidauthor=S.+Dannerauthor=C.+R.+Schnellauthor=M.+Muellerauthor=B.+Kinzelauthor=A.+Grevotauthor=F.+Bolognaniauthor=M.+Stirnauthor=R.+R.+Kuhnauthor=K.+Kaupmannauthor=P.+H.+van+der%0APuttenauthor=G.+Rovelliauthor=D.+R.+Shimshek&title=LRRK2+protein+levels+are+determined+by+kinase+function+and+are+crucial+for+kidney+and+lung+homeostasis+in+mice&doi=10.1093%2Fhmg%2Fddr348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice</span></div><div class="casAuthors">Herzig, Martin C.; Kolly, Carine; Persohn, Elke; Theil, Diethilde; Schweizer, Tatjana; Hafner, Thomas; Stemmelen, Christine; Troxler, Thomas J.; Schmid, Peter; Danner, Simone; Schnell, Christian R.; Mueller, Matthias; Kinzel, Bernd; Grevot, Armelle; Bolognani, Federico; Stirn, Martina; Kuhn, Rainer R.; Kaupmann, Klemens; van der Putten, P. Herman; Rovelli, Giorgio; Shimshek, Derya R.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4209-4223</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson's disease (PD), but the underlying pathophysiol. mechanisms and the normal function of this large multidomain protein remain speculative.  To address the role of this protein in vivo, we generated three different LRRK2 mutant mouse lines.  Mice completely lacking the LRRK2 protein (knock-out, KO) showed an early-onset (age 6 wk) marked increase in no. and size of secondary lysosomes in kidney proximal tubule cells and lamellar bodies in lung type II cells.  Mice expressing a LRRK2 kinase-dead (KD) mutant from the endogenous locus displayed similar early-onset pathophysiol. changes in kidney but not lung.  KD mutants had dramatically reduced full-length LRRK2 protein levels in the kidney and this genetic effect was mimicked pharmacol. in wild-type mice treated with a LRRK2-selective kinase inhibitor.  Knock-in (KI) mice expressing the G2019S PD-assocd. mutation that increases LRRK2 kinase activity showed none of the LRRK2 protein level and histopathol. changes obsd. in KD and KO mice.  The autophagy marker LC3 remained unchanged but kidney mTOR and TCS2 protein levels decreased in KD and increased in KO and KI mice.  Unexpectedly, KO and KI mice suffered from diastolic hypertension opposed to normal blood pressure in KD mice.  Our findings demonstrate a role for LRRK2 in kidney and lung physiol. and further show that LRRK2 kinase function affects LRRK2 protein steady-state levels thereby altering putative scaffold/GTPase activity.  These novel aspects of peripheral LRRK2 biol. critically impact ongoing attempts to develop LRRK2 selective kinase inhibitors as therapeutics for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol714w-ZIM5rVg90H21EOLACvtfcHk0lgytyryZF4_og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI&md5=9c7935965c8f21e13b42bdc9e794cde0</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddr348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddr348%26sid%3Dliteratum%253Aachs%26aulast%3DHerzig%26aufirst%3DM.%2BC.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DPersohn%26aufirst%3DE.%26aulast%3DTheil%26aufirst%3DD.%26aulast%3DSchweizer%26aufirst%3DT.%26aulast%3DHafner%26aufirst%3DT.%26aulast%3DStemmelen%26aufirst%3DC.%26aulast%3DTroxler%26aufirst%3DT.%2BJ.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DDanner%26aufirst%3DS.%26aulast%3DSchnell%26aufirst%3DC.%2BR.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DB.%26aulast%3DGrevot%26aufirst%3DA.%26aulast%3DBolognani%26aufirst%3DF.%26aulast%3DStirn%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DR.%2BR.%26aulast%3DKaupmann%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BPutten%26aufirst%3DP.%2BH.%26aulast%3DRovelli%26aufirst%3DG.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26atitle%3DLRRK2%2520protein%2520levels%2520are%2520determined%2520by%2520kinase%2520function%2520and%2520are%2520crucial%2520for%2520kidney%2520and%2520lung%2520homeostasis%2520in%2520mice%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26spage%3D4209%26epage%3D4223%26doi%3D10.1093%2Fhmg%2Fddr348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaime, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelleher, R. J.,  III.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">9879</span>– <span class="NLM_lpage">9884</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004676107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1073%2Fpnas.1004676107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=20457918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFWltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=9879-9884&author=Y.+Tongauthor=H.+Yamaguchiauthor=E.+Giaimeauthor=S.+Boyleauthor=R.+Kopanauthor=R.+J.+Kelleherauthor=J.+Shen&title=Loss+of+leucine-rich+repeat+kinase+2+causes+impairment+of+protein+degradation+pathways%2C+accumulation+of+alpha-synuclein%2C+and+apoptotic+cell+death+in+aged+mice&doi=10.1073%2Fpnas.1004676107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice</span></div><div class="casAuthors">Tong, Youren; Yamaguchi, Hiroo; Giaime, Emilie; Boyle, Scott; Kopan, Raphael; Kelleher, Raymond J., III; Shen, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9879-9884, S9879/1-S9879/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease.  LRRK2 is a large protein contg. a small GTPase domain and a kinase domain, but its physiol. role is unknown.  To identify the normal function of LRRK2 in vivo, we generated two independent lines of germ-line deletion mice.  The dopaminergic system of LRRK2-/- mice appears normal, and nos. of dopaminergic neurons and levels of striatal dopamine are unchanged.  However, LRRK2-/- kidneys, which suffer the greatest loss of LRRK compared with other organs, develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins at 20 mo of age.  The autophagy-lysosomal pathway is also impaired in the absence of LRRK2, as indicated by accumulation of lipofuscin granules as well as altered levels of LC3-II and p62.  Furthermore, loss of LRRK2 dramatically increases apoptotic cell death, inflammatory responses, and oxidative damage.  Collectively, our findings show that LRRK2 plays an essential and unexpected role in the regulation of protein homeostasis during aging, and suggest that LRRK2 mutations may cause Parkinson's disease and cell death via impairment of protein degrdn. pathways, leading to α-synuclein accumulation and aggregation over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwJUmT5o1nLLVg90H21EOLACvtfcHk0lgPIm5rIPCyMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFWltrc%253D&md5=09474f2cb0fa155bb88311a5af0afbe1</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004676107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004676107%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DGiaime%26aufirst%3DE.%26aulast%3DBoyle%26aufirst%3DS.%26aulast%3DKopan%26aufirst%3DR.%26aulast%3DKelleher%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DLoss%2520of%2520leucine-rich%2520repeat%2520kinase%25202%2520causes%2520impairment%2520of%2520protein%2520degradation%2520pathways%252C%2520accumulation%2520of%2520alpha-synuclein%252C%2520and%2520apoptotic%2520cell%2520death%2520in%2520aged%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D9879%26epage%3D9884%26doi%3D10.1073%2Fpnas.1004676107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ness, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpnack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaharski, A. J.</span></span> <span> </span><span class="NLM_article-title">Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e66164</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0066164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1371%2Fjournal.pone.0066164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23799078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVemsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=D.+Nessauthor=Z.+Renauthor=S.+Gardaiauthor=D.+Sharpnackauthor=V.+J.+Johnsonauthor=R.+J.+Brennanauthor=E.+F.+Brighamauthor=A.+J.+Olaharski&title=Leucine-rich+repeat+kinase+2+%28LRRK2%29-deficient+rats+exhibit+renal+tubule+injury+and+perturbations+in+metabolic+and+immunological+homeostasis&doi=10.1371%2Fjournal.pone.0066164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis</span></div><div class="casAuthors">Ness, Daniel; Ren, Zhao; Gardai, Shyra; Sharpnack, Douglas; Johnson, Victor J.; Brennan, Richard J.; Brigham, Elizabeth F.; Olaharski, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e66164</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Genetic evidence links mutations in the LRRK2 gene with an increased risk of Parkinson's disease, for which no neuroprotective or neurorestorative therapies currently exist.  While the role of LRRK2 in normal cellular function has yet to be fully described, evidence suggests involvement with immune and kidney functions.  A comparative study of LRRK2-deficient and wild type rats investigated the influence that this gene has on the phenotype of these rats.  Significant wt. gain in the LRRK2 null rats was obsd. and was accompanied by significant increases in insulin and insulin-like growth factors.  Addnl., LRRK2-deficient rats displayed kidney morphol. and histopathol. alterations in the renal tubule epithelial cells of all animals assessed.  These perturbations in renal morphol. were accompanied by significant decreases of lipocalin-2, in both the urine and plasma of knockout animals.  Significant alterations in the cellular compn. of the spleen between LRRK2 knockout and wild type animals were identified by immunophenotyping and were assocd. with subtle differences in response to dual infection with rat-adapted influenza virus (RAIV) and Streptococcus pneumoniae.  Ontol. pathway anal. of LRRK2 across metabolic and kidney processes and pathol. categories suggested that the thioredoxin network may play a role in perturbing these organ systems.  The phenotype of the LRRK2 null rat is suggestive of a complex biol. influencing metab., immune function and kidney homeostasis.  These data need to be extended to better understand the role of the kinase domain or other biol. functions of the gene to better inform the development of pharmacol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6CzTkNcDvLVg90H21EOLACvtfcHk0lgPIm5rIPCyMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVemsLvL&md5=26f0300a87dc9c5441bdbdbeabb2c50c</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0066164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0066164%26sid%3Dliteratum%253Aachs%26aulast%3DNess%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DGardai%26aufirst%3DS.%26aulast%3DSharpnack%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DV.%2BJ.%26aulast%3DBrennan%26aufirst%3DR.%2BJ.%26aulast%3DBrigham%26aufirst%3DE.%2BF.%26aulast%3DOlaharski%26aufirst%3DA.%2BJ.%26atitle%3DLeucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529-deficient%2520rats%2520exhibit%2520renal%2520tubule%2520injury%2520and%2520perturbations%2520in%2520metabolic%2520and%2520immunological%2520homeostasis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0066164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greeley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varsho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshul, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span> <span> </span><span class="NLM_article-title">Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e80705</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0080705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1371%2Fjournal.pone.0080705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=24244710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+A.+Baptistaauthor=K.+D.+Daveauthor=M.+A.+Frasierauthor=T.+B.+Shererauthor=M.+Greeleyauthor=M.+J.+Beckauthor=J.+S.+Varshoauthor=G.+A.+Parkerauthor=C.+Mooreauthor=M.+J.+Churchillauthor=C.+K.+Meshulauthor=B.+K.+Fiske&title=Loss+of+leucine-rich+repeat+kinase+2+%28LRRK2%29+in+rats+leads+to+progressive+abnormal+phenotypes+in+peripheral+organs&doi=10.1371%2Fjournal.pone.0080705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of leucine-rich repeat kinase 2 (LRKK2) in rats leads to progressive abnormal phenotypes in peripheral organs</span></div><div class="casAuthors">Baptista, Marco A. S.; Dave, Kuldip D.; Frasier, Mark A.; Sherer, Todd B.; Greeley, Melanie; Beck, Melissa J.; Varsho, Julie S.; Parker, George A.; Moore, Cindy; Churchill, Madeline J.; Meshul, Charles K.; Fiske, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e80705/1-e80705/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate the pathol. time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-mo of age.  The evaluation consisted of histopathol. and ultrastructure examn. of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematol., serum, and urine anal.  The LRRK2 knockout rat, starting at 2-mo of age, displayed abnormal kidney staining patterns and/or morphol. changes that were assocd. with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat.  Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine sp. gr., total vol., urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-mo of age.  Electron microscopy of 16-mo old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype.  In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats.  These findings partially replicate data from a recent study in 4-mo old LRRK2 knockout rats and expand the anal. to demonstrate that the renal and possibly lung and liver abnormalities progress with age.  The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0nBkK8AbyV7Vg90H21EOLACvtfcHk0lgPIm5rIPCyMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D&md5=f10ad0059276bf1b2894df72772a8151</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0080705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0080705%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DM.%2BA.%26aulast%3DDave%26aufirst%3DK.%2BD.%26aulast%3DFrasier%26aufirst%3DM.%2BA.%26aulast%3DSherer%26aufirst%3DT.%2BB.%26aulast%3DGreeley%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DM.%2BJ.%26aulast%3DVarsho%26aufirst%3DJ.%2BS.%26aulast%3DParker%26aufirst%3DG.%2BA.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DChurchill%26aufirst%3DM.%2BJ.%26aulast%3DMeshul%26aufirst%3DC.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26atitle%3DLoss%2520of%2520leucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529%2520in%2520rats%2520leads%2520to%2520progressive%2520abnormal%2520phenotypes%2520in%2520peripheral%2520organs%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0080705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeggo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotty, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thougaard, A.</span></span> <span> </span><span class="NLM_article-title">PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2Fj.tox.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=29307545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2018&pages=15-22&author=M.+A.+Andersenauthor=K.+M.+Wegenerauthor=S.+Larsenauthor=L.+Badoloauthor=G.+P.+Smithauthor=R.+Jeggoauthor=P.+H.+Jensenauthor=F.+Sottyauthor=K.+V.+Christensenauthor=A.+Thougaard&title=PFE-360-induced+LRRK2+inhibition+induces+reversible%2C+non-adverse+renal+changes+in+rats&doi=10.1016%2Fj.tox.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats</span></div><div class="casAuthors">Andersen, Michael Aagaard; Wegener, Karen Malene; Larsen, Steen; Badolo, Lassina; Smith, Garrick Paul; Jeggo, Ross; Jensen, Poul Henning; Sotty, Florence; Christensen, Kenneth Vielsted; Thougaard, Annemette</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-22</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no existing therapeutic approach to delay or stop progression.  Genetic, biochem. and pre-clin. studies have provided evidence that leucine-rich-repeat-kinase-2 (LRRK2) kinase is involved in the pathogenesis of PD, and small mol. LRRK2 inhibitors represent a novel potential therapeutic approach.  However, potentially adverse target-related effects have been discovered in the lung and kidneys of LRRK2 knock-out (ko) mice and rats.  It is unclear if the LRRK2 ko effect in the kidneys and lung is also induced by pharmacol. inhibition of the LRRK2 kinase.  Here, we show that treatment with the LRRK2 inhibitor PFE-360 in rats induces a morphol. kidney phenotype resembling that of the LRRK2 ko rats, whereas no effects were obsd. in the lung.  The PFE-360 treatment induced morphol. changes characterised by darkened kidneys and progressive accumulation of hyaline droplets in the renal proximal tubular epithelium.  However, no histopathol. evidence of renal tubular injury or changes in the blood and urine parameters that would be indicative of kidney toxicity or impaired kidney function were obsd. after up to 12 wk of treatment.  Morphol. changes were detected in the kidney after 2 wk of treatment and were partially reversible within a 30 day treatment-free period.  Our findings suggest that pharmacol. LRRK2 inhibition may not have adverse consequences for kidney function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjrIewka3O1rVg90H21EOLACvtfcHk0liJdUs3afsfsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFamtw%253D%253D&md5=f576f650ba63043dcf13937e547ab3b6</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DM.%2BA.%26aulast%3DWegener%26aufirst%3DK.%2BM.%26aulast%3DLarsen%26aufirst%3DS.%26aulast%3DBadolo%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BP.%26aulast%3DJeggo%26aufirst%3DR.%26aulast%3DJensen%26aufirst%3DP.%2BH.%26aulast%3DSotty%26aufirst%3DF.%26aulast%3DChristensen%26aufirst%3DK.%2BV.%26aulast%3DThougaard%26aufirst%3DA.%26atitle%3DPFE-360-induced%2520LRRK2%2520inhibition%2520induces%2520reversible%252C%2520non-adverse%2520renal%2520changes%2520in%2520rats%26jtitle%3DToxicology%26date%3D2018%26volume%3D395%26spage%3D15%26epage%3D22%26doi%3D10.1016%2Fj.tox.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheewatrakoolpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMong, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgraf, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulet, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, J. A.</span></span> <span> </span><span class="NLM_article-title">MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">397</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.227587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1124%2Fjpet.115.227587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=26407721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=397&author=M.+J.+Fellauthor=C.+Mirescuauthor=K.+Basuauthor=B.+Cheewatrakoolpongauthor=D.+E.+DeMongauthor=J.+M.+Ellisauthor=L.+A.+Hydeauthor=Y.+Linauthor=C.+G.+Markgrafauthor=H.+Meiauthor=M.+Millerauthor=F.+M.+Pouletauthor=J.+D.+Scottauthor=M.+D.+Smithauthor=Z.+Yinauthor=X.+Zhouauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=J.+A.+Morrow&title=MLi-2%2C+a+potent%2C+selective%2C+and+centrally+active+compound+for+exploring+the+therapeutic+potential+and+safety+of+LRRK2+kinase+inhibition&doi=10.1124%2Fjpet.115.227587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition</span></div><div class="casAuthors">Fell, Matthew J.; Mirescu, Christian; Basu, Kallol; Cheewatrakoolpong, Boonlert; DeMong, Duane E.; Ellis, J. Michael; Hyde, Lynn A.; Lin, Yinghui; Markgraf, Carrie G.; Mei, Hong; Miller, Michael; Poulet, Frederique M.; Scott, Jack D.; Smith, Michelle D.; Yin, Zhizhang; Zhou, Xiaoping; Parker, Eric M.; Kennedy, Matthew E.; Morrow, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of familial and sporadic Parkinson's disease (PD).  That the most prevalent mutation, G2019S, leads to increased kinase activity has led to a concerted effort to identify LRRK2 kinase inhibitors as a potential disease-modifying therapy for PD.  An internal medicinal chem. effort identified several potent and highly selective compds. with favorable drug-like properties.  Here, we characterize the pharmacol. properties of cis-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine (MLi-2), a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.  MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).  MLi-2 has greater than 295-fold selectivity for over 300 kinases in addn. to a diverse panel of receptors and ion channels.  Acute oral and subchronic dosing in MLi-2 mice resulted in dose-dependent central and peripheral target inhibition over a 24-h period as measured by dephosphorylation of pSer935 LRRK2.  Treatment of MitoPark mice with MLi-2 was well tolerated over a 15-wk period at brain and plasma exposures >100× the in vivo plasma IC50 for LRRK2 kinase inhibition as measured by pSer935 dephosphorylation.  Morphol. changes in the lung, consistent with enlarged type II pneumocytes, were obsd. in MLi-2-treated MitoPark mice.  These data demonstrate the suitability of MLi-2 as a compd. to explore LRRK2 biol. in cellular and animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpot402TvUrkbVg90H21EOLACvtfcHk0liJdUs3afsfsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D&md5=83c68f7bb731bef2fa9db880196dbabe</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227587%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DMirescu%26aufirst%3DC.%26aulast%3DBasu%26aufirst%3DK.%26aulast%3DCheewatrakoolpong%26aufirst%3DB.%26aulast%3DDeMong%26aufirst%3DD.%2BE.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DMarkgraf%26aufirst%3DC.%2BG.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPoulet%26aufirst%3DF.%2BM.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DMorrow%26aufirst%3DJ.%2BA.%26atitle%3DMLi-2%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520centrally%2520active%2520compound%2520for%2520exploring%2520the%2520therapeutic%2520potential%2520and%2520safety%2520of%2520LRRK2%2520kinase%2520inhibition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D397%26doi%3D10.1124%2Fjpet.115.227587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katavolos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roose-Girma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urkowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warming, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaylaoglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span> <span> </span><span class="NLM_article-title">Effect of selective LRRK2 kinase inhibition on nonhuman primate lung</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">273ra15</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa3634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.aaa3634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=25653221" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=R.+N.+Fujiauthor=M.+Flagellaauthor=M.+Bacaauthor=M.+A.+Baptistaauthor=J.+Brodbeckauthor=B.+K.+Chanauthor=B.+K.+Fiskeauthor=L.+Honigbergauthor=A.+M.+Jubbauthor=P.+Katavolosauthor=D.+W.+Leeauthor=S.+C.+Lewin-Kohauthor=T.+Linauthor=X.+Liuauthor=S.+Liuauthor=J.+P.+Lyssikatosauthor=J.+O%E2%80%99Mahonyauthor=M.+Reicheltauthor=M.+Roose-Girmaauthor=Z.+Shengauthor=T.+Shererauthor=A.+Smithauthor=M.+Solonauthor=Z.+K.+Sweeneyauthor=J.+Tarrantauthor=A.+Urkowitzauthor=S.+Warmingauthor=M.+Yaylaogluauthor=S.+Zhangauthor=H.+Zhuauthor=A.+A.+Estradaauthor=R.+J.+Watts&title=Effect+of+selective+LRRK2+kinase+inhibition+on+nonhuman+primate+lung&doi=10.1126%2Fscitranslmed.aaa3634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa3634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa3634%26sid%3Dliteratum%253Aachs%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DBaca%26aufirst%3DM.%26aulast%3DBaptista%26aufirst%3DM.%2BA.%26aulast%3DBrodbeck%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26aulast%3DHonigberg%26aufirst%3DL.%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DKatavolos%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DLewin-Koh%26aufirst%3DS.%2BC.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DJ.%26aulast%3DReichelt%26aufirst%3DM.%26aulast%3DRoose-Girma%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSherer%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSolon%26aufirst%3DM.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DUrkowitz%26aufirst%3DA.%26aulast%3DWarming%26aufirst%3DS.%26aulast%3DYaylaoglu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26atitle%3DEffect%2520of%2520selective%2520LRRK2%2520kinase%2520inhibition%2520on%2520nonhuman%2520primate%2520lung%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26doi%3D10.1126%2Fscitranslmed.aaa3634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhargava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryce, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galatsis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddess, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgraf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T. B.</span></span> <span> </span><span class="NLM_article-title">LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">eaav0820</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aav0820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.aav0820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=32321864" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=M.+A.+S.+Baptistaauthor=K.+Merchantauthor=T.+Barrettauthor=S.+Bhargavaauthor=D.+K.+Bryceauthor=J.+M.+Ellisauthor=A.+A.+Estradaauthor=M.+J.+Fellauthor=B.+K.+Fiskeauthor=R.+N.+Fujiauthor=P.+Galatsisauthor=A.+G.+Henryauthor=S.+Hillauthor=W.+Hirstauthor=C.+Houleauthor=M.+E.+Kennedyauthor=X.+Liuauthor=M.+L.+Maddessauthor=C.+Markgrafauthor=H.+Meiauthor=W.+A.+Meierauthor=E.+Needleauthor=S.+Plochauthor=C.+Royerauthor=K.+Rudolphauthor=A.+K.+Sharmaauthor=A.+Stepanauthor=S.+Steynauthor=C.+Trostauthor=Z.+Yinauthor=H.+Yuauthor=X.+Wangauthor=T.+B.+Sherer&title=LRRK2+inhibitors+induce+reversible+changes+in+nonhuman+primate+lungs+without+measurable+pulmonary+deficits&doi=10.1126%2Fscitranslmed.aav0820"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aav0820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aav0820%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DM.%2BA.%2BS.%26aulast%3DMerchant%26aufirst%3DK.%26aulast%3DBarrett%26aufirst%3DT.%26aulast%3DBhargava%26aufirst%3DS.%26aulast%3DBryce%26aufirst%3DD.%2BK.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DGalatsis%26aufirst%3DP.%26aulast%3DHenry%26aufirst%3DA.%2BG.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DW.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMaddess%26aufirst%3DM.%2BL.%26aulast%3DMarkgraf%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMeier%26aufirst%3DW.%2BA.%26aulast%3DNeedle%26aufirst%3DE.%26aulast%3DPloch%26aufirst%3DS.%26aulast%3DRoyer%26aufirst%3DC.%26aulast%3DRudolph%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DStepan%26aufirst%3DA.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DTrost%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSherer%26aufirst%3DT.%2BB.%26atitle%3DLRRK2%2520inhibitors%2520induce%2520reversible%2520changes%2520in%2520nonhuman%2520primate%2520lungs%2520without%2520measurable%2520pulmonary%2520deficits%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26doi%3D10.1126%2Fscitranslmed.aav0820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fonzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohé, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabrizio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanacore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwurm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampaio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oostra, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifati, V.</span></span> <span> </span><span class="NLM_article-title">A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)17829-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2FS0140-6736%2805%2917829-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=15680456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslWitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=412-415&author=A.+Di+Fonzoauthor=C.+F.+Roh%C3%A9author=J.+Ferreiraauthor=H.+F.+Chienauthor=L.+Vaccaauthor=F.+Stocchiauthor=L.+Guedesauthor=E.+Fabrizioauthor=M.+Manfrediauthor=N.+Vanacoreauthor=S.+Goldwurmauthor=G.+Breedveldauthor=C.+Sampaioauthor=G.+Mecoauthor=E.+Barbosaauthor=B.+A.+Oostraauthor=V.+Bonifati&title=A+frequent+LRRK2+gene+mutation+associated+with+autosomal+dominant+Parkinson%E2%80%99s+disease&doi=10.1016%2FS0140-6736%2805%2917829-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease</span></div><div class="casAuthors">Di Fonzo, Alessio; Rohe, Christan F.; Ferreira, Joaquim; Chien, Hsin F.; Vacca, Laura; Stocchi, Fabrizio; Guedes, Leonor; Fabrizio, Edito; Manfredi, Mario; Vanacore, Nicola; Goldwurm, Stefano; Breedveld, Guido; Sampaio, Cristina; Meco, Giuseppe; Barbosa, Egberto; Oostra, Ben A.; Bonifati, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9457</span>),
    <span class="NLM_cas:pages">412-415</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutations in the LRRK2 gene have been identified in families with autosomal dominant parkinsonism.  We amplified and sequenced the coding region of LRRK2 from genomic DNA by PCR, and identified a heterozygous mutation (Gly2019 ser) present in four of 61 (6.6%) unrelated families with Parkinson's disease and autosomal dominant inheritance.  The families originated from Italy, Portugal, and Brazil, indicating the presence of the mutation in different populations.  The assocd. phenotype was broad, including early and late disease onset.  These findings confirm the assocn. of LRRK2 with neurodegeneration, and identify a common mutation assocd. with dominantly inherited Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnS_VZvZOVD7Vg90H21EOLACvtfcHk0ljL3r1dCpSv7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslWitg%253D%253D&md5=bbe725d2adbbdbc5fbce57fca70b3bff</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2917829-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252917829-5%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BFonzo%26aufirst%3DA.%26aulast%3DRoh%25C3%25A9%26aufirst%3DC.%2BF.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DChien%26aufirst%3DH.%2BF.%26aulast%3DVacca%26aufirst%3DL.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DGuedes%26aufirst%3DL.%26aulast%3DFabrizio%26aufirst%3DE.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DVanacore%26aufirst%3DN.%26aulast%3DGoldwurm%26aufirst%3DS.%26aulast%3DBreedveld%26aufirst%3DG.%26aulast%3DSampaio%26aufirst%3DC.%26aulast%3DMeco%26aufirst%3DG.%26aulast%3DBarbosa%26aufirst%3DE.%26aulast%3DOostra%26aufirst%3DB.%2BA.%26aulast%3DBonifati%26aufirst%3DV.%26atitle%3DA%2520frequent%2520LRRK2%2520gene%2520mutation%2520associated%2520with%2520autosomal%2520dominant%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D412%26epage%3D415%26doi%3D10.1016%2FS0140-6736%2805%2917829-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kestenbaum, M.</span>; <span class="NLM_string-name">Alcalay, R. N.</span></span> <span> </span><span class="NLM_article-title">Clinical Features of LRRK2 Carriers with Parkinson’s Disease</span>. In  <i>Leucine-Rich Repeat Kinase 2 (LRRK2)</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideout, H. J.</span></span>, Ed.; <span class="NLM_series">Advances in Neurobiology 14</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2017</span>; p  <span class="NLM_fpage">36</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1007%2F978-3-319-49969-7_2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=36&author=M.+Kestenbaum&author=R.+N.+Alcalayauthor=H.+J.+Rideout&title=Leucine-Rich+Repeat+Kinase+2+%28LRRK2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-49969-7_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-49969-7_2%26sid%3Dliteratum%253Aachs%26aulast%3DKestenbaum%26aufirst%3DM.%26atitle%3DClinical%2520Features%2520of%2520LRRK2%2520Carriers%2520with%2520Parkinson%25E2%2580%2599s%2520Disease%26btitle%3DLeucine-Rich%2520Repeat%2520Kinase%25202%2520%2528LRRK2%2529%26aulast%3DRideout%26aufirst%3DH.%2BJ.%26pub%3DSpringer%26date%3D2017%26spage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span> </span><span class="NLM_article-title">The Aptuit library
is now part of Evotec’s screening collection</span>. See Evotec hit identificaton website: <a href="https://www.evotec.com/en/execute/drug-discovery-services/hit-identification" class="extLink">https://www.evotec.com/en/execute/drug-discovery-services/hit-identification</a> (accessed May <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Aptuit+library%0Ais+now+part+of+Evotec%E2%80%99s+screening+collection.+See+Evotec+hit+identificaton+website%3A+https%3A%2F%2Fwww.evotec.com%2Fen%2Fexecute%2Fdrug-discovery-services%2Fhit-identification+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Aptuit%2520library%250Ais%2520now%2520part%2520of%2520Evotec%25E2%2580%2599s%2520screening%2520collection%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagnerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+the+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520the%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">MLi-2 PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OPB">5OPB</a>; as of Jan. 2020, there were over 70 indazole-containing kinase inhibitor structures in the PDB with an indazole contributing the key hinge binding interactions.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, G. O.</span></span> <span> </span><span class="NLM_article-title">Proton magnetic resonance spectra of thiocarboxamides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">823</span>, <span class="refDoi"> DOI: 10.1021/jo01278a074</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01278a074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADyaF2sXkt1Wgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1967&pages=823&author=E.+P.+Dudekauthor=G.+O.+Dudek&title=Proton+magnetic+resonance+spectra+of+thiocarboxamides&doi=10.1021%2Fjo01278a074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Proton magnetic resonance spectra of thiocarboxamides</span></div><div class="casAuthors">Dudek, Emily P.; Dudek, Gerald O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">823-4</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The proton magnetic spectra of I (R = Ph) (Goerdeler and Keuser, CA 61: 11983h), I (R = Et, m. 54.6-5.4°), I (R = Me, m. 138.8-9.6°), and 4,4-dimethyl-2-(methylamino)-6-oxo-1-cyclohexene-1-thiocarboxanilide (loc. cit.) were detd. in CDCl3 and (or) CCl4.  The substitution of S for the amide O does not greatly alter the nature of the conjugated system and the results suggest that S is as able as O to participate in the unusual cross-conjugation and H bonding in these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE10qPUW44LrVg90H21EOLACvtfcHk0li-7oCq5kpc8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXkt1Wgsbc%253D&md5=51aafa9e4fbc85089b21f9a474b0e471</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo01278a074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01278a074%26sid%3Dliteratum%253Aachs%26aulast%3DDudek%26aufirst%3DE.%2BP.%26aulast%3DDudek%26aufirst%3DG.%2BO.%26atitle%3DProton%2520magnetic%2520resonance%2520spectra%2520of%2520thiocarboxamides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1967%26volume%3D32%26spage%3D823%26doi%3D10.1021%2Fjo01278a074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Pichon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanoy, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Brug, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span> <span> </span><span class="NLM_article-title">Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">164ra161</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.3004485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23241745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=Z.+Shengauthor=S.+Zhangauthor=D.+Bustosauthor=T.+Kleinheinzauthor=C.+E.+Le+Pichonauthor=S.+L.+Dominguezauthor=H.+O.+Solanoyauthor=J.+Drummondauthor=X.+Zhangauthor=X.+Dingauthor=F.+Caiauthor=Q.+Songauthor=X.+Liauthor=Z.+Yueauthor=M.+P.+van+der+Brugauthor=D.+J.+Burdickauthor=J.+Gunzner-Tosteauthor=H.+Chenauthor=X.+Liuauthor=A.+A.+Estradaauthor=Z.+K.+Sweeneyauthor=K.+Scearce-Levieauthor=J.+G.+Moffatauthor=D.+S.+Kirkpatrickauthor=H.+Zhu&title=Ser1292+autophosphorylation+is+an+indicator+of+LRRK2+kinase+activity+and+contributes+to+the+cellular+effects+of+PD+mutations&doi=10.1126%2Fscitranslmed.3004485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004485%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBustos%26aufirst%3DD.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLe%2BPichon%26aufirst%3DC.%2BE.%26aulast%3DDominguez%26aufirst%3DS.%2BL.%26aulast%3DSolanoy%26aufirst%3DH.%2BO.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3Dvan%2Bder%2BBrug%26aufirst%3DM.%2BP.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DSer1292%2520autophosphorylation%2520is%2520an%2520indicator%2520of%2520LRRK2%2520kinase%2520activity%2520and%2520contributes%2520to%2520the%2520cellular%2520effects%2520of%2520PD%2520mutations%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzamko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser<sup>910</sup>/Ser<sup>935</sup>, disruption of 14-3-3 binding and altered cytoplasmic localization</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">405</span>, <span class="refDoi"> DOI: 10.1042/BJ20100784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1042%2FBJ20100784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=20659021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=405&author=N.+Dzamkoauthor=M.+Deakauthor=F.+Hentatiauthor=A.+D.+Reithauthor=A.+R.+Prescottauthor=D.+R.+Alessiauthor=R.+J.+Nichols&title=Inhibition+of+LRRK2+kinase+activity+leads+to+dephosphorylation+of+Ser910%2FSer935%2C+disruption+of+14-3-3+binding+and+altered+cytoplasmic+localization&doi=10.1042%2FBJ20100784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization</span></div><div class="casAuthors">Dzamko, Nicolas; Deak, Maria; Hentati, Faycal; Reith, Alastair D.; Prescott, Alan R.; Alessi, Dario R.; Nichols, R. Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant no. of Parkinson's disease patients.  Since a common mutation that replaces Gly2019 with a serine residue enhances kinase catalytic activity, small-mol. LRRK2 inhibitors might have utility in treating Parkinson's disease.  However, the effectiveness of inhibitors is difficult to assess, as no physiol. substrates or downstream effectors have been identified that could be exploited to develop a robust cell-based assay.  The authors recently established that LRRK2 bound 14-3-3 protein isoforms via its phosphorylation of Ser910 and Ser935.  In the present study they show that treatment of Swiss 3T3 cells or lymphoblastoid cells derived from control or a Parkinson's disease patient harboring a homozygous LRRK2(G2019S) mutation with two structurally unrelated inhibitors of LRRK2 (H-1152 or sunitinib) induced dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, thereby disrupting 14-3-3 interaction.  The results suggest that H-1152 and sunitinib induce dephosphorylation of Ser910 and Ser935 by inhibiting LRRK2 kinase activity, as these compds. failed to induce significant dephosphorylation of a drug-resistant LRRK2(A2016T) mutant.  Moreover, consistent with the finding that non-14-3-3-binding mutants of LRRK2 accumulated within discrete cytoplasmic pools resembling inclusion bodies, the authors obsd. that H-1152 causes LRRK2 to accumulate within inclusion bodies.  These findings indicate that dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and/or monitoring LRRK2 cytoplasmic localization can be used as an assay to assess the relative activity of LRRK2 inhibitors in vivo.  These results will aid the elaboration and evaluation of LRRK2 inhibitors.  They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwgToKFLmVu7Vg90H21EOLACvtfcHk0lgX53hIr03h7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL&md5=f14dd622d2b2fa3f7495c990e65bbbfc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1042%2FBJ20100784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100784%26sid%3Dliteratum%253Aachs%26aulast%3DDzamko%26aufirst%3DN.%26aulast%3DDeak%26aufirst%3DM.%26aulast%3DHentati%26aufirst%3DF.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26atitle%3DInhibition%2520of%2520LRRK2%2520kinase%2520activity%2520leads%2520to%2520dephosphorylation%2520of%2520Ser910%252FSer935%252C%2520disruption%2520of%252014-3-3%2520binding%2520and%2520altered%2520cytoplasmic%2520localization%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D405%26doi%3D10.1042%2FBJ20100784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhaiyan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishna, S.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial and antioxidant activity evaluation of tetrazolo[1,5-<i>a</i>]pyrimidines: A simple diisopropylammonium trifluoroacetate mediated synthesis</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">11657</span>– <span class="NLM_lpage">11663</span>, <span class="refDoi"> DOI: 10.1039/c2ra21330c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1039%2Fc2ra21330c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ahu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=11657-11663&author=C.+Rajuauthor=K.+Madhaiyanauthor=R.+Umaauthor=R.+Sridharauthor=S.+Ramakrishna&title=Antimicrobial+and+antioxidant+activity+evaluation+of+tetrazolo%5B1%2C5-a%5Dpyrimidines%3A+A+simple+diisopropylammonium+trifluoroacetate+mediated+synthesis&doi=10.1039%2Fc2ra21330c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial and antioxidant activity evaluation of tetrazolo[1,5-a]pyrimidines: A simple diisopropylammonium trifluoroacetate mediated synthesis</span></div><div class="casAuthors">Raju, Chandran; Madhaiyan, Kalaipriya; Uma, Ramakrishnan; Sridhar, Radhakrishnan; Ramakrishna, Seeram</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11657-11663</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A simple, efficient, economic synthesis of tetrazolo[1,5-a]pyrimidine-6-carboxylate derivs. was accomplished by three-component reaction of β-keto esters with a mixt. of arom. aldehyde and 5-aminotetrazole using TFA:DIPEA (1:1) as the catalyst [N-ethyl-N-(1-methylethyl)-2-propanamine trifluoroacetate].  The synthesized tetrazole compds. are evaluated for their antimicrobial and antioxidant activity.  The synthesis of the target compds. was achieved using 2H-tetrazol-5-amine, 2-naphthalenecarboxaldehyde, [1,1'-biphenyl]-2-carboxaldehyde, 3-pyridinecarboxaldehyde, 3-Furancarboxaldehyde, etc., 3-oxobutanoic acid Et ester, 5,5-dimethyl-1,3-cyclohexanedione as starting materials.  The title compds. thus formed included 1,7-dihydro-5-methyl-7-(2-naphthalenyl)tetrazolo[1,5-a]pyrimidine-6-carboxylic acid Et ester (I) and related compds., such as tetrazolo[5,1-b]quinazolin-8(1H)-one derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjLUiEx3NRPrVg90H21EOLACvtfcHk0lgX53hIr03h7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ahu7%252FE&md5=2c8dd0ce0aa4bd3d9fc4481690796a9e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2Fc2ra21330c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ra21330c%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DC.%26aulast%3DMadhaiyan%26aufirst%3DK.%26aulast%3DUma%26aufirst%3DR.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DRamakrishna%26aufirst%3DS.%26atitle%3DAntimicrobial%2520and%2520antioxidant%2520activity%2520evaluation%2520of%2520tetrazolo%255B1%252C5-a%255Dpyrimidines%253A%2520A%2520simple%2520diisopropylammonium%2520trifluoroacetate%2520mediated%2520synthesis%26jtitle%3DRSC%2520Adv.%26date%3D2012%26volume%3D2%26spage%3D11657%26epage%3D11663%26doi%3D10.1039%2Fc2ra21330c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikunaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohyama, Y.</span></span> <span> </span><span class="NLM_article-title">Synthetic studies on novel 1,4-dihydro-2-methylthio-4,4,6-trisubstituted pyrimidine-5-carboxylic acid esters and their tautomers</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1458</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1248/cpb.59.1458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1248%2Fcpb.59.1458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=22130366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Kisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=1458-1466&author=Y.+Nishimuraauthor=Y.+Okamotoauthor=M.+Ikunakaauthor=Y.+Ohyama&title=Synthetic+studies+on+novel+1%2C4-dihydro-2-methylthio-4%2C4%2C6-trisubstituted+pyrimidine-5-carboxylic+acid+esters+and+their+tautomers&doi=10.1248%2Fcpb.59.1458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic studies on novel 1,4-dihydro-2-methylthio-4,4,6-trisubstituted pyrimidine-5-carboxylic acid esters and their tautomers</span></div><div class="casAuthors">Nishimura, Yoshio; Okamoto, Yasuko; Ikunaka, Masaya; Ohyama, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1458-1466</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A mixt. of alkyl 1,4-dihydro-2-methylthio-4,4,6-trisubstituted pyrimidine-5-carboxylate I [R1 = R2 = R3 = R4 = Me; R1 = Ph, R2 = R4 = Et, R3 = Me; R1 = R2 = (CH2)2Me, R3 = Me, R4 = Et; etc.] and its tautomeric isomer, alkyl 1,6-dihydro-2-methylthio-4,6,6-trisubstituted pyrimidine-5-carboxylate II is synthesized by the Atwal-Biginelli cyclocondensation reaction of S-methylisothiourea hemisulfate salt with 2-(gem-disubstituted)methylene-3-oxo-esters R3COC(CO2R4):CR1R2 that can be accessed by the Lehnert procedure for the Knoevenagel-type condensation.  The structures of the tautomeric products of the Atwal-Biginelli cyclocondensation reaction, I and II, which are inseparable from each other, are detd. unambiguously by 1H-NMR spectroscopy at various temps. and nuclear Overhauser enhancement spectroscopy (NOESY) expt.  Because these dihydropyrimidine products are otherwise inaccessible and thus hitherto unavailable, the synthetic methods established in this study will help to expand the mol. diversity of their related derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt8e2S8zAemrVg90H21EOLACvtfcHk0lgX53hIr03h7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Kisbs%253D&md5=f3fa9b4d69f7b0bfa481c97ae938a783</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1248%2Fcpb.59.1458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.59.1458%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DIkunaka%26aufirst%3DM.%26aulast%3DOhyama%26aufirst%3DY.%26atitle%3DSynthetic%2520studies%2520on%2520novel%25201%252C4-dihydro-2-methylthio-4%252C4%252C6-trisubstituted%2520pyrimidine-5-carboxylic%2520acid%2520esters%2520and%2520their%2520tautomers%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2011%26volume%3D59%26spage%3D1458%26epage%3D1466%26doi%3D10.1248%2Fcpb.59.1458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':[],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominika Natalia  Wojewska</span>, <span class="hlFld-ContribAuthor ">Arjan  Kortholt</span>. </span><span class="cited-content_cbyCitation_article-title">LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (8)
                                     , 1101. <a href="https://doi.org/10.3390/biom11081101" title="DOI URL">https://doi.org/10.3390/biom11081101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11081101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11081101%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DLRRK2%252BTargeting%252BStrategies%252Bas%252BPotential%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DWojewska%26aufirst%3DDominika%2BNatalia%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D8%26spage%3D1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keyvan  Pedrood</span>, <span class="hlFld-ContribAuthor ">Mohammad Nazari  Montazer</span>, <span class="hlFld-ContribAuthor ">Bagher  Larijani</span>, <span class="hlFld-ContribAuthor ">Mohammad  Mahdavi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Synthesis of Heterocycles by the Aza-Wittig Reaction. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>53 </em>
                                    (14)
                                     , 2342-2366. <a href="https://doi.org/10.1055/a-1394-7511" title="DOI URL">https://doi.org/10.1055/a-1394-7511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1394-7511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1394-7511%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BSynthesis%252Bof%252BHeterocycles%252Bby%252Bthe%252BAza-Wittig%252BReaction%26aulast%3DPedrood%26aufirst%3DKeyvan%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D14%26spage%3D2342%26epage%3D2366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonia  Azeggagh</span>, <span class="hlFld-ContribAuthor ">Daniel C.  Berwick</span>. </span><span class="cited-content_cbyCitation_article-title">The development of inhibitors of leucine‐rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.1111/bph.15575" title="DOI URL">https://doi.org/10.1111/bph.15575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15575%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DThe%252Bdevelopment%252Bof%252Binhibitors%252Bof%252Bleucine%2525E2%252580%252590rich%252Brepeat%252Bkinase%252B2%252B%252528LRRK2%252529%252Bas%252Ba%252Btherapeutic%252Bstrategy%252Bfor%252BParkinson%252527s%252Bdisease%25253A%252Bthe%252Bcurrent%252Bstate%252Bof%252Bplay%26aulast%3DAzeggagh%26aufirst%3DSonia%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica M.  Bright</span>, <span class="hlFld-ContribAuthor ">Holly J.  Carlisle</span>, <span class="hlFld-ContribAuthor ">Alyssa M. A.  Toda</span>, <span class="hlFld-ContribAuthor ">Molly  Murphy</span>, <span class="hlFld-ContribAuthor ">Tyler P.  Molitor</span>, <span class="hlFld-ContribAuthor ">Paul  Wren</span>, <span class="hlFld-ContribAuthor ">Kristin M.  Andruska</span>, <span class="hlFld-ContribAuthor ">Enchi  Liu</span>, <span class="hlFld-ContribAuthor ">Carrolee  Barlow</span>. </span><span class="cited-content_cbyCitation_article-title">Differential Inhibition of
              LRRK2
              in Parkinson's Disease Patient Blood by a
              G2019S
              Selective
              LRRK2
              Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Movement Disorders</span><span> <strong>2021,</strong> <em>36 </em>
                                    (6)
                                     , 1362-1371. <a href="https://doi.org/10.1002/mds.28490" title="DOI URL">https://doi.org/10.1002/mds.28490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mds.28490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmds.28490%26sid%3Dliteratum%253Aachs%26jtitle%3DMovement%2520Disorders%26atitle%3DDifferential%252BInhibition%252Bof%252BLRRK2%252Bin%252BParkinson%252527s%252BDisease%252BPatient%252BBlood%252Bby%252Ba%252BG2019S%252BSelective%252BLRRK2%252BInhibitor%26aulast%3DBright%26aufirst%3DJessica%2BM.%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D6%26spage%3D1362%26epage%3D1371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Markella  Konstantinidou</span>, <span class="hlFld-ContribAuthor ">Asmaa  Oun</span>, <span class="hlFld-ContribAuthor ">Pragya  Pathak</span>, <span class="hlFld-ContribAuthor ">Bidong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zefeng  Wang</span>, <span class="hlFld-ContribAuthor ">Frans  ter Brake</span>, <span class="hlFld-ContribAuthor ">Amalia M.  Dolga</span>, <span class="hlFld-ContribAuthor ">Arjan  Kortholt</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (6)
                                     , 959-965. <a href="https://doi.org/10.1002/cmdc.202000872" title="DOI URL">https://doi.org/10.1002/cmdc.202000872</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000872%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252Btale%252Bof%252Bproteolysis%252Btargeting%252Bchimeras%252B%252528PROTACs%252529%252Bfor%252BLeucine%2525E2%252580%252590Rich%252BRepeat%252BKinase%252B2%252B%252528LRRK2%252529%26aulast%3DKonstantinidou%26aufirst%3DMarkella%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D6%26spage%3D959%26epage%3D965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Homology model of the LRRK2 kinase domain depicting compound <b>1</b> docked into the ATP pocket. Principal hydrogen-bonding interactions involve both N-1 and N-2 of the indazole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Amide substitutions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0004.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Determination of absolute stereochemistry from chiral carboxylic acids. (a) Chiral HPLC separation using an (R,R)-Whelk-O 1 column (25 cm × 2 cm), 10 μm, eluting with 40:60 <i>n</i>-hexane:EtOH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0005.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of pThr73-Rab10 in HEK293 cell lines overexpressing either WT-LRRK2 or G2019S-LRRK2. (A) Compound <b>31</b> inhibited phosphorylation of the LRRK2 substrate, Rab10, 344-fold more potently in the G2019S-LRRK2 overexpression line (IC<sub>50</sub> = 11.4 ± 1.1 nM, <i>n</i> = 3) compared to that in the WT-LRRK2 overexpression line (IC<sub>50</sub> = 3,924 ± 1.6 nM, <i>n</i> = 3). (B) MLi-2 showed similar potency on pThr73-Rab10 in both cell lines (HEK/G2019S-LRRK2 IC<sub>50</sub> = 8.5 ± 1.3 nM, <i>n</i> = 3; HEK/WT-LRRK2 IC<sub>50</sub> = 12.5 ± 1.1 nM, <i>n</i> = 3). (C) Compound <b>31</b> inhibited pS935-LRRK2 837-fold more potently in the G2019S-LRRK2 line (IC<sub>50</sub> = 2.5 ± 1.1 nM, <i>n</i> = 3) compared to that in the WT-LRRK2 line (IC<sub>50</sub> = 2,092 ± 1.4 nM, <i>n</i> = 3). (D) MLi-2 showed similar potency on pS935-LRRK2 in both cell lines (HEK/G2019S-LRRK2 IC<sub>50</sub> = 2.8 ± 1.2 nM, <i>n</i> = 3; HEK/WT-LRRK2 IC<sub>50</sub> = 3.9 ± 1.1 nM, <i>n</i> = 3). Potency is reported as the geometric mean of IC<sub>50</sub> values ± geometric standard deviation. Error bars show standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Inhibitor <b>3</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) 4-pyridylboronic acid, KOAc, Pd(amphos)Cl<sub>2</sub>, EtOH, 100 °C; (b) Zn, NH<sub>4</sub>Cl, EtOH, 80 °C, 56%, two steps; (c) EtOAc, formaldehyde (37 wt % in H<sub>2</sub>O), AcOH, EtOH, 120 °C, microwave, 62%; (d) MeI, Cs<sub>2</sub>CO<sub>3</sub>, 50 °C; (e) LiOH, EtOH, tetrahydrofuran (THF), H<sub>2</sub>O, 55 °C, 59%, two steps; and (f) T3P, EtOAc, Et<sub>3</sub>N, 15 °C or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), pyridine, 30 °C, 5%.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Inhibitor <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) <b>49</b>, T3P, Et<sub>3</sub>N, EtOAc, 60 °C, 16%; and (b) (4-sulfamoylphenyl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, <i>N</i>,<i>N</i>-dimethylformamide (DMF), H<sub>2</sub>O, 100 °C, 16%.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Inhibitor <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) allyl bromide, NaH, THF, 15 °C, 27%; (b) LiOH·H<sub>2</sub>O, EtOH, H<sub>2</sub>O, 15 °C, 66%; (c) 1<i>H</i>-indazol-5-amine, T3P, EtOAc, Et<sub>3</sub>N, 20 °C, 50%; (d) 1,3-dimethylbarbituric acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, DCM, EtOH, 55 °C, 57%; and (e) CH<sub>3</sub>COCl, Et<sub>3</sub>N, DCM, 15 °C, 6%.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-Methyl Amide <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate (HATU), DMF, Et<sub>3</sub>N, 21%.</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Thioamide <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) Lawesson’s reagent, dioxane, 18 h, 100 °C, 3%.</p></p></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Inhibitors <b>26</b> and <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) SEM-Cl, NaH, DMF, 0 °C - r.t., 60%; (b) bis(pinacolato)diboron, KOAc, 1,4-dioxane, Pd(dppf)Cl<sub>2</sub>, 100 °C; (c) 4-(4-bromopyridin-2-yl)morpholine, Cs<sub>2</sub>CO<sub>3</sub>, THF, water, Pd(dppf)Cl<sub>2</sub>, 100 °C, 44%, two steps; (d) NH<sub>4</sub>Cl, Fe, EtOH, water, 80 °C, 80%; (e) <b>(</b><i><b>R</b></i><b>)-32</b>, Et<sub>3</sub>N, HATU, DMF, 0 °C - r.t., 33%; (f) 4 M HCl, dioxane, THF, r.t., 18%; and (g) chiral chromatography.</p></p></figure><figure data-id="sch7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Inhibitor <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) EtOH, 4 Å molecular sieves, reflux, 56%; (b) MeI, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 97%; (c) LiOH, THF; (d) <i>N</i>-(1)-Boc-5-aminoindazole, HATU, Et<sub>3</sub>N, DMF, r.t.; and (e) trifluoroacetic acid (TFA), DCM, 0 °C - r.t., 4%, three steps.</p></p></figure><figure data-id="sch8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Inhibitor <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) 2-methyl-5-nitropyridine, <i>N</i>-bromosuccinimide (NBS), benzoyl peroxide, CCl<sub>4</sub>, 80 °C, 31%; (b) NH<sub>4</sub>OH, dioxane, 25 °C; (c) Ac<sub>2</sub>O, PTSA, 100 °C, 32%, two steps; (d) H<sub>2</sub>, 10% Pd/C, MeOH, 25 °C; and (e) <b>49</b>, HATU, <i>i</i>-Pr<sub>2</sub>NEt, DMF, 25 °C, 16%, two steps.</p></p></figure><figure data-id="sch9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Inhibitor <b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) MeMgBr, NaBH<sub>4</sub>, THF, MeOH, 25 °C, 94%; (b) ethyl formate, AlMe<sub>3</sub>, toluene, 90 °C, 10%; (c) POCl<sub>3</sub>, toluene, 80 °C, 93%; (d) CDI, NH<sub>3</sub>·H<sub>2</sub>O, THF, 20 °C, 5%; and (e) Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, dioxane, 90 °C, 2%.</p></p></figure><figure data-id="sch10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/medium/jm0c01243_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0015.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Inhibitor <b>43</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01243/20201203/images/large/jm0c01243_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01243&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents: (a) (Boc)<sub>2</sub>O, 4-dimethylaminopyridine (DMAP), CH<sub>3</sub>CN, 70 °C, 70%; (b) H<sub>2</sub>, 10% Pd/C, EtOH, r.t., 97%; (c) <b>(</b><i><b>R</b></i><b>)-32</b>, EDCI, DMAP, pyridine, 70 °C, 93%; and (d) TFA, DCM, r.t, 51%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i103">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 16 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Paisán-Ruı́z, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilks, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Brug, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez de Munain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Silva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti-Masso, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Tur, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span> <span> </span><span class="NLM_article-title">Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2004.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2Fj.neuron.2004.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=15541308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=595-600&author=C.+Pais%C3%A1n-Ru%C4%B1%CC%81zauthor=S.+Jainauthor=E.+W.+Evansauthor=W.+P.+Gilksauthor=J.+Simonauthor=M.+van+der+Brugauthor=A.+Lopez+de+Munainauthor=S.+Aparicioauthor=A.+M.+Gilauthor=N.+Khanauthor=J.+Johnsonauthor=J.+R.+Martinezauthor=D.+Nichollauthor=I.+M.+Carreraauthor=A.+S.+Penaauthor=R.+de+Silvaauthor=A.+Leesauthor=J.+F.+Marti-Massoauthor=J.+Perez-Turauthor=N.+W.+Woodauthor=A.+B.+Singleton&title=Cloning+of+the+gene+containing+mutations+that+cause+PARK8-linked+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neuron.2004.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the gene containing mutations that cause PARK8-linked parkinson's disease</span></div><div class="casAuthors">Paisan-Ruiz, Coro; Jain, Shushant; Evans, E. Whitney; Gilks, William P.; Simon, Javier; van der Brug, Marcel; Lopez de Munain, Adolfo; Aparicio, Silvia; Gil, Angel Martinez; Khan, Naheed; Johnson, Janel; Martinez, Javier Ruiz; Nicholl, David; Carrera, Itxaso Marti; Pena, Amets Saenz; de Silva, Rohan; Lees, Andrew; Marti-Masso, Jose Felix; Perez-Tur, Jordi; Wood, Nick W.; Singleton, Andrew B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">595-600</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Parkinson's disease (PD; OMIM #168600) is the second most common neurodegenerative disorder in the Western world and presents as a progressive movement disorder.  The hallmark pathol. features of PD are loss of dopaminergic neurons from the substantia nigra and neuronal intracellular Lewy body inclusions.  Parkinsonism is typically sporadic in nature; however, several rare familial forms are linked to genetic loci, and the identification of causal mutations has provided insight into the disease process.  PARK8, identified in 2002 by Funayama and colleagues, appears to be a common cause of familial PD.  We describe here the cloning of a novel gene that contains missense mutations segregating with PARK8-linked PD in five families from England and Spain.  Because of the tremor obsd. in PD and because a no. of the families are of Basque descent, we have named this protein dardarin, derived from the Basque word dardara, meaning tremor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGrs2XdLqQkrVg90H21EOLACvtfcHk0lhurKLiBaPuEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjK&md5=8f00086cb6a3d80e9a5ee4229c1055d5</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2004.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2004.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DPais%25C3%25A1n-Ru%25C4%25B1%25CC%2581z%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DEvans%26aufirst%3DE.%2BW.%26aulast%3DGilks%26aufirst%3DW.%2BP.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BBrug%26aufirst%3DM.%26aulast%3DLopez%2Bde%2BMunain%26aufirst%3DA.%26aulast%3DAparicio%26aufirst%3DS.%26aulast%3DGil%26aufirst%3DA.%2BM.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DJ.%26aulast%3DMartinez%26aufirst%3DJ.%2BR.%26aulast%3DNicholl%26aufirst%3DD.%26aulast%3DCarrera%26aufirst%3DI.%2BM.%26aulast%3DPena%26aufirst%3DA.%2BS.%26aulast%3Dde%2BSilva%26aufirst%3DR.%26aulast%3DLees%26aufirst%3DA.%26aulast%3DMarti-Masso%26aufirst%3DJ.%2BF.%26aulast%3DPerez-Tur%26aufirst%3DJ.%26aulast%3DWood%26aufirst%3DN.%2BW.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26atitle%3DCloning%2520of%2520the%2520gene%2520containing%2520mutations%2520that%2520cause%2520PARK8-linked%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuron%26date%3D2004%26volume%3D44%26spage%3D595%26epage%3D600%26doi%3D10.1016%2Fj.neuron.2004.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biskup, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lincoln, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachergus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulihan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uitti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calne, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoessl, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patenge, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajal, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieregge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asmus, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Myhsok, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meitinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strom, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wszolek, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasser, T.</span></span> <span> </span><span class="NLM_article-title">Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2004.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2Fj.neuron.2004.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=15541309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=601-607&author=A.+Zimprichauthor=S.+Biskupauthor=P.+Leitnerauthor=P.+Lichtnerauthor=M.+Farrerauthor=S.+Lincolnauthor=J.+Kachergusauthor=M.+Hulihanauthor=R.+J.+Uittiauthor=D.+B.+Calneauthor=A.+J.+Stoesslauthor=R.+F.+Pfeifferauthor=N.+Patengeauthor=I.+C.+Carbajalauthor=P.+Viereggeauthor=F.+Asmusauthor=B.+M%C3%BCller-Myhsokauthor=D.+W.+Dicksonauthor=T.+Meitingerauthor=T.+M.+Stromauthor=Z.+K.+Wszolekauthor=T.+Gasser&title=Mutations+in+LRRK2+cause+autosomal-dominant+parkinsonism+with+pleomorphic+pathology&doi=10.1016%2Fj.neuron.2004.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology</span></div><div class="casAuthors">Zimprich, Alexander; Biskup, Saskia; Leitner, Petra; Lichtner, Peter; Farrer, Matthew; Lincoln, Sarah; Kachergus, Jennifer; Hulihan, Mary; Uitti, Ryan J.; Calne, Donald B.; Stoessl, A. Jon; Pfeiffer, Ronald F.; Patenge, Nadja; Carbajal, Iria Carballo; Vieregge, Peter; Asmus, Friedrich; Mueller-Myhsok, Bertram; Dickson, Dennis W.; Meitinger, Thomas; Strom, Tim M.; Wszolek, Zbigniew K.; Gasser, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-607</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We have previously linked families with autosomaldominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8).  By high-resoln. recombination mapping and candidate gene sequencing in 46 families, we have found six disease-segregating mutations (five missense and one putative splice site mutation) in a gene encoding a large, multifunctional protein, LRRK2 (leucine-rich repeat kinase 2).  It belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.  Within affected carriers of families A and D, six post mortem diagnoses reveal brainstem dopaminergic degeneration accompanied by strikingly diverse pathologies.  These include abnormalities consistent with Lewy body Parkinson's disease, diffuse Lewy body disease, nigral degeneration without distinctive histopathol., and progressive supranuclear palsy-like pathol.  Clin. diagnoses of Parkinsonism with dementia or amyotrophy or both, with their assocd. pathologies, are also noted.  Hence, LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders assocd. with parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9aK6wacZJhbVg90H21EOLACvtfcHk0lhYQjSY5auwvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVKhurjL&md5=9ae4c87ce3172e29829e317d94b5cdaa</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2004.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2004.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DZimprich%26aufirst%3DA.%26aulast%3DBiskup%26aufirst%3DS.%26aulast%3DLeitner%26aufirst%3DP.%26aulast%3DLichtner%26aufirst%3DP.%26aulast%3DFarrer%26aufirst%3DM.%26aulast%3DLincoln%26aufirst%3DS.%26aulast%3DKachergus%26aufirst%3DJ.%26aulast%3DHulihan%26aufirst%3DM.%26aulast%3DUitti%26aufirst%3DR.%2BJ.%26aulast%3DCalne%26aufirst%3DD.%2BB.%26aulast%3DStoessl%26aufirst%3DA.%2BJ.%26aulast%3DPfeiffer%26aufirst%3DR.%2BF.%26aulast%3DPatenge%26aufirst%3DN.%26aulast%3DCarbajal%26aufirst%3DI.%2BC.%26aulast%3DVieregge%26aufirst%3DP.%26aulast%3DAsmus%26aufirst%3DF.%26aulast%3DM%25C3%25BCller-Myhsok%26aufirst%3DB.%26aulast%3DDickson%26aufirst%3DD.%2BW.%26aulast%3DMeitinger%26aufirst%3DT.%26aulast%3DStrom%26aufirst%3DT.%2BM.%26aulast%3DWszolek%26aufirst%3DZ.%2BK.%26aulast%3DGasser%26aufirst%3DT.%26atitle%3DMutations%2520in%2520LRRK2%2520cause%2520autosomal-dominant%2520parkinsonism%2520with%2520pleomorphic%2520pathology%26jtitle%3DNeuron%26date%3D2004%26volume%3D44%26spage%3D601%26epage%3D607%26doi%3D10.1016%2Fj.neuron.2004.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Paisán-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span> <span> </span><span class="NLM_article-title">LRRK2: Cause, risk, and mechanism</span>. <i>J. Parkinson’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.3233/JPD-130192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.3233%2FJPD-130192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23938341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=85-103&author=C.+Pais%C3%A1n-Ruizauthor=P.+A.+Lewisauthor=A.+B.+Singleton&title=LRRK2%3A+Cause%2C+risk%2C+and+mechanism&doi=10.3233%2FJPD-130192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2: cause, risk, and mechanism</span></div><div class="casAuthors">Paisan-Ruiz, Coro; Lewis, Patrick A.; Singleton, Andrew B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Parkinson's Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-103</span>CODEN:
                <span class="NLM_cas:coden">JPDOAP</span>;
        ISSN:<span class="NLM_cas:issn">1877-7171</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">A review.  In 2004 it was first shown that mutations in LRRK2 can cause Parkinson's disease.  This initial discovery was quickly followed by the observation that a single particular mutation is a relatively common cause of Parkinson's disease across varied populations.  Further genetic investigation has revealed a variety of genetic ties to Parkinson's disease across this gene.  These include common alleles with quite broad effects on risk, likely through both alterations at the protein sequence level, and in the context of expression.  A great deal of functional characterization of LRRK2 and disease-causing mutations in this protein has occurred over the last 9 years, and considerable progress has been made.  Particular attention has been paid to the kinase activity of LRRK2 as a therapeutic target, and while it is no means certain that this is viable target it is likely that this hypothesis will be tested in clin. trials sooner rather than later.  We believe that the future goals for LRRK2 research are, while challenging, relatively clear and that the next 10 years of research promises to be perhaps more exciting than the last.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1IVJK9Tqs7Vg90H21EOLACvtfcHk0lhYQjSY5auwvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygs73M&md5=6e7ceb0477f0a4551ac71849daa4a0b1</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.3233%2FJPD-130192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJPD-130192%26sid%3Dliteratum%253Aachs%26aulast%3DPais%25C3%25A1n-Ruiz%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DP.%2BA.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26atitle%3DLRRK2%253A%2520Cause%252C%2520risk%252C%2520and%2520mechanism%26jtitle%3DJ.%2520Parkinson%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D3%26spage%3D85%26epage%3D103%26doi%3D10.3233%2FJPD-130192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Monfrini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fonzo, A.</span></span> <span> </span><span class="NLM_article-title">Leucine-rich repeat kinase (LRRK2) genetics and Parkinson’s Disease</span>. <i>Adv. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1007%2F978-3-319-49969-7_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=28353276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A280%3ADC%252BC1cvit1Wktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=3-30&author=E.+Monfriniauthor=A.+Di+Fonzo&title=Leucine-rich+repeat+kinase+%28LRRK2%29+genetics+and+Parkinson%E2%80%99s+Disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease</span></div><div class="casAuthors">Monfrini Edoardo; Di Fonzo Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Advances in neurobiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-30</span>
        ISSN:<span class="NLM_cas:issn">2190-5215</span>.
    </div><div class="casAbstract">The discovery of LRRK2 mutations as a cause of Parkinson's disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research.  Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide.  The G2385R and R1628P variants represent validated risk factors for PD in Asian populations.  Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations.  Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2.  Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling.  In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnB6AiTVLfbGK_SFaaT9INfW6udTcc2ebIC5t01Th5Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvit1Wktw%253D%253D&md5=a1539e7798089f0919e6315c12d2ee9f</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-49969-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-49969-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DMonfrini%26aufirst%3DE.%26aulast%3DDi%2BFonzo%26aufirst%3DA.%26atitle%3DLeucine-rich%2520repeat%2520kinase%2520%2528LRRK2%2529%2520genetics%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DAdv.%2520Neurobiol.%26date%3D2017%26volume%3D14%26spage%3D3%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tolosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vila, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rascol, O.</span></span> <span> </span><span class="NLM_article-title">LRRK2 in Parkinson disease: challenges of clinical trials</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/s41582-019-0301-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1038%2Fs41582-019-0301-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=31980808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FksVWgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=97-107&author=E.+Tolosaauthor=M.+Vilaauthor=C.+Kleinauthor=O.+Rascol&title=LRRK2+in+Parkinson+disease%3A+challenges+of+clinical+trials&doi=10.1038%2Fs41582-019-0301-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 in Parkinson disease: challenges of clinical trials</span></div><div class="casAuthors">Tolosa Eduardo; Tolosa Eduardo; Vila Miquel; Vila Miquel; Vila Miquel; Klein Christine; Rascol Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">One of the most common monogenic forms of Parkinson disease (PD) is caused by mutations in the LRRK2 gene that encodes leucine-rich repeat kinase 2 (LRRK2).  LRRK2 mutations, and particularly the most common mutation Gly2019Ser, are observed in patients with autosomal dominant PD and in those with apparent sporadic PD, who are clinically indistinguishable from those with idiopathic PD.  The discoveries that pathogenic mutations in the LRRK2 gene increase LRRK2 kinase activity and that small-molecule LRRK2 kinase inhibitors can be neuroprotective in preclinical models of PD have placed LRRK2 at the centre of disease modification efforts in PD.  Recent investigations also suggest that LRRK2 has a role in the pathogenesis of idiopathic PD and that LRRK2 therapies might, therefore, be beneficial in this common subtype of PD.  In this Review, we describe the characteristics of LRRK2-associated PD that are most relevant to the development of LRRK2-targeted therapies and the design and implementation of clinical trials.  We highlight strategies for correcting the effects of mutations in the LRRK2 gene, focusing on how to identify which patients are the optimal candidates and how to decide on the timing of such trials.  In addition, we discuss challenges in implementing trials of disease-modifying treatment in people who carry LRRK2 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMCbhG8-7gs-xsqfvU0ziafW6udTcc2ebIC5t01Th5Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FksVWgtw%253D%253D&md5=31b4f3fb058921649726eafedc11c8a3</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fs41582-019-0301-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-019-0301-2%26sid%3Dliteratum%253Aachs%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DVila%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DRascol%26aufirst%3DO.%26atitle%3DLRRK2%2520in%2520Parkinson%2520disease%253A%2520challenges%2520of%2520clinical%2520trials%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2020%26volume%3D16%26spage%3D97%26epage%3D107%26doi%3D10.1038%2Fs41582-019-0301-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Pichon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanoy, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Brug, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span> <span> </span><span class="NLM_article-title">Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">164ra161</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.3004485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23241745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=Z.+Shengauthor=S.+Zhangauthor=D.+Bustosauthor=T.+Kleinheinzauthor=C.+E.+Le+Pichonauthor=S.+L.+Dominguezauthor=H.+O.+Solanoyauthor=J.+Drummondauthor=X.+Zhangauthor=X.+Dingauthor=F.+Caiauthor=Q.+Songauthor=X.+Liauthor=Z.+Yueauthor=M.+P.+van+der+Brugauthor=D.+J.+Burdickauthor=J.+Gunzner-Tosteauthor=H.+Chenauthor=X.+Liuauthor=A.+A.+Estradaauthor=Z.+K.+Sweeneyauthor=K.+Scearce-Levieauthor=J.+G.+Moffatauthor=D.+S.+Kirkpatrickauthor=H.+Zhu&title=Ser1292+autophosphorylation+is+an+indicator+of+LRRK2+kinase+activity+and+contributes+to+the+cellular+effects+of+PD+mutations&doi=10.1126%2Fscitranslmed.3004485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004485%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBustos%26aufirst%3DD.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLe%2BPichon%26aufirst%3DC.%2BE.%26aulast%3DDominguez%26aufirst%3DS.%2BL.%26aulast%3DSolanoy%26aufirst%3DH.%2BO.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3Dvan%2Bder%2BBrug%26aufirst%3DM.%2BP.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DSer1292%2520autophosphorylation%2520is%2520an%2520indicator%2520of%2520LRRK2%2520kinase%2520activity%2520and%2520contributes%2520to%2520the%2520cellular%2520effects%2520of%2520PD%2520mutations%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persohn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theil, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stemmelen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troxler, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grevot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Putten, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span> <span> </span><span class="NLM_article-title">LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4209</span>– <span class="NLM_lpage">4223</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddr348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1093%2Fhmg%2Fddr348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=21828077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=4209-4223&author=M.+C.+Herzigauthor=C.+Kollyauthor=E.+Persohnauthor=D.+Theilauthor=T.+Schweizerauthor=T.+Hafnerauthor=C.+Stemmelenauthor=T.+J.+Troxlerauthor=P.+Schmidauthor=S.+Dannerauthor=C.+R.+Schnellauthor=M.+Muellerauthor=B.+Kinzelauthor=A.+Grevotauthor=F.+Bolognaniauthor=M.+Stirnauthor=R.+R.+Kuhnauthor=K.+Kaupmannauthor=P.+H.+van+der%0APuttenauthor=G.+Rovelliauthor=D.+R.+Shimshek&title=LRRK2+protein+levels+are+determined+by+kinase+function+and+are+crucial+for+kidney+and+lung+homeostasis+in+mice&doi=10.1093%2Fhmg%2Fddr348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice</span></div><div class="casAuthors">Herzig, Martin C.; Kolly, Carine; Persohn, Elke; Theil, Diethilde; Schweizer, Tatjana; Hafner, Thomas; Stemmelen, Christine; Troxler, Thomas J.; Schmid, Peter; Danner, Simone; Schnell, Christian R.; Mueller, Matthias; Kinzel, Bernd; Grevot, Armelle; Bolognani, Federico; Stirn, Martina; Kuhn, Rainer R.; Kaupmann, Klemens; van der Putten, P. Herman; Rovelli, Giorgio; Shimshek, Derya R.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4209-4223</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) cause late-onset Parkinson's disease (PD), but the underlying pathophysiol. mechanisms and the normal function of this large multidomain protein remain speculative.  To address the role of this protein in vivo, we generated three different LRRK2 mutant mouse lines.  Mice completely lacking the LRRK2 protein (knock-out, KO) showed an early-onset (age 6 wk) marked increase in no. and size of secondary lysosomes in kidney proximal tubule cells and lamellar bodies in lung type II cells.  Mice expressing a LRRK2 kinase-dead (KD) mutant from the endogenous locus displayed similar early-onset pathophysiol. changes in kidney but not lung.  KD mutants had dramatically reduced full-length LRRK2 protein levels in the kidney and this genetic effect was mimicked pharmacol. in wild-type mice treated with a LRRK2-selective kinase inhibitor.  Knock-in (KI) mice expressing the G2019S PD-assocd. mutation that increases LRRK2 kinase activity showed none of the LRRK2 protein level and histopathol. changes obsd. in KD and KO mice.  The autophagy marker LC3 remained unchanged but kidney mTOR and TCS2 protein levels decreased in KD and increased in KO and KI mice.  Unexpectedly, KO and KI mice suffered from diastolic hypertension opposed to normal blood pressure in KD mice.  Our findings demonstrate a role for LRRK2 in kidney and lung physiol. and further show that LRRK2 kinase function affects LRRK2 protein steady-state levels thereby altering putative scaffold/GTPase activity.  These novel aspects of peripheral LRRK2 biol. critically impact ongoing attempts to develop LRRK2 selective kinase inhibitors as therapeutics for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol714w-ZIM5rVg90H21EOLACvtfcHk0lidwc5r-kJTwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yltrnI&md5=9c7935965c8f21e13b42bdc9e794cde0</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddr348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddr348%26sid%3Dliteratum%253Aachs%26aulast%3DHerzig%26aufirst%3DM.%2BC.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DPersohn%26aufirst%3DE.%26aulast%3DTheil%26aufirst%3DD.%26aulast%3DSchweizer%26aufirst%3DT.%26aulast%3DHafner%26aufirst%3DT.%26aulast%3DStemmelen%26aufirst%3DC.%26aulast%3DTroxler%26aufirst%3DT.%2BJ.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DDanner%26aufirst%3DS.%26aulast%3DSchnell%26aufirst%3DC.%2BR.%26aulast%3DMueller%26aufirst%3DM.%26aulast%3DKinzel%26aufirst%3DB.%26aulast%3DGrevot%26aufirst%3DA.%26aulast%3DBolognani%26aufirst%3DF.%26aulast%3DStirn%26aufirst%3DM.%26aulast%3DKuhn%26aufirst%3DR.%2BR.%26aulast%3DKaupmann%26aufirst%3DK.%26aulast%3Dvan%2Bder%2BPutten%26aufirst%3DP.%2BH.%26aulast%3DRovelli%26aufirst%3DG.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26atitle%3DLRRK2%2520protein%2520levels%2520are%2520determined%2520by%2520kinase%2520function%2520and%2520are%2520crucial%2520for%2520kidney%2520and%2520lung%2520homeostasis%2520in%2520mice%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2011%26volume%3D20%26spage%3D4209%26epage%3D4223%26doi%3D10.1093%2Fhmg%2Fddr348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaime, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelleher, R. J.,  III.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">9879</span>– <span class="NLM_lpage">9884</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004676107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1073%2Fpnas.1004676107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=20457918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFWltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=9879-9884&author=Y.+Tongauthor=H.+Yamaguchiauthor=E.+Giaimeauthor=S.+Boyleauthor=R.+Kopanauthor=R.+J.+Kelleherauthor=J.+Shen&title=Loss+of+leucine-rich+repeat+kinase+2+causes+impairment+of+protein+degradation+pathways%2C+accumulation+of+alpha-synuclein%2C+and+apoptotic+cell+death+in+aged+mice&doi=10.1073%2Fpnas.1004676107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice</span></div><div class="casAuthors">Tong, Youren; Yamaguchi, Hiroo; Giaime, Emilie; Boyle, Scott; Kopan, Raphael; Kelleher, Raymond J., III; Shen, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9879-9884, S9879/1-S9879/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease.  LRRK2 is a large protein contg. a small GTPase domain and a kinase domain, but its physiol. role is unknown.  To identify the normal function of LRRK2 in vivo, we generated two independent lines of germ-line deletion mice.  The dopaminergic system of LRRK2-/- mice appears normal, and nos. of dopaminergic neurons and levels of striatal dopamine are unchanged.  However, LRRK2-/- kidneys, which suffer the greatest loss of LRRK compared with other organs, develop striking accumulation and aggregation of α-synuclein and ubiquitinated proteins at 20 mo of age.  The autophagy-lysosomal pathway is also impaired in the absence of LRRK2, as indicated by accumulation of lipofuscin granules as well as altered levels of LC3-II and p62.  Furthermore, loss of LRRK2 dramatically increases apoptotic cell death, inflammatory responses, and oxidative damage.  Collectively, our findings show that LRRK2 plays an essential and unexpected role in the regulation of protein homeostasis during aging, and suggest that LRRK2 mutations may cause Parkinson's disease and cell death via impairment of protein degrdn. pathways, leading to α-synuclein accumulation and aggregation over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwJUmT5o1nLLVg90H21EOLACvtfcHk0lidwc5r-kJTwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFWltrc%253D&md5=09474f2cb0fa155bb88311a5af0afbe1</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004676107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004676107%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DGiaime%26aufirst%3DE.%26aulast%3DBoyle%26aufirst%3DS.%26aulast%3DKopan%26aufirst%3DR.%26aulast%3DKelleher%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DLoss%2520of%2520leucine-rich%2520repeat%2520kinase%25202%2520causes%2520impairment%2520of%2520protein%2520degradation%2520pathways%252C%2520accumulation%2520of%2520alpha-synuclein%252C%2520and%2520apoptotic%2520cell%2520death%2520in%2520aged%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D9879%26epage%3D9884%26doi%3D10.1073%2Fpnas.1004676107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ness, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpnack, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olaharski, A. J.</span></span> <span> </span><span class="NLM_article-title">Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e66164</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0066164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1371%2Fjournal.pone.0066164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23799078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVemsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=D.+Nessauthor=Z.+Renauthor=S.+Gardaiauthor=D.+Sharpnackauthor=V.+J.+Johnsonauthor=R.+J.+Brennanauthor=E.+F.+Brighamauthor=A.+J.+Olaharski&title=Leucine-rich+repeat+kinase+2+%28LRRK2%29-deficient+rats+exhibit+renal+tubule+injury+and+perturbations+in+metabolic+and+immunological+homeostasis&doi=10.1371%2Fjournal.pone.0066164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis</span></div><div class="casAuthors">Ness, Daniel; Ren, Zhao; Gardai, Shyra; Sharpnack, Douglas; Johnson, Victor J.; Brennan, Richard J.; Brigham, Elizabeth F.; Olaharski, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e66164</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Genetic evidence links mutations in the LRRK2 gene with an increased risk of Parkinson's disease, for which no neuroprotective or neurorestorative therapies currently exist.  While the role of LRRK2 in normal cellular function has yet to be fully described, evidence suggests involvement with immune and kidney functions.  A comparative study of LRRK2-deficient and wild type rats investigated the influence that this gene has on the phenotype of these rats.  Significant wt. gain in the LRRK2 null rats was obsd. and was accompanied by significant increases in insulin and insulin-like growth factors.  Addnl., LRRK2-deficient rats displayed kidney morphol. and histopathol. alterations in the renal tubule epithelial cells of all animals assessed.  These perturbations in renal morphol. were accompanied by significant decreases of lipocalin-2, in both the urine and plasma of knockout animals.  Significant alterations in the cellular compn. of the spleen between LRRK2 knockout and wild type animals were identified by immunophenotyping and were assocd. with subtle differences in response to dual infection with rat-adapted influenza virus (RAIV) and Streptococcus pneumoniae.  Ontol. pathway anal. of LRRK2 across metabolic and kidney processes and pathol. categories suggested that the thioredoxin network may play a role in perturbing these organ systems.  The phenotype of the LRRK2 null rat is suggestive of a complex biol. influencing metab., immune function and kidney homeostasis.  These data need to be extended to better understand the role of the kinase domain or other biol. functions of the gene to better inform the development of pharmacol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd6CzTkNcDvLVg90H21EOLACvtfcHk0lgNbZUS8aUKSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVemsLvL&md5=26f0300a87dc9c5441bdbdbeabb2c50c</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0066164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0066164%26sid%3Dliteratum%253Aachs%26aulast%3DNess%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DGardai%26aufirst%3DS.%26aulast%3DSharpnack%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DV.%2BJ.%26aulast%3DBrennan%26aufirst%3DR.%2BJ.%26aulast%3DBrigham%26aufirst%3DE.%2BF.%26aulast%3DOlaharski%26aufirst%3DA.%2BJ.%26atitle%3DLeucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529-deficient%2520rats%2520exhibit%2520renal%2520tubule%2520injury%2520and%2520perturbations%2520in%2520metabolic%2520and%2520immunological%2520homeostasis%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0066164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dave, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasier, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greeley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varsho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meshul, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span> <span> </span><span class="NLM_article-title">Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e80705</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0080705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1371%2Fjournal.pone.0080705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=24244710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+A.+Baptistaauthor=K.+D.+Daveauthor=M.+A.+Frasierauthor=T.+B.+Shererauthor=M.+Greeleyauthor=M.+J.+Beckauthor=J.+S.+Varshoauthor=G.+A.+Parkerauthor=C.+Mooreauthor=M.+J.+Churchillauthor=C.+K.+Meshulauthor=B.+K.+Fiske&title=Loss+of+leucine-rich+repeat+kinase+2+%28LRRK2%29+in+rats+leads+to+progressive+abnormal+phenotypes+in+peripheral+organs&doi=10.1371%2Fjournal.pone.0080705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of leucine-rich repeat kinase 2 (LRKK2) in rats leads to progressive abnormal phenotypes in peripheral organs</span></div><div class="casAuthors">Baptista, Marco A. S.; Dave, Kuldip D.; Frasier, Mark A.; Sherer, Todd B.; Greeley, Melanie; Beck, Melissa J.; Varsho, Julie S.; Parker, George A.; Moore, Cindy; Churchill, Madeline J.; Meshul, Charles K.; Fiske, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e80705/1-e80705/16, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate the pathol. time course of the LRRK2 knockout rat model of Parkinson's disease at 1-, 2-, 4-, 8-, 12-, and 16-mo of age.  The evaluation consisted of histopathol. and ultrastructure examn. of selected organs, including the kidneys, lungs, spleen, heart, and liver, as well as hematol., serum, and urine anal.  The LRRK2 knockout rat, starting at 2-mo of age, displayed abnormal kidney staining patterns and/or morphol. changes that were assocd. with higher serum phosphorous, creatinine, cholesterol, and sorbitol dehydrogenase, and lower serum sodium and chloride compared to the LRRK2 wild-type rat.  Urinalysis indicated pronounced changes in LRRK2 knockout rats in urine sp. gr., total vol., urine potassium, creatinine, sodium, and chloride that started as early as 1- to 2-mo of age.  Electron microscopy of 16-mo old LRRK2 knockout rats displayed an abnormal kidney, lung, and liver phenotype.  In contrast, there were equivocal or no differences in the heart and spleen of LRRK2 wild-type and knockout rats.  These findings partially replicate data from a recent study in 4-mo old LRRK2 knockout rats and expand the anal. to demonstrate that the renal and possibly lung and liver abnormalities progress with age.  The characterization of LRRK2 knockout rats may prove to be extremely valuable in understanding potential safety liabilities of LRRK2 kinase inhibitor therapeutics for treating Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0nBkK8AbyV7Vg90H21EOLACvtfcHk0lh9Ud-qnYR1iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVGjsL0%253D&md5=f10ad0059276bf1b2894df72772a8151</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0080705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0080705%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DM.%2BA.%26aulast%3DDave%26aufirst%3DK.%2BD.%26aulast%3DFrasier%26aufirst%3DM.%2BA.%26aulast%3DSherer%26aufirst%3DT.%2BB.%26aulast%3DGreeley%26aufirst%3DM.%26aulast%3DBeck%26aufirst%3DM.%2BJ.%26aulast%3DVarsho%26aufirst%3DJ.%2BS.%26aulast%3DParker%26aufirst%3DG.%2BA.%26aulast%3DMoore%26aufirst%3DC.%26aulast%3DChurchill%26aufirst%3DM.%2BJ.%26aulast%3DMeshul%26aufirst%3DC.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26atitle%3DLoss%2520of%2520leucine-rich%2520repeat%2520kinase%25202%2520%2528LRRK2%2529%2520in%2520rats%2520leads%2520to%2520progressive%2520abnormal%2520phenotypes%2520in%2520peripheral%2520organs%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0080705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeggo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotty, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thougaard, A.</span></span> <span> </span><span class="NLM_article-title">PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2018.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2Fj.tox.2018.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=29307545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvFamtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2018&pages=15-22&author=M.+A.+Andersenauthor=K.+M.+Wegenerauthor=S.+Larsenauthor=L.+Badoloauthor=G.+P.+Smithauthor=R.+Jeggoauthor=P.+H.+Jensenauthor=F.+Sottyauthor=K.+V.+Christensenauthor=A.+Thougaard&title=PFE-360-induced+LRRK2+inhibition+induces+reversible%2C+non-adverse+renal+changes+in+rats&doi=10.1016%2Fj.tox.2018.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats</span></div><div class="casAuthors">Andersen, Michael Aagaard; Wegener, Karen Malene; Larsen, Steen; Badolo, Lassina; Smith, Garrick Paul; Jeggo, Ross; Jensen, Poul Henning; Sotty, Florence; Christensen, Kenneth Vielsted; Thougaard, Annemette</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15-22</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no existing therapeutic approach to delay or stop progression.  Genetic, biochem. and pre-clin. studies have provided evidence that leucine-rich-repeat-kinase-2 (LRRK2) kinase is involved in the pathogenesis of PD, and small mol. LRRK2 inhibitors represent a novel potential therapeutic approach.  However, potentially adverse target-related effects have been discovered in the lung and kidneys of LRRK2 knock-out (ko) mice and rats.  It is unclear if the LRRK2 ko effect in the kidneys and lung is also induced by pharmacol. inhibition of the LRRK2 kinase.  Here, we show that treatment with the LRRK2 inhibitor PFE-360 in rats induces a morphol. kidney phenotype resembling that of the LRRK2 ko rats, whereas no effects were obsd. in the lung.  The PFE-360 treatment induced morphol. changes characterised by darkened kidneys and progressive accumulation of hyaline droplets in the renal proximal tubular epithelium.  However, no histopathol. evidence of renal tubular injury or changes in the blood and urine parameters that would be indicative of kidney toxicity or impaired kidney function were obsd. after up to 12 wk of treatment.  Morphol. changes were detected in the kidney after 2 wk of treatment and were partially reversible within a 30 day treatment-free period.  Our findings suggest that pharmacol. LRRK2 inhibition may not have adverse consequences for kidney function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjrIewka3O1rVg90H21EOLACvtfcHk0lh9Ud-qnYR1iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvFamtw%253D%253D&md5=f576f650ba63043dcf13937e547ab3b6</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2018.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2018.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DM.%2BA.%26aulast%3DWegener%26aufirst%3DK.%2BM.%26aulast%3DLarsen%26aufirst%3DS.%26aulast%3DBadolo%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%2BP.%26aulast%3DJeggo%26aufirst%3DR.%26aulast%3DJensen%26aufirst%3DP.%2BH.%26aulast%3DSotty%26aufirst%3DF.%26aulast%3DChristensen%26aufirst%3DK.%2BV.%26aulast%3DThougaard%26aufirst%3DA.%26atitle%3DPFE-360-induced%2520LRRK2%2520inhibition%2520induces%2520reversible%252C%2520non-adverse%2520renal%2520changes%2520in%2520rats%26jtitle%3DToxicology%26date%3D2018%26volume%3D395%26spage%3D15%26epage%3D22%26doi%3D10.1016%2Fj.tox.2018.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheewatrakoolpong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMong, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgraf, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulet, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, J. A.</span></span> <span> </span><span class="NLM_article-title">MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">397</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.227587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1124%2Fjpet.115.227587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=26407721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=397&author=M.+J.+Fellauthor=C.+Mirescuauthor=K.+Basuauthor=B.+Cheewatrakoolpongauthor=D.+E.+DeMongauthor=J.+M.+Ellisauthor=L.+A.+Hydeauthor=Y.+Linauthor=C.+G.+Markgrafauthor=H.+Meiauthor=M.+Millerauthor=F.+M.+Pouletauthor=J.+D.+Scottauthor=M.+D.+Smithauthor=Z.+Yinauthor=X.+Zhouauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=J.+A.+Morrow&title=MLi-2%2C+a+potent%2C+selective%2C+and+centrally+active+compound+for+exploring+the+therapeutic+potential+and+safety+of+LRRK2+kinase+inhibition&doi=10.1124%2Fjpet.115.227587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition</span></div><div class="casAuthors">Fell, Matthew J.; Mirescu, Christian; Basu, Kallol; Cheewatrakoolpong, Boonlert; DeMong, Duane E.; Ellis, J. Michael; Hyde, Lynn A.; Lin, Yinghui; Markgraf, Carrie G.; Mei, Hong; Miller, Michael; Poulet, Frederique M.; Scott, Jack D.; Smith, Michelle D.; Yin, Zhizhang; Zhou, Xiaoping; Parker, Eric M.; Kennedy, Matthew E.; Morrow, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of familial and sporadic Parkinson's disease (PD).  That the most prevalent mutation, G2019S, leads to increased kinase activity has led to a concerted effort to identify LRRK2 kinase inhibitors as a potential disease-modifying therapy for PD.  An internal medicinal chem. effort identified several potent and highly selective compds. with favorable drug-like properties.  Here, we characterize the pharmacol. properties of cis-2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholine (MLi-2), a structurally novel, highly potent, and selective LRRK2 kinase inhibitor with central nervous system activity.  MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro (IC50 = 0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC50 = 1.4 nM), and a radioligand competition binding assay (IC50 = 3.4 nM).  MLi-2 has greater than 295-fold selectivity for over 300 kinases in addn. to a diverse panel of receptors and ion channels.  Acute oral and subchronic dosing in MLi-2 mice resulted in dose-dependent central and peripheral target inhibition over a 24-h period as measured by dephosphorylation of pSer935 LRRK2.  Treatment of MitoPark mice with MLi-2 was well tolerated over a 15-wk period at brain and plasma exposures >100× the in vivo plasma IC50 for LRRK2 kinase inhibition as measured by pSer935 dephosphorylation.  Morphol. changes in the lung, consistent with enlarged type II pneumocytes, were obsd. in MLi-2-treated MitoPark mice.  These data demonstrate the suitability of MLi-2 as a compd. to explore LRRK2 biol. in cellular and animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpot402TvUrkbVg90H21EOLACvtfcHk0lh-fNAXm0vxjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsbk%253D&md5=83c68f7bb731bef2fa9db880196dbabe</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227587%26sid%3Dliteratum%253Aachs%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DMirescu%26aufirst%3DC.%26aulast%3DBasu%26aufirst%3DK.%26aulast%3DCheewatrakoolpong%26aufirst%3DB.%26aulast%3DDeMong%26aufirst%3DD.%2BE.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DMarkgraf%26aufirst%3DC.%2BG.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DPoulet%26aufirst%3DF.%2BM.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DMorrow%26aufirst%3DJ.%2BA.%26atitle%3DMLi-2%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520centrally%2520active%2520compound%2520for%2520exploring%2520the%2520therapeutic%2520potential%2520and%2520safety%2520of%2520LRRK2%2520kinase%2520inhibition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D397%26doi%3D10.1124%2Fjpet.115.227587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katavolos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roose-Girma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urkowitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warming, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaylaoglu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span> <span> </span><span class="NLM_article-title">Effect of selective LRRK2 kinase inhibition on nonhuman primate lung</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">273ra15</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aaa3634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.aaa3634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=25653221" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&author=R.+N.+Fujiauthor=M.+Flagellaauthor=M.+Bacaauthor=M.+A.+Baptistaauthor=J.+Brodbeckauthor=B.+K.+Chanauthor=B.+K.+Fiskeauthor=L.+Honigbergauthor=A.+M.+Jubbauthor=P.+Katavolosauthor=D.+W.+Leeauthor=S.+C.+Lewin-Kohauthor=T.+Linauthor=X.+Liuauthor=S.+Liuauthor=J.+P.+Lyssikatosauthor=J.+O%E2%80%99Mahonyauthor=M.+Reicheltauthor=M.+Roose-Girmaauthor=Z.+Shengauthor=T.+Shererauthor=A.+Smithauthor=M.+Solonauthor=Z.+K.+Sweeneyauthor=J.+Tarrantauthor=A.+Urkowitzauthor=S.+Warmingauthor=M.+Yaylaogluauthor=S.+Zhangauthor=H.+Zhuauthor=A.+A.+Estradaauthor=R.+J.+Watts&title=Effect+of+selective+LRRK2+kinase+inhibition+on+nonhuman+primate+lung&doi=10.1126%2Fscitranslmed.aaa3634"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaa3634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaa3634%26sid%3Dliteratum%253Aachs%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DBaca%26aufirst%3DM.%26aulast%3DBaptista%26aufirst%3DM.%2BA.%26aulast%3DBrodbeck%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26aulast%3DHonigberg%26aufirst%3DL.%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DKatavolos%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DLewin-Koh%26aufirst%3DS.%2BC.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DJ.%26aulast%3DReichelt%26aufirst%3DM.%26aulast%3DRoose-Girma%26aufirst%3DM.%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DSherer%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSolon%26aufirst%3DM.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%26aulast%3DUrkowitz%26aufirst%3DA.%26aulast%3DWarming%26aufirst%3DS.%26aulast%3DYaylaoglu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26atitle%3DEffect%2520of%2520selective%2520LRRK2%2520kinase%2520inhibition%2520on%2520nonhuman%2520primate%2520lung%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26doi%3D10.1126%2Fscitranslmed.aaa3634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, M. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhargava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryce, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiske, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galatsis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddess, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgraf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trost, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, T. B.</span></span> <span> </span><span class="NLM_article-title">LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">eaav0820</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aav0820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.aav0820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=32321864" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=M.+A.+S.+Baptistaauthor=K.+Merchantauthor=T.+Barrettauthor=S.+Bhargavaauthor=D.+K.+Bryceauthor=J.+M.+Ellisauthor=A.+A.+Estradaauthor=M.+J.+Fellauthor=B.+K.+Fiskeauthor=R.+N.+Fujiauthor=P.+Galatsisauthor=A.+G.+Henryauthor=S.+Hillauthor=W.+Hirstauthor=C.+Houleauthor=M.+E.+Kennedyauthor=X.+Liuauthor=M.+L.+Maddessauthor=C.+Markgrafauthor=H.+Meiauthor=W.+A.+Meierauthor=E.+Needleauthor=S.+Plochauthor=C.+Royerauthor=K.+Rudolphauthor=A.+K.+Sharmaauthor=A.+Stepanauthor=S.+Steynauthor=C.+Trostauthor=Z.+Yinauthor=H.+Yuauthor=X.+Wangauthor=T.+B.+Sherer&title=LRRK2+inhibitors+induce+reversible+changes+in+nonhuman+primate+lungs+without+measurable+pulmonary+deficits&doi=10.1126%2Fscitranslmed.aav0820"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aav0820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aav0820%26sid%3Dliteratum%253Aachs%26aulast%3DBaptista%26aufirst%3DM.%2BA.%2BS.%26aulast%3DMerchant%26aufirst%3DK.%26aulast%3DBarrett%26aufirst%3DT.%26aulast%3DBhargava%26aufirst%3DS.%26aulast%3DBryce%26aufirst%3DD.%2BK.%26aulast%3DEllis%26aufirst%3DJ.%2BM.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DFell%26aufirst%3DM.%2BJ.%26aulast%3DFiske%26aufirst%3DB.%2BK.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DGalatsis%26aufirst%3DP.%26aulast%3DHenry%26aufirst%3DA.%2BG.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHirst%26aufirst%3DW.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMaddess%26aufirst%3DM.%2BL.%26aulast%3DMarkgraf%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMeier%26aufirst%3DW.%2BA.%26aulast%3DNeedle%26aufirst%3DE.%26aulast%3DPloch%26aufirst%3DS.%26aulast%3DRoyer%26aufirst%3DC.%26aulast%3DRudolph%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DA.%2BK.%26aulast%3DStepan%26aufirst%3DA.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DTrost%26aufirst%3DC.%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSherer%26aufirst%3DT.%2BB.%26atitle%3DLRRK2%2520inhibitors%2520induce%2520reversible%2520changes%2520in%2520nonhuman%2520primate%2520lungs%2520without%2520measurable%2520pulmonary%2520deficits%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26doi%3D10.1126%2Fscitranslmed.aav0820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fonzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohé, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabrizio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanacore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwurm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breedveld, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampaio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oostra, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifati, V.</span></span> <span> </span><span class="NLM_article-title">A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)17829-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1016%2FS0140-6736%2805%2917829-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=15680456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BD2MXoslWitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=412-415&author=A.+Di+Fonzoauthor=C.+F.+Roh%C3%A9author=J.+Ferreiraauthor=H.+F.+Chienauthor=L.+Vaccaauthor=F.+Stocchiauthor=L.+Guedesauthor=E.+Fabrizioauthor=M.+Manfrediauthor=N.+Vanacoreauthor=S.+Goldwurmauthor=G.+Breedveldauthor=C.+Sampaioauthor=G.+Mecoauthor=E.+Barbosaauthor=B.+A.+Oostraauthor=V.+Bonifati&title=A+frequent+LRRK2+gene+mutation+associated+with+autosomal+dominant+Parkinson%E2%80%99s+disease&doi=10.1016%2FS0140-6736%2805%2917829-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease</span></div><div class="casAuthors">Di Fonzo, Alessio; Rohe, Christan F.; Ferreira, Joaquim; Chien, Hsin F.; Vacca, Laura; Stocchi, Fabrizio; Guedes, Leonor; Fabrizio, Edito; Manfredi, Mario; Vanacore, Nicola; Goldwurm, Stefano; Breedveld, Guido; Sampaio, Cristina; Meco, Giuseppe; Barbosa, Egberto; Oostra, Ben A.; Bonifati, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9457</span>),
    <span class="NLM_cas:pages">412-415</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutations in the LRRK2 gene have been identified in families with autosomal dominant parkinsonism.  We amplified and sequenced the coding region of LRRK2 from genomic DNA by PCR, and identified a heterozygous mutation (Gly2019 ser) present in four of 61 (6.6%) unrelated families with Parkinson's disease and autosomal dominant inheritance.  The families originated from Italy, Portugal, and Brazil, indicating the presence of the mutation in different populations.  The assocd. phenotype was broad, including early and late disease onset.  These findings confirm the assocn. of LRRK2 with neurodegeneration, and identify a common mutation assocd. with dominantly inherited Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnS_VZvZOVD7Vg90H21EOLACvtfcHk0li8LXwoUkyr1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXoslWitg%253D%253D&md5=bbe725d2adbbdbc5fbce57fca70b3bff</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2917829-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252917829-5%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BFonzo%26aufirst%3DA.%26aulast%3DRoh%25C3%25A9%26aufirst%3DC.%2BF.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DChien%26aufirst%3DH.%2BF.%26aulast%3DVacca%26aufirst%3DL.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DGuedes%26aufirst%3DL.%26aulast%3DFabrizio%26aufirst%3DE.%26aulast%3DManfredi%26aufirst%3DM.%26aulast%3DVanacore%26aufirst%3DN.%26aulast%3DGoldwurm%26aufirst%3DS.%26aulast%3DBreedveld%26aufirst%3DG.%26aulast%3DSampaio%26aufirst%3DC.%26aulast%3DMeco%26aufirst%3DG.%26aulast%3DBarbosa%26aufirst%3DE.%26aulast%3DOostra%26aufirst%3DB.%2BA.%26aulast%3DBonifati%26aufirst%3DV.%26atitle%3DA%2520frequent%2520LRRK2%2520gene%2520mutation%2520associated%2520with%2520autosomal%2520dominant%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D412%26epage%3D415%26doi%3D10.1016%2FS0140-6736%2805%2917829-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kestenbaum, M.</span>; <span class="NLM_string-name">Alcalay, R. N.</span></span> <span> </span><span class="NLM_article-title">Clinical Features of LRRK2 Carriers with Parkinson’s Disease</span>. In  <i>Leucine-Rich Repeat Kinase 2 (LRRK2)</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideout, H. J.</span></span>, Ed.; <span class="NLM_series">Advances in Neurobiology 14</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2017</span>; p  <span class="NLM_fpage">36</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1007%2F978-3-319-49969-7_2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=36&author=M.+Kestenbaum&author=R.+N.+Alcalayauthor=H.+J.+Rideout&title=Leucine-Rich+Repeat+Kinase+2+%28LRRK2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-49969-7_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-49969-7_2%26sid%3Dliteratum%253Aachs%26aulast%3DKestenbaum%26aufirst%3DM.%26atitle%3DClinical%2520Features%2520of%2520LRRK2%2520Carriers%2520with%2520Parkinson%25E2%2580%2599s%2520Disease%26btitle%3DLeucine-Rich%2520Repeat%2520Kinase%25202%2520%2528LRRK2%2529%26aulast%3DRideout%26aufirst%3DH.%2BJ.%26pub%3DSpringer%26date%3D2017%26spage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span> </span><span class="NLM_article-title">The Aptuit library
is now part of Evotec’s screening collection</span>. See Evotec hit identificaton website: <a href="https://www.evotec.com/en/execute/drug-discovery-services/hit-identification" class="extLink">https://www.evotec.com/en/execute/drug-discovery-services/hit-identification</a> (accessed May <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=The+Aptuit+library%0Ais+now+part+of+Evotec%E2%80%99s+screening+collection.+See+Evotec+hit+identificaton+website%3A+https%3A%2F%2Fwww.evotec.com%2Fen%2Fexecute%2Fdrug-discovery-services%2Fhit-identification+%28accessed+May+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DThe%2520Aptuit%2520library%250Ais%2520now%2520part%2520of%2520Evotec%25E2%2580%2599s%2520screening%2520collection%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span> <span> </span><span class="NLM_article-title">Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">435</span>– <span class="NLM_lpage">449</span>, <span class="refDoi"> DOI: 10.1021/cn100008c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100008c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=435-449&author=T.+T.+Wagnerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Moving+beyond+rules%3A+the+development+of+a+central+nervous+system+multiparameter+optimization+%28CNS+MPO%29+approach+to+enable+alignment+of+druglike+properties&doi=10.1021%2Fcn100008c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fcn100008c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100008c%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DMoving%2520beyond%2520rules%253A%2520the%2520development%2520of%2520a%2520central%2520nervous%2520system%2520multiparameter%2520optimization%2520%2528CNS%2520MPO%2529%2520approach%2520to%2520enable%2520alignment%2520of%2520druglike%2520properties%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2010%26volume%3D1%26spage%3D435%26epage%3D449%26doi%3D10.1021%2Fcn100008c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">MLi-2 PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OPB">5OPB</a>; as of Jan. 2020, there were over 70 indazole-containing kinase inhibitor structures in the PDB with an indazole contributing the key hinge binding interactions.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, G. O.</span></span> <span> </span><span class="NLM_article-title">Proton magnetic resonance spectra of thiocarboxamides</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">823</span>, <span class="refDoi"> DOI: 10.1021/jo01278a074</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01278a074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADyaF2sXkt1Wgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1967&pages=823&author=E.+P.+Dudekauthor=G.+O.+Dudek&title=Proton+magnetic+resonance+spectra+of+thiocarboxamides&doi=10.1021%2Fjo01278a074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Proton magnetic resonance spectra of thiocarboxamides</span></div><div class="casAuthors">Dudek, Emily P.; Dudek, Gerald O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">823-4</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">The proton magnetic spectra of I (R = Ph) (Goerdeler and Keuser, CA 61: 11983h), I (R = Et, m. 54.6-5.4°), I (R = Me, m. 138.8-9.6°), and 4,4-dimethyl-2-(methylamino)-6-oxo-1-cyclohexene-1-thiocarboxanilide (loc. cit.) were detd. in CDCl3 and (or) CCl4.  The substitution of S for the amide O does not greatly alter the nature of the conjugated system and the results suggest that S is as able as O to participate in the unusual cross-conjugation and H bonding in these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE10qPUW44LrVg90H21EOLACvtfcHk0ljVqqDdvlwzow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXkt1Wgsbc%253D&md5=51aafa9e4fbc85089b21f9a474b0e471</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjo01278a074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01278a074%26sid%3Dliteratum%253Aachs%26aulast%3DDudek%26aufirst%3DE.%2BP.%26aulast%3DDudek%26aufirst%3DG.%2BO.%26atitle%3DProton%2520magnetic%2520resonance%2520spectra%2520of%2520thiocarboxamides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1967%26volume%3D32%26spage%3D823%26doi%3D10.1021%2Fjo01278a074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bustos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Pichon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solanoy, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Brug, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span> <span> </span><span class="NLM_article-title">Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">164ra161</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1126%2Fscitranslmed.3004485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=23241745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=Z.+Shengauthor=S.+Zhangauthor=D.+Bustosauthor=T.+Kleinheinzauthor=C.+E.+Le+Pichonauthor=S.+L.+Dominguezauthor=H.+O.+Solanoyauthor=J.+Drummondauthor=X.+Zhangauthor=X.+Dingauthor=F.+Caiauthor=Q.+Songauthor=X.+Liauthor=Z.+Yueauthor=M.+P.+van+der+Brugauthor=D.+J.+Burdickauthor=J.+Gunzner-Tosteauthor=H.+Chenauthor=X.+Liuauthor=A.+A.+Estradaauthor=Z.+K.+Sweeneyauthor=K.+Scearce-Levieauthor=J.+G.+Moffatauthor=D.+S.+Kirkpatrickauthor=H.+Zhu&title=Ser1292+autophosphorylation+is+an+indicator+of+LRRK2+kinase+activity+and+contributes+to+the+cellular+effects+of+PD+mutations&doi=10.1126%2Fscitranslmed.3004485"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004485%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBustos%26aufirst%3DD.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLe%2BPichon%26aufirst%3DC.%2BE.%26aulast%3DDominguez%26aufirst%3DS.%2BL.%26aulast%3DSolanoy%26aufirst%3DH.%2BO.%26aulast%3DDrummond%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3Dvan%2Bder%2BBrug%26aufirst%3DM.%2BP.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DEstrada%26aufirst%3DA.%2BA.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26aulast%3DKirkpatrick%26aufirst%3DD.%2BS.%26aulast%3DZhu%26aufirst%3DH.%26atitle%3DSer1292%2520autophosphorylation%2520is%2520an%2520indicator%2520of%2520LRRK2%2520kinase%2520activity%2520and%2520contributes%2520to%2520the%2520cellular%2520effects%2520of%2520PD%2520mutations%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzamko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hentati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alessi, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, R. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser<sup>910</sup>/Ser<sup>935</sup>, disruption of 14-3-3 binding and altered cytoplasmic localization</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">405</span>, <span class="refDoi"> DOI: 10.1042/BJ20100784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1042%2FBJ20100784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=20659021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=405&author=N.+Dzamkoauthor=M.+Deakauthor=F.+Hentatiauthor=A.+D.+Reithauthor=A.+R.+Prescottauthor=D.+R.+Alessiauthor=R.+J.+Nichols&title=Inhibition+of+LRRK2+kinase+activity+leads+to+dephosphorylation+of+Ser910%2FSer935%2C+disruption+of+14-3-3+binding+and+altered+cytoplasmic+localization&doi=10.1042%2FBJ20100784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization</span></div><div class="casAuthors">Dzamko, Nicolas; Deak, Maria; Hentati, Faycal; Reith, Alastair D.; Prescott, Alan R.; Alessi, Dario R.; Nichols, R. Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">LRRK2 (leucine-rich repeat protein kinase 2) is mutated in a significant no. of Parkinson's disease patients.  Since a common mutation that replaces Gly2019 with a serine residue enhances kinase catalytic activity, small-mol. LRRK2 inhibitors might have utility in treating Parkinson's disease.  However, the effectiveness of inhibitors is difficult to assess, as no physiol. substrates or downstream effectors have been identified that could be exploited to develop a robust cell-based assay.  The authors recently established that LRRK2 bound 14-3-3 protein isoforms via its phosphorylation of Ser910 and Ser935.  In the present study they show that treatment of Swiss 3T3 cells or lymphoblastoid cells derived from control or a Parkinson's disease patient harboring a homozygous LRRK2(G2019S) mutation with two structurally unrelated inhibitors of LRRK2 (H-1152 or sunitinib) induced dephosphorylation of endogenous LRRK2 at Ser910 and Ser935, thereby disrupting 14-3-3 interaction.  The results suggest that H-1152 and sunitinib induce dephosphorylation of Ser910 and Ser935 by inhibiting LRRK2 kinase activity, as these compds. failed to induce significant dephosphorylation of a drug-resistant LRRK2(A2016T) mutant.  Moreover, consistent with the finding that non-14-3-3-binding mutants of LRRK2 accumulated within discrete cytoplasmic pools resembling inclusion bodies, the authors obsd. that H-1152 causes LRRK2 to accumulate within inclusion bodies.  These findings indicate that dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and/or monitoring LRRK2 cytoplasmic localization can be used as an assay to assess the relative activity of LRRK2 inhibitors in vivo.  These results will aid the elaboration and evaluation of LRRK2 inhibitors.  They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwgToKFLmVu7Vg90H21EOLACvtfcHk0lj-yWg8-DmesQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyrtbzL&md5=f14dd622d2b2fa3f7495c990e65bbbfc</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1042%2FBJ20100784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20100784%26sid%3Dliteratum%253Aachs%26aulast%3DDzamko%26aufirst%3DN.%26aulast%3DDeak%26aufirst%3DM.%26aulast%3DHentati%26aufirst%3DF.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DNichols%26aufirst%3DR.%2BJ.%26atitle%3DInhibition%2520of%2520LRRK2%2520kinase%2520activity%2520leads%2520to%2520dephosphorylation%2520of%2520Ser910%252FSer935%252C%2520disruption%2520of%252014-3-3%2520binding%2520and%2520altered%2520cytoplasmic%2520localization%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D405%26doi%3D10.1042%2FBJ20100784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raju, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhaiyan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishna, S.</span></span> <span> </span><span class="NLM_article-title">Antimicrobial and antioxidant activity evaluation of tetrazolo[1,5-<i>a</i>]pyrimidines: A simple diisopropylammonium trifluoroacetate mediated synthesis</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">11657</span>– <span class="NLM_lpage">11663</span>, <span class="refDoi"> DOI: 10.1039/c2ra21330c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1039%2Fc2ra21330c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ahu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=11657-11663&author=C.+Rajuauthor=K.+Madhaiyanauthor=R.+Umaauthor=R.+Sridharauthor=S.+Ramakrishna&title=Antimicrobial+and+antioxidant+activity+evaluation+of+tetrazolo%5B1%2C5-a%5Dpyrimidines%3A+A+simple+diisopropylammonium+trifluoroacetate+mediated+synthesis&doi=10.1039%2Fc2ra21330c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antimicrobial and antioxidant activity evaluation of tetrazolo[1,5-a]pyrimidines: A simple diisopropylammonium trifluoroacetate mediated synthesis</span></div><div class="casAuthors">Raju, Chandran; Madhaiyan, Kalaipriya; Uma, Ramakrishnan; Sridhar, Radhakrishnan; Ramakrishna, Seeram</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11657-11663</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A simple, efficient, economic synthesis of tetrazolo[1,5-a]pyrimidine-6-carboxylate derivs. was accomplished by three-component reaction of β-keto esters with a mixt. of arom. aldehyde and 5-aminotetrazole using TFA:DIPEA (1:1) as the catalyst [N-ethyl-N-(1-methylethyl)-2-propanamine trifluoroacetate].  The synthesized tetrazole compds. are evaluated for their antimicrobial and antioxidant activity.  The synthesis of the target compds. was achieved using 2H-tetrazol-5-amine, 2-naphthalenecarboxaldehyde, [1,1'-biphenyl]-2-carboxaldehyde, 3-pyridinecarboxaldehyde, 3-Furancarboxaldehyde, etc., 3-oxobutanoic acid Et ester, 5,5-dimethyl-1,3-cyclohexanedione as starting materials.  The title compds. thus formed included 1,7-dihydro-5-methyl-7-(2-naphthalenyl)tetrazolo[1,5-a]pyrimidine-6-carboxylic acid Et ester (I) and related compds., such as tetrazolo[5,1-b]quinazolin-8(1H)-one derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjLUiEx3NRPrVg90H21EOLACvtfcHk0lj-yWg8-DmesQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ahu7%252FE&md5=2c8dd0ce0aa4bd3d9fc4481690796a9e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2Fc2ra21330c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ra21330c%26sid%3Dliteratum%253Aachs%26aulast%3DRaju%26aufirst%3DC.%26aulast%3DMadhaiyan%26aufirst%3DK.%26aulast%3DUma%26aufirst%3DR.%26aulast%3DSridhar%26aufirst%3DR.%26aulast%3DRamakrishna%26aufirst%3DS.%26atitle%3DAntimicrobial%2520and%2520antioxidant%2520activity%2520evaluation%2520of%2520tetrazolo%255B1%252C5-a%255Dpyrimidines%253A%2520A%2520simple%2520diisopropylammonium%2520trifluoroacetate%2520mediated%2520synthesis%26jtitle%3DRSC%2520Adv.%26date%3D2012%26volume%3D2%26spage%3D11657%26epage%3D11663%26doi%3D10.1039%2Fc2ra21330c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikunaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohyama, Y.</span></span> <span> </span><span class="NLM_article-title">Synthetic studies on novel 1,4-dihydro-2-methylthio-4,4,6-trisubstituted pyrimidine-5-carboxylic acid esters and their tautomers</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1458</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1248/cpb.59.1458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=10.1248%2Fcpb.59.1458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=22130366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Kisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2011&pages=1458-1466&author=Y.+Nishimuraauthor=Y.+Okamotoauthor=M.+Ikunakaauthor=Y.+Ohyama&title=Synthetic+studies+on+novel+1%2C4-dihydro-2-methylthio-4%2C4%2C6-trisubstituted+pyrimidine-5-carboxylic+acid+esters+and+their+tautomers&doi=10.1248%2Fcpb.59.1458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic studies on novel 1,4-dihydro-2-methylthio-4,4,6-trisubstituted pyrimidine-5-carboxylic acid esters and their tautomers</span></div><div class="casAuthors">Nishimura, Yoshio; Okamoto, Yasuko; Ikunaka, Masaya; Ohyama, Yoshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1458-1466</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A mixt. of alkyl 1,4-dihydro-2-methylthio-4,4,6-trisubstituted pyrimidine-5-carboxylate I [R1 = R2 = R3 = R4 = Me; R1 = Ph, R2 = R4 = Et, R3 = Me; R1 = R2 = (CH2)2Me, R3 = Me, R4 = Et; etc.] and its tautomeric isomer, alkyl 1,6-dihydro-2-methylthio-4,6,6-trisubstituted pyrimidine-5-carboxylate II is synthesized by the Atwal-Biginelli cyclocondensation reaction of S-methylisothiourea hemisulfate salt with 2-(gem-disubstituted)methylene-3-oxo-esters R3COC(CO2R4):CR1R2 that can be accessed by the Lehnert procedure for the Knoevenagel-type condensation.  The structures of the tautomeric products of the Atwal-Biginelli cyclocondensation reaction, I and II, which are inseparable from each other, are detd. unambiguously by 1H-NMR spectroscopy at various temps. and nuclear Overhauser enhancement spectroscopy (NOESY) expt.  Because these dihydropyrimidine products are otherwise inaccessible and thus hitherto unavailable, the synthetic methods established in this study will help to expand the mol. diversity of their related derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt8e2S8zAemrVg90H21EOLACvtfcHk0lhqAYNMIYtT5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Kisbs%253D&md5=f3fa9b4d69f7b0bfa481c97ae938a783</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1248%2Fcpb.59.1458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.59.1458%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DY.%26aulast%3DOkamoto%26aufirst%3DY.%26aulast%3DIkunaka%26aufirst%3DM.%26aulast%3DOhyama%26aufirst%3DY.%26atitle%3DSynthetic%2520studies%2520on%2520novel%25201%252C4-dihydro-2-methylthio-4%252C4%252C6-trisubstituted%2520pyrimidine-5-carboxylic%2520acid%2520esters%2520and%2520their%2520tautomers%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2011%26volume%3D59%26spage%3D1458%26epage%3D1466%26doi%3D10.1248%2Fcpb.59.1458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OPB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OPB','PDB','5OPB'); return false;">PDB: 5OPB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i101"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_08077"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01243?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Compound <b>1</b> homology model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">CSV</a>)</p></li><li><p class="inline">Kinase panel for compound <b>31</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">CSV</a>)</p></li><li><p class="inline">Crystal data for compound <b>(</b><i><b>R</b></i><b>)-32</b>; <sup>1</sup>H NMR and HPLC traces for compounds <b>1</b>, <b>4</b>, <b>7</b>, <b>19</b>, <b>20</b>, <b>21</b>, <b>22</b>, <b>23</b>, <b>25</b>, <b>26</b>, <b>30</b>, and <b>31</b>; and table of geometric mean and geometric standard deviation of biochemical potency (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">jm0c01243_si_001.pdb (337.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">jm0c01243_si_002.csv (2.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">jm0c01243_si_003.csv (14.76 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">jm0c01243_si_004.pdf (1.18 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01243&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01243%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01243" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994102afab191d","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
